phv00006877.v1 ::: phs000007.v18.p7 ::: pht000028.v3 ::: ex0_26s ::: FS268 ::: ASPIRIN: USUAL ASPIRIN DOSE ::: NONE ::: NONE ::: NONE ::: NONE ::: aspirin  usual aspirin dose ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin;dose number:number:point in time:^patient:quantitative ::: C0004057;C1114758 ::: orch,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00017388.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V360 ::: E6. Clozaril. Antipsychotics. (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  clozaril  antipsychotics   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: clozaril;antipsychotic agents;diagnosis;genetic study ::: C0719386;C0040615;C0011900;C2827447 ::: orch,phsu;phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00012904.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I17497 ::: M25e. A questions about how you have felt in social situations. The possible answers are always, often, sometimes, or never.  Again, answer the question for what would be most typical for you for most of your adult life: When you are in a social situation, how much of the time are you worrying that you'll say the wrong thing or appear foolish? (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: m25 e  a questions about how you have felt in social situations  the possible answers are always, often, sometimes, or never  again, answer the question for what would be most typical for you for most of your adult life  when you are in a social situation, how much of the time are you worrying that you ll say the wrong thing or appear foolish   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: emotions;feelings;worried;ll;simian acquired immunodeficiency syndrome ::: C0013987;C1527305;C0233481;C1996244;C0080151 ::: menp;menp;fndg;phsu;dsyn ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Medical History
phv00123256.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: COMBIPAT ::: 76 Ever use -  Combipatch ::: encoded ::: NONE ::: NONE ::: NONE ::: 76 ever use combipatch ::: NULL ::: NULL ::: NULL ::: NULL ::: combipatch ::: C0719447 ::: horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00155112.v2 ::: phs000200.v8.p2 ::: pht002118.v2 ::: ecg_rel2 ::: BTA_V6 ::: T wave area, lead bta_v6 ::: integer ::: NONE ::: -6951 ::: 7893 ::: t wave area, lead bta_v6 ::: NULL ::: NULL ::: NULL ::: NULL ::: t wave feature;urinary bladder tumor antigen ::: C0429103;C1519830 ::: fndg;aapp,imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure
phv00060900.v2 ::: phs000128.v3.p3 ::: pht000485.v2 ::: simphen086 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126897.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: ravg_ca ::: RECALL: calcium ::: decimal ::: NONE ::: 139.885 ::: 2034.49 ::: recall  calcium ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;calcium;recall:-:point in time:^patient:- ::: C0034770;C0006675;C2361119 ::: menp;bacs,elii,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding
phv00158159.v1 ::: phs000007.v18.p7 ::: pht002153.v1 ::: ffreq0_22s ::: SCORE76 ::: DERIVED FIELD: NUTRIENT VALUE - IRON WITHOUT VITAMIN PILLS (MG) ::: NONE ::: mg ::: NONE ::: NONE ::: derived field  nutrient value iron without vitamin pills  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;iron;ferrum metallicum, homeopathic preparation;vitamins ::: C0678695;C0302583;C1166521;C0042890 ::: food;bacs,elii,phsu;phsu;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00096798.v1 ::: phs000280.v1.p1 ::: pht001389.v1 ::: ARIC_CARE_SBPBV2C1 ::: SBPB02 ::: ANY TOBACCO IN LAST 4 HOURS?      Q2 ::: encoded ::: NONE ::: NONE ::: NONE ::: any tobacco in last 4 hours  q2 ::: NULL ::: NULL ::: NULL ::: NULL ::: tobacco ::: C0040329 ::: hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History;Substance Use History
phv00126381.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: lffq_mfa18_1 ::: LFFQ: MUFA 18:1 (oleic acid) (gm) ::: decimal ::: gm ::: 5.159826 ::: 90.19738 ::: lffq  mufa 18 1  oleic acid   gm ::: NULL ::: NULL ::: NULL ::: NULL ::: oleic acid ::: C0028928 ::: bacs,lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00100217.v1 ::: phs000287.v2.p1 ::: pht001451.v1 ::: BASE2 ::: PKNPIE25 ::: PUMPKIN PIE, SWEET POTATO PIE ::: encoded ::: NONE ::: NONE ::: NONE ::: pumpkin pie, sweet potato pie ::: NULL ::: NULL ::: NULL ::: NULL ::: pumpkins;pulmonary eosinophilia;pumpkin preparation;pumpkin allergenic extract;sweet potato - dietary;sweet potato allergenic extract ::: C0453137;C0034068;C1095888;C2726205;C1146616;C2741492 ::: food;dsyn;phsu;imft,phsu;food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Eating or Nutritional Finding
phv00153633.v2 ::: phs000209.v10.p2 ::: pht002109.v2 ::: MESA_MesaFamily_LungCT ::: RMC_a_int ::: RIGHT LUNG, MIDDLE CORE: THE INTERCEPT OF THE LINE AT THE ANKLE ::: Numeric ::: NONE ::: NONE ::: NONE ::: right lung, middle core  the intercept of the line at the ankle ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126966.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: ravg_sfol ::: RECALL: synthetic folate ::: decimal ::: NONE ::: 0 ::: 520.68 ::: recall  synthetic folate ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;recall:-:point in time:^patient:-;folate ::: C0034770;C2361119;C0178638 ::: menp;clna;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding
phv00124003.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: fibrinogenam_flag ::: Fibrinogen am - data flag ::: encoded ::: NONE ::: NONE ::: NONE ::: fibrinogen am data flag ::: NULL ::: NULL ::: NULL ::: NULL ::: fibrinogen ::: C0016006 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00017238.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V210 ::: C18. Conciousness. INTERVIEWER:  assess level of consciousness. (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: c18   conciousness  interviewer  assess level of consciousness   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: level;consciousness related finding;conscious;diagnosis;genetic study ::: C2946261;C0009791;C0234421;C0011900;C2827447 ::: phsu;fndg;menp;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Research Attributes;Medical History
phv00079350.v3 ::: phs000200.v8.p2 ::: pht001010.v3 ::: f42_rel1 ::: DRNKAG14 ::: Drinks of alcohol (age 14-17) ::: encoded value ::: NONE ::: NONE ::: NONE ::: drinks of alcohol  age 1417 ::: Age ::: age ::: C0001779 ::: orga ::: drink (dietary substance);alcohols;alcohol measurement ::: C0452428;C0001975;C0202304 ::: food;orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Demographics;Medication Patient;Lab Tests Patient;Drinking History;Eating or Nutritional Finding
phv00048962.v1 ::: phs000086.v2.p1 ::: pht000326.v1 ::: EDIC_f0024 ::: OBF4A ::: F4. Diabetes management: total number of units/day of insulin ::: byte ::: units/day ::: NONE ::: NONE ::: f4  diabetes management  total number of units day of insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;disease management;diabetes mellitus;insulin;recombinant insulin ::: C0011847;C0376636;C0011849;C0021641;C1533581 ::: dsyn;hlca;dsyn;aapp,horm,phsu;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00086941.v2 ::: phs000209.v10.p2 ::: pht001120.v7 ::: MESA_Exam4Main ::: amlod4c ::: AMLODIPINE ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: amlodipine ::: NULL ::: NULL ::: NULL ::: NULL ::: amlodipine ::: C0051696 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00085227.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: heptpb1 ::: HEPATITIS, TYPE B ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: hepatitis, type b ::: NULL ::: NULL ::: NULL ::: NULL ::: hepatitis;hepatitis a;hepatitis a vaccine, inactivated ::: C0019158;C0019159;C0795623 ::: dsyn;dsyn;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00114783.v2 ::: phs000285.v2.p2 ::: pht001630.v2 ::: B2F17 ::: B17HER24 ::: USED HEROIN, PAST 24 HOURS ::: encoded ::: NONE ::: NONE ::: NONE ::: used heroin, past 24 hours ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;heroin ::: C1273517;C0011892 ::: fndg;hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00156979.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: nut_b1 ::: Derived field: Nutrient value - Vitamin B1 ::: decimal, encoded ::: mg ::: 0.1 ::: 251.16 ::: derived field  nutrient value vitamin b1 ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;thiamine ::: C0678695;C0039840 ::: food;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00002951.v1 ::: phs000007.v18.p7 ::: pht000019.v3 ::: ex0_17s ::: FJ8 ::: INTERIM HISTORY OF MEDICINE USED: CARDIAC GLYCOSIDES ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of medicine used  cardiac glycosides ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations;used by;cardiac glycosides ::: C0262926;C2004062;C0013227;C1273517;C0007158 ::: fndg;fndg;phsu;fndg;carb,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00104462.v1 ::: phs000287.v2.p1 ::: pht001488.v1 ::: YR3 ::: DIURET06 ::: Any diuretic ::: encoded ::: NONE ::: NONE ::: NONE ::: any diuretic ::: NULL ::: NULL ::: NULL ::: NULL ::: diuretics ::: C0012798 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00095587.v1 ::: phs000280.v1.p1 ::: pht001354.v1 ::: ARIC_CARE_PFTAV1C1 ::: PFTA02 ::: Sex (M, F) ::: encoded ::: NONE ::: NONE ::: NONE ::: gender  m, f ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal;fluorides ::: C0804628;C0016327 ::: clna;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Demographics;Medication Patient
phv00049725.v1 ::: phs000086.v2.p1 ::: pht000330.v1 ::: EDIC_f0302 ::: COONVERE ::: F. Ophthalmoscopic examination: are there new vessels (NVE) outside 7 standard fields? Right eye ::: byte ::: NONE ::: NONE ::: NONE ::: f  ophthalmoscopic examination  are there new vessels  nve  outside 7 standard fields  right eye ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;ophthalmoscopy;no visible estrus ::: C0016327;C0029090;C0232915 ::: inch,phsu;diap;sosy ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure;Medical History
phv00107253.v1 ::: phs000287.v2.p1 ::: pht001491.v1 ::: YR5OLD ::: ESTROP29 ::: TOOK ESTROGEN IN THE PAST ::: encoded ::: NONE ::: NONE ::: NONE ::: took estrogen in the past ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00052185.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V383 ::: E6 Provigil, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6 provigil,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: provigil;diagnosis;genetic study ::: C0722882;C0011900;C2827447 ::: orch,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00093568.v1 ::: phs000280.v1.p1 ::: pht001318.v1 ::: ARIC_CARE_ESMAV2C1 ::: ESMA114 ::: COND 16- LEAD 1, EV7 ::: encoded ::: NONE ::: NONE ::: NONE ::: cond 16 lead 1, ev7 ::: NULL ::: NULL ::: NULL ::: NULL ::: hutterite cerebroosteonephrodysplasia syndrome;lead;plumbum metallicum, homeopathic preparation ::: C1856054;C0023175;C1442948 ::: dsyn;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Medical History
phv00068251.v2 ::: phs000007.v18.p7 ::: pht000681.v3 ::: ffreq1_6s ::: CD ::: FFQ: VITAMIN C SUPPLEMENT DOSE PER DAY ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  vitamin c supplement dose per day ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;ascorbic acid;dose number:number:point in time:^patient:quantitative ::: C0524813;C0003968;C1114758 ::: food;orch,phsu,vita;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00120353.v2 ::: phs000285.v2.p2 ::: pht001825.v2 ::: F1F48 ::: F48VITAN ::: NUMBER TAKEN (VITAMIN A). Q 2 ::: encoded ::: NONE ::: NONE ::: NONE ::: number taken  vitamin a   q 2 ::: NULL ::: NULL ::: NULL ::: NULL ::: vitamin a2 ::: C0078364 ::: orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00002220.v1 ::: phs000007.v18.p7 ::: pht000016.v3 ::: ex0_14s ::: FG85 ::: INTERIM HISTORY OF MEDICINE USED: NITRITES ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of medicine used  nitrites ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations;used by ::: C0262926;C2004062;C0013227;C1273517 ::: fndg;fndg;phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00052228.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V454 ::: F7e One hour early, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: f7 e one hour early,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: blood coagulation factor vii;diagnosis;genetic study ::: C0015502;C0011900;C2827447 ::: aapp,bacs,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00026195.v1 ::: phs000086.v2.p1 ::: pht000214.v1 ::: DCCT_f0034 ::: OCDM6A ::: Infusion pump: units of basal insulin rate/day ::: byte ::: I.U./DAY ::: NONE ::: NONE ::: infusion pump  units of basal insulin rate day ::: NULL ::: NULL ::: NULL ::: NULL ::: basal rate;insulin;recombinant insulin;basal insulin ::: C1648294;C0021641;C1533581;C0650607 ::: clna;aapp,horm,phsu;aapp,horm,phsu;aapp,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00061700.v2 ::: phs000128.v3.p3 ::: pht000510.v2 ::: simphen111 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00071180.v2 ::: phs000166.v2.p1 ::: pht000704.v2 ::: ACRN_CData ::: edhos_event1_month ::: No. of months from Baseline to first ER visit or Hospitalization.  See month assignments in pred_bursts_event1_month. ::: decimal ::: month ::: -0.73 ::: 14.21 ::: no  of months from baseline to first estrogen receptor visit or hospitalization  see month assignments in pred_bursts_event1 _month ::: NULL ::: NULL ::: NULL ::: NULL ::: health care visit;hospitalization;vision;prednisone;prednylidene ::: C1512346;C0019993;C0042789;C0032952;C0044955 ::: inbe;hlca;orgf;horm,phsu,strd;phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00156479.v2 ::: phs000200.v8.p2 ::: pht002125.v2 ::: f60_nutr_rel1 ::: F60PHNYL ::: Dietary Phenylalanine (g) ::: decimal ::: g ::: 0 ::: 50.70668 ::: dietary phenylalanine  gram ::: NULL ::: NULL ::: NULL ::: NULL ::: diet;phenylalanine ::: C0012155;C0031453 ::: food;aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00044571.v1 ::: phs000017.v3.p1 ::: pht000317.v1 ::: DIGS4_DiagnosisPage1 ::: V93 ::: Alcohol Abuse/Dependence, age last dep., (Participants with European ancestry). DIGS4. Page1 ::: NONE ::: Years old ::: NONE ::: NONE ::: alcohol abuse dependence, age last dep ,  participants with european ancestry   diagnostic interview for genetic studies  page1 ::: Age;Ethnicity ::: age;ethnic european ::: C0001779;C0239307 ::: orga;popg ::: alcoholic intoxication, chronic;drug abuse;victim of abuse finding;abuse;alcohol abuse;emotional dependency;dependence;1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride;diagnosis;genetic study ::: C0001973;C0013146;C0562381;C1328247;C0085762;C0011546;C0439857;C0057472;C0011900;C2827447 ::: mobd;mobd;fndg;mobd;mobd;menp;mobd;orch,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Drinking History;Research Attributes
phv00018477.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1449 ::: J49. Cocaine.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j49   cocaine   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: cocaine;cocaine measurement;diagnosis;genetic study ::: C0009170;C0202362;C0011900;C2827447 ::: hops,orch,phsu;lbpr;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes
phv00127086.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: sffq_caff ::: SFFQ: caffeine (mg) ::: decimal ::: mg ::: 0 ::: 1531.351 ::: sffq  caffeine  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: caffeine ::: C0006644 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00033326.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL31A30 ::: Bedtime blood glucose mg/dl (quarterly visit 30) ::: int ::: MG/DL ::: NONE ::: NONE ::: bedtime blood glucose magnesium distolingual  quarterly visit 30 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00093907.v1 ::: phs000280.v1.p1 ::: pht001320.v1 ::: ARIC_CARE_ESMCV4C1 ::: ESMC153 ::: CLN OVERREAD NOVA 0=NO 1=ANT 2=INF 3=LAT ::: encoded ::: NONE ::: NONE ::: NONE ::: cln overread nova 0=no 1=ant 2=inf 3=lat ::: NULL ::: NULL ::: NULL ::: NULL ::: infed ::: C0721062 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00127036.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: sffq_cu ::: SFFQ: copper (mg) ::: decimal ::: mg ::: 0.095603 ::: 9.007545 ::: sffq  copper  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: copper ::: C0009968 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00010516.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G462 ::: URINALYSIS: GLUCOSE ::: NONE ::: NONE ::: NONE ::: NONE ::: urinalysis  glucose ::: NULL ::: NULL ::: NULL ::: NULL ::: urinalysis;glucose;plasma glucose measurement ::: C0042014;C0017725;C0202042 ::: lbpr;bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00013312.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I17150 ::: V10. Delusions of guilt or sin: the patient believes that he has committed some terrible sin or done something unforgivable. See SAPS Manual for detailed coding definitions (N. Andreason, 1984). (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: v10   delusions of guilt or sin  the patient believes that he has committed some terrible sin or done something unforgivable  see saps manual for detailed coding definitions  n  andreason, 1984     participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: delusions;guilt;commit lozenge;vision ::: C0011253;C0018379;C1171947;C0042789 ::: mobd;menp;orch,phsu;orgf ::: patients;participant ::: C0030705;C0679646 ::: podg;popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Medical History
phv00157120.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: nut_pfn302_wo ::: Derived field: Nutrient value - Total Omega 3 without supplements, Sacks 2002 ::: decimal, encoded ::: gm ::: 0.08 ::: 26.3 ::: derived field  nutrient value total omega 3 without supplements, sacks 2002 ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;omega-3 fatty acids;dietary supplements ::: C0678695;C0015689;C0242295 ::: food;bacs,lipd,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00157404.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: SELDUR ::: FFQ: SELENIUM SUPPLEMENT YEARS OF DURATION ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  selenium supplement years of duration ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;selenium;food;selenium supplement;duration ::: C0524813;C0036581;C0016452;C0521939;C2926735 ::: food;elii,hops;food;inch,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Eating or Nutritional Finding
phv00001445.v1 ::: phs000007.v18.p7 ::: pht000012.v3 ::: ex0_10s ::: FC91 ::: INTERIM HISTORY OF MEDICINE USED: HYPOGLYCEMIC AGENTS ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of medicine used  hypoglycemic agents ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations;used by;hypoglycemic agents ::: C0262926;C2004062;C0013227;C1273517;C0020616 ::: fndg;fndg;phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00113357.v2 ::: phs000285.v2.p2 ::: pht001575.v2 ::: A4F12 ::: A12SOB ::: SOB WHEN HURRYING ON LEVEL/SLIGHT HILL ::: encoded ::: NONE ::: NONE ::: NONE ::: shortness of breath when hurrying on level slight hill ::: NULL ::: NULL ::: NULL ::: NULL ::: level ::: C2946261 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00000954.v1 ::: phs000007.v18.p7 ::: pht000009.v2 ::: ex0_7s ::: MF512 ::: INTERIM HISTORY OF DRUGS TAKEN: HYPOCHOLESTEROL, EXAM 7 ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of drugs taken  hypocholesterol, exam 7 ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations;medical examination ::: C0262926;C2004062;C0013227;C0582103 ::: fndg;fndg;phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00054305.v2 ::: phs000001.v3.p1 ::: pht000381.v2 ::: nsaids ::: OTHASPSP ::: OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS) ::: string ::: NONE ::: NONE ::: NONE ::: other regular strength aspirin name  all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin ::: C0004057 ::: orch,phsu ::: participant ::: C0679646 ::: popg ::: Medication Patient
phv00016040.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: COCAINE_HIGH_IN_SCH_WORK ::: J51. Cocaine High in Sch/Work, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: j51   cocaine high in sch work,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: cocaine;cocaine measurement;spindle cell hemangioma ::: C0009170;C0202362;C1304508 ::: hops,orch,phsu;lbpr;neop ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Medical History
phv00127076.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: sffq_argi ::: SFFQ: arginine (gm) ::: decimal ::: gm ::: 0.149252 ::: 23.92065 ::: sffq  arginine  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: arginine ::: C0003765 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00105031.v1 ::: phs000287.v2.p1 ::: pht001489.v1 ::: YR4 ::: BETAD06 ::: Beta-blockers with diuretics ::: encoded ::: NONE ::: NONE ::: NONE ::: beta blockers with diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: adrenergic beta-antagonists;diuretics ::: C0001645;C0012798 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00011963.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I3270 ::: E4. Have you ever taken medications for your nerves or any emotional or mental problems? Antidepressants: Wellbutrin. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: e4  have you ever taken medications for your nerves or any emotional or mental problems  antidepressants  wellbutrin   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;emotions;emotional;mental problem;antidepressive agents;wellbutrin;antidepressant measurement ::: C0013227;C0802604;C2598133;C0013987;C0849912;C0848067;C0003289;C0085934;C2698157 ::: phsu;clna;clna;menp;fndg;fndg;phsu;orch,phsu;lbpr ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Mental or Emotional Finding;Medical History
phv00068905.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: BEET ::: FFQ: BEETS (1/2 CUP) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  beets  1 2 cup ::: NULL ::: NULL ::: NULL ::: NULL ::: food;beets;beets preparation ::: C0016452;C0600054;C1095905 ::: food;food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00095245.v1 ::: phs000280.v1.p1 ::: pht001349.v1 ::: ARIC_CARE_MSRV4C1 ::: MSDM7C ::: MEDICATION CODE NO. -- REPLACES Q7C ::: string ::: NONE ::: NONE ::: NONE ::: medication code no  replaces q7 c ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00083806.v2 ::: phs000209.v10.p2 ::: pht001114.v2 ::: MESA_AncilMesaLungSpirometry ::: qmed3a4 ::: NAME OF 3RD MEDICATION ::: STRING ::: NONE ::: NONE ::: NONE ::: name of 3rd medication ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00068103.v2 ::: phs000007.v18.p7 ::: pht000680.v3 ::: ffreq1_5s ::: BEEF ::: FFQ: BEEF, PORK, LAMB AS MAIN (4-6 OZ) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  beef, pork, lamb as main  46 oz ::: NULL ::: NULL ::: NULL ::: NULL ::: food;beef (dietary);beef prepartion;pork;pork allergenic extract;lamb - meat ::: C0016452;C0452849;C2362309;C0452867;C2702371;C0452875 ::: food;food;phsu;food;imft,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00095290.v1 ::: phs000280.v1.p1 ::: pht001349.v1 ::: ARIC_CARE_MSRV4C1 ::: MSRD15D ::: TAKE MEDICATION L IN PAST 24 HRS? Q15D ::: encoded ::: NONE ::: NONE ::: NONE ::: take medication l in past 24 hours  q15 d ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00162210.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: GARLIC ::: FFQ: GARLIC ::: encoded ::: 1 clove or shake ::: NONE ::: NONE ::: food frequency questionnaire  garlic ::: NULL ::: NULL ::: NULL ::: NULL ::: food;garlic preparation;garlic ::: C0016452;C0885057;C0993630 ::: food;orch,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00093847.v1 ::: phs000280.v1.p1 ::: pht001320.v1 ::: ARIC_CARE_ESMCV4C1 ::: ESMC93 ::: COND 9 - LEAD 1, EV1 ::: encoded ::: NONE ::: NONE ::: NONE ::: cond 9 lead 1, ev1 ::: NULL ::: NULL ::: NULL ::: NULL ::: hutterite cerebroosteonephrodysplasia syndrome;lead;plumbum metallicum, homeopathic preparation ::: C1856054;C0023175;C1442948 ::: dsyn;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Medical History
phv00173730.v1 ::: phs000490.v1.p1 ::: pht002968.v1 ::: ADHD_Phenotype ::: Cardiovascular_Agents ::: Cardiovascular agents that have been prescribed to the patient ::: String ::: NONE ::: NONE ::: NONE ::: cardiovascular agents that have been prescribed to the patient ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;prescribed ::: C0007220;C0278329 ::: phsu;hlca ::: patients ::: C0030705 ::: podg ::: Medication Patient;Healthcare Activity Finding
phv00007335.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT296 ::: ORAL HYPOGLYCEMICS: UNKNOWN ::: NONE ::: NONE ::: NONE ::: NONE ::: oral hypoglycemics  unknown ::: NULL ::: NULL ::: NULL ::: NULL ::: oral hypoglycemic ::: C0359086 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00113080.v2 ::: phs000285.v2.p2 ::: pht001570.v2 ::: A4F09GEN ::: A09OTDDN ::: DESC OF OTHER THYROID PROB ::: string ::: NONE ::: NONE ::: NONE ::: desc of other thyroid prob ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;thyroid (usp);thyroid preparation ::: C0037088;C0040134;C0279175 ::: sosy;bacs,orch,phsu;horm,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00172682.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: nut_iron ::: Derived field: Nutrient value - Iron ::: decimal, encoded ::: mg ::: 0.5 ::: 101.67 ::: derived field  nutrient value iron ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;iron;ferrum metallicum, homeopathic preparation ::: C0678695;C0302583;C1166521 ::: food;bacs,elii,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00048496.v1 ::: phs000086.v2.p1 ::: pht000324.v1 ::: EDIC_cbldata ::: BOSGLUC2 ::: Serum glucose-t 2 (mg/dl) ::: int ::: mg/dl ::: NONE ::: NONE ::: serum glucose t 2  magnesium distolingual ::: NULL ::: NULL ::: NULL ::: NULL ::: serum magnesium finding;glucose;plasma glucose measurement;glucose measurement, serum ::: C1826990;C0017725;C0202042;C0202041 ::: fndg;bacs,carb,phsu;lbpr;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00162171.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: H20MEL ::: FFQ: WATERMELON ::: encoded ::: 1 slice ::: NONE ::: NONE ::: food frequency questionnaire  watermelon ::: NULL ::: NULL ::: NULL ::: NULL ::: food;watermelon preparation;watermelon (dietary);watermelon flavor ::: C0016452;C0874041;C0973455;C1337222 ::: food;orch,phsu;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00126680.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: sffq_spoly ::: SFFQ: sucrose polyester (gm) ::: encoded ::: gm ::: NONE ::: NONE ::: sffq  sucrose polyester  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: sucrose polyester ::: C0075483 ::: carb,lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00147449.v2 ::: phs000209.v10.p2 ::: pht002102.v2 ::: MESA_AncilMesaLungExam3CT ::: RC_k_int ::: RIGHT LUNG, CORE: THE INTERCEPT OF THE LINE AT THE KNEE ::: Numeric ::: NONE ::: NONE ::: NONE ::: right lung, core  the intercept of the line at the knee ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00090182.v2 ::: phs000209.v10.p2 ::: pht001208.v2 ::: MESA_AncilMesaSexHormone ::: tottst1 ::: TOTAL TESTOSTERONE ::: NUMERIC ::: nmoI/L ::: NONE ::: NONE ::: total testosterone ::: NULL ::: NULL ::: NULL ::: NULL ::: testosterone;total testosterone measurement ::: C0039601;C0202227 ::: horm,phsu,strd;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00086002.v2 ::: phs000209.v10.p2 ::: pht001118.v5 ::: MESA_Exam2Main ::: aced2c ::: ACE INHIBITORS WITH DIURETICS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: angiotensin converting enzyme inhibitors with diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: angiotensin-converting enzyme inhibitors;diuretics ::: C0003015;C0012798 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00029514.v1 ::: phs000086.v2.p1 ::: pht000243.v1 ::: DCCT_ms4exprt ::: SV_99 ::: Sural nerve - conduction velocity (m/sec): close-out - Note: As reported in the NeuropathyCodebook (phd000387) the original data show three coding options (.G, .B, .L) which were not properly translated from the original SAS file; instead each of these coded values appears as '.' value in the dataset available through dbGaP. ::: float ::: M/SEC ::: NONE ::: NONE ::: sural nerve conduction velocity  m sec   close out note  as reported in the neuropathycodebook  phd000387  the original data show three coding options   g,  b,  l  which were not properly translated from the original sas file  instead each of these coded values appears as     value in the dataset available through dbgap ::: NULL ::: NULL ::: NULL ::: NULL ::: sural;nerve conduction velocity;reporting ::: C0626053;C0429381;C0700287 ::: phsu;fndg;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00076339.v3 ::: phs000007.v18.p7 ::: pht000904.v4 ::: ctaopulm3_2005s ::: MPA ::: The maximum diameter of the main pulmonary artery obtained at the level of the right pulmonary artery. ::: decimal, encoded ::: mm ::: 16.61 ::: 37.94 ::: the maximum diameter of the main pulmonary artery obtained at the level of the right pulmonary artery ::: NULL ::: NULL ::: NULL ::: NULL ::: level ::: C2946261 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Clinical Attributes
phv00069876.v2 ::: phs000007.v18.p7 ::: pht000680.v3 ::: ffreq1_5s ::: ZN ::: FFQ: TAKE ZINC SUPPLEMENT ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  take zinc supplement ::: NULL ::: NULL ::: NULL ::: NULL ::: food;zinc supplement ::: C0016452;C1268859 ::: food;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00078288.v3 ::: phs000200.v8.p2 ::: pht000995.v3 ::: f148_rel1 ::: EPDUR_8 ::: Months comb estr/progesterone ::: encoded value ::: NONE ::: NONE ::: NONE ::: months comb estr progesterone ::: NULL ::: NULL ::: NULL ::: NULL ::: estring;progesterone ::: C0591465;C0033308 ::: horm,phsu,strd;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049597.v1 ::: phs000086.v2.p1 ::: pht000329.v1 ::: EDIC_f0044 ::: ODB15RE ::: B15. Current medication: ocular medication require prescription, right eye ::: byte ::: NONE ::: NONE ::: NONE ::: b15   current medication  ocular medication require prescription, right eye ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;vision;prescription procedure ::: C0746467;C0042789;C0033080 ::: fndg;orgf;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00115251.v2 ::: phs000285.v2.p2 ::: pht001651.v2 ::: C1ECHO ::: QSCD ::: COLOR DOPPLER QUALITY SCORE ::: encoded ::: NONE ::: NONE ::: NONE ::: color doppler quality score ::: NULL ::: NULL ::: NULL ::: NULL ::: doppler studies;coloring excipient;color assessment ::: C0554756;C1705245;C1880121 ::: diap;phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Diagnostic Procedure
phv00029229.v1 ::: phs000086.v2.p1 ::: pht000242.v1 ::: DCCT_f003cmb2 ::: OCO12B ::: Change insulin regimen to: units of NPH or lente insulin ::: byte ::: I.U. ::: NONE ::: NONE ::: change insulin regimen to  units of neutral protamine hagedor or lente insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin;treatment protocols;recombinant insulin;protamines;insulin, lente ::: C0021641;C0040808;C1533581;C0033603;C0021659 ::: aapp,horm,phsu;topp;aapp,horm,phsu;aapp,bacs,phsu;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00031671.v1 ::: phs000086.v2.p1 ::: pht000268.v1 ::: DCCT_f0561 ::: EFB1A2 ::: Patient's performance rating: task 1 - draw 9 U of insulin in 0.5cc syringe, trial 2 ::: byte ::: NONE ::: NONE ::: NONE ::: patient s performance rating  task 1 draw 9 u of insulin in 0 5cc syringe, trial 2 ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin;recombinant insulin;clinical trials ::: C0021641;C1533581;C0008976 ::: aapp,horm,phsu;aapp,horm,phsu;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Research Attributes
phv00099575.v1 ::: phs000287.v2.p1 ::: pht001450.v1 ::: BASE1 ::: A2AD06 ::: Combinations of angiotensin II antagonists ::: encoded ::: NONE ::: NONE ::: NONE ::: combinations of angiotensin ii antagonists ::: NULL ::: NULL ::: NULL ::: NULL ::: angiotensin ii ::: C0003009 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007292.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT253 ::: BETA BLOCKER GROUP ::: NONE ::: NONE ::: NONE ::: NONE ::: beta blocker group ::: NULL ::: NULL ::: NULL ::: NULL ::: adrenergic beta-antagonists ::: C0001645 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00064342.v2 ::: phs000128.v3.p3 ::: pht000593.v2 ::: simphen194 ::: chol1 ::: Cranial Hydroencephalic oleo level v1 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v1 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v1 stage;level ::: C0982301;C0457422;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00013158.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I15200 ::: P32. Do you think that you should have been that anxious? (social). (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: p32   do you think that you should have been that anxious   social    participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: p-32;thinking, function;anxiety ::: C0069881;C0039869;C0003467 ::: irda,orch,phsu;menp;menp ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding
phv00117157.v2 ::: phs000285.v2.p2 ::: pht001718.v2 ::: D1F17 ::: D17LIFCO ::: TIMES USED OTHER FORMS OF COCAINE IN LIF. Q 6 ::: integer ::: Times ::: NONE ::: NONE ::: times used other forms of cocaine in lif  q 6 ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;others;cocaine;cocaine measurement ::: C1273517;C1955473;C0009170;C0202362 ::: fndg;fndg;hops,orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Substance Use History;Medical History
phv00108754.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: ECOSPC59 ::: SPECIFY OTHER REASONS FOR TAKING ESTROGEN ::: string ::: NONE ::: NONE ::: NONE ::: specify other reasons for taking estrogen ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00079476.v3 ::: phs000200.v8.p2 ::: pht001011.v3 ::: f43_rel1 ::: PCYCLE ::: Progesterone cycle during last PERT use ::: encoded value ::: NONE ::: NONE ::: NONE ::: progesterone cycle during last progestin estrogen replacement therapy use ::: NULL ::: NULL ::: NULL ::: NULL ::: progesterone;progestin replacement therapy;estrogens;progestins;estrogen replacement therapy ::: C0033308;C0854639;C0014939;C0033306;C0014935 ::: horm,phsu,strd;topp;horm,phsu,strd;horm,phsu,strd;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00061686.v2 ::: phs000128.v3.p3 ::: pht000510.v2 ::: simphen111 ::: chol1 ::: Cranial Hydroencephalic oleo level v1 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v1 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v1 stage;level ::: C0982301;C0457422;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00145665.v1 ::: phs000209.v10.p2 ::: pht002101.v1 ::: MESA_AncilMesaLungExam2CT ::: RLC_k_int ::: RIGHT LUNG, LOWER CORE: THE INTERCEPT OF THE LINE AT THE KNEE ::: Numeric ::: NONE ::: NONE ::: NONE ::: right lung, lower core  the intercept of the line at the knee ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00108114.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: ECDAY59 ::: DAYS PER MONTH TAKE ESTROGEN ::: integer ::: NONE ::: 1 ::: 31 ::: days per month take estrogen ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00013465.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I11520 ::: K12. Have you ever seen things in magazines or on TV that seem to refer specifically to you or contain a special message for you? Other medications. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: k12   have you ever seen things in magazines or on tv that seem to refer specifically to you or contain a special message for you  other medications   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: other medications:finding:point in time:^patient:nominal;other medications ::: C1114750;C1115771 ::: clna;phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00090842.v1 ::: phs000252.v2.p1 ::: pht001271.v1 ::: HMP_Gut_Crohns_Diet_COMBO_Subject_Phenotypes ::: COM10A8 ::: Rifaximin (Xifaxan) ::: encoded values ::: NONE ::: NONE ::: NONE ::: rifaximin  xifaxan ::: NULL ::: NULL ::: NULL ::: NULL ::: rifaximin;xifaxan ::: C0073374;C1615611 ::: orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00053892.v2 ::: phs000001.v3.p1 ::: pht000373.v2 ::: enrollment_randomization ::: NITROGLY ::: YEARS TAKING NITROGLYCERIN (ALL PARTICIPANTS) ::: enumerated integer ::: NONE ::: NONE ::: NONE ::: years taking nitroglycerin  all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: nitroglycerin;glonoine, nitroglycerine, homeopathic preparation ::: C0017887;C0885378 ::: orch,phsu;orch,phsu ::: participant ::: C0679646 ::: popg ::: Medication Patient
phv00062813.v2 ::: phs000128.v3.p3 ::: pht000545.v2 ::: simphen146 ::: chol2 ::: Cranial Hydroencephalic oleo level v2 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v2 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v2 stage;level ::: C0982301;C0457423;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00010183.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G040 ::: ASPIRIN: USUAL ASPIRIN DOSE FOR ABOVE ::: NONE ::: NONE ::: NONE ::: NONE ::: aspirin  usual aspirin dose for above ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin;dose number:number:point in time:^patient:quantitative ::: C0004057;C1114758 ::: orch,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00086965.v2 ::: phs000209.v10.p2 ::: pht001120.v7 ::: MESA_Exam4Main ::: iprtr4c ::: ANTICHOLINERGICS + COMBINATION WITH BETA2-AGONIST (121200) ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: anticholinergics + combination with beta2 agonist  121200 ::: NULL ::: NULL ::: NULL ::: NULL ::: anticholinergic agents;agonists ::: C0242896;C0243192 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00083148.v1 ::: phs000209.v10.p2 ::: pht001111.v3 ::: MESA_AirNRExamMain ::: sympth1c ::: SYMPATHOMIMETICS, ORAL AND INHALED ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: sympathomimetics, oral and inhaled ::: NULL ::: NULL ::: NULL ::: NULL ::: sympathomimetics;inspiration function ::: C0039052;C0004048 ::: phsu;orgf ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00049575.v1 ::: phs000086.v2.p1 ::: pht000329.v1 ::: EDIC_f0044 ::: ODB12D ::: B12d. Current medication: specify - other antihypsarrythmic ::: byte ::: NONE ::: NONE ::: NONE ::: b12 d  current medication  specify other antihypsarrythmic ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current ::: C0746467 ::: fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00110689.v1 ::: phs000287.v2.p1 ::: pht001495.v1 ::: YR9 ::: PVDL06 ::: Peripheral vasodilators,  exclude dipyrid ::: encoded ::: NONE ::: NONE ::: NONE ::: peripheral vasodilators, exclude dipyrid ::: NULL ::: NULL ::: NULL ::: NULL ::: peripheral vasodilators ::: C0724804 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00142401.v2 ::: phs000007.v18.p7 ::: pht002078.v3 ::: l_ckd_ex06_1_0536s ::: GSTA ::: Glutathione S-Transferase alpha (sample: urine) ::: decimal ::: ng/ml ::: 0.1694 ::: 107 ::: glutathione stransferase alpha  sample  urine ::: NULL ::: NULL ::: NULL ::: NULL ::: reduced glutathione ::: C0034917 ::: aapp,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00089316.v1 ::: phs000007.v18.p7 ::: pht001179.v2 ::: shorm0_21s ::: EST_18 ::: Estrogen - Exam 18 ::: decimal, encoded ::: pg/mL ::: 2 ::: 245.6 ::: estrogen exam 18 ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;medical examination ::: C0014939;C0582103 ::: horm,phsu,strd;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00095001.v1 ::: phs000280.v1.p1 ::: pht001346.v1 ::: ARIC_CARE_MSRV1C1 ::: MSRA03 ::: GET MEDICATIONS INFO LATER?       Q3 ::: encoded ::: NONE ::: NONE ::: NONE ::: get medications info later  q3 ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0013227;C0802604;C2598133 ::: phsu;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00062468.v2 ::: phs000128.v3.p3 ::: pht000534.v2 ::: simphen135 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00095158.v1 ::: phs000280.v1.p1 ::: pht001347.v1 ::: ARIC_CARE_MSRV2C1 ::: MSRAHF8 ::: MEDICATION CODE (AHF CODE) - Q11B ::: string ::: NONE ::: NONE ::: NONE ::: medication code  ahf code  q11 b ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;factor viii ::: C0013227;C0015506 ::: phsu;aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00027677.v1 ::: phs000086.v2.p1 ::: pht000231.v1 ::: DCCT_ms5exprt ::: EXERCS28 ::: Typical level of exercise: quarterly visit 28 ::: byte ::: NONE ::: NONE ::: NONE ::: typical level of exercise  quarterly visit 28 ::: NULL ::: NULL ::: NULL ::: NULL ::: level;exercise;exercise pain management;health care visit ::: C2946261;C0015259;C1522704;C1512346 ::: phsu;dora;topp;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Daily or Recreational Activity
phv00092509.v1 ::: phs000280.v1.p1 ::: pht001300.v1 ::: ARIC_CARE_DENTAL_JUNE_2009 ::: NTEETH ::: Number of Teeth (Sound, D&F, Crown, RFs) ::: integer ::: NONE ::: 1 ::: 32 ::: number of teeth  sound, d&f, crown, relapse-free survival ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;hair whorl;recurrent disease ::: C0016327;C1841697;C0277556 ::: inch,phsu;fndg;dsyn ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00084534.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: agatu21c ::: SCAN 2: AGATSTON CALCIUM SCORE, UNADJUSTED ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: scan 2  agatston calcium score, unadjusted ::: NULL ::: NULL ::: NULL ::: NULL ::: radionuclide imaging;calcium;scanning;related to cancer ::: C0034606;C0006675;C0441633;C2826292 ::: diap;bacs,elii,phsu;diap;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure
phv00105422.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: INFLAT14 ::: MAXIMUM INFLATION LEVEL ::: integer ::: NONE ::: 120 ::: 280 ::: maximum inflation level ::: NULL ::: NULL ::: NULL ::: NULL ::: total lung capacity;level ::: C0040509;C2946261 ::: fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00032648.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL33A00 ::: Blood glucose profile 8 - mg/dl (quarterly visit 00) ::: int ::: MG/DL ::: NONE ::: NONE ::: blood glucose profile 8 magnesium distolingual  quarterly visit 00 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;profile (lab procedure);plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C1979963;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00011779.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I1620 ::: C7. Now I am going to ask you to perform some quick tasks. Record total score. MAXIMUM SCORE=35; SUBJECT SCORE. (Participants with European ancestry). DIGS2 ::: NONE ::: Subject score ::: NONE ::: NONE ::: c7  now i am going to ask you to perform some quick tasks  record total score  maximum score=35  subject score   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: perform ::: C2947996 ::: phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00073716.v2 ::: phs000007.v18.p7 ::: pht000820.v3 ::: adma1_6s ::: ADMA ::: Asymmetric Dimethyl Arginine ::: decimal ::: umol/L ::: 0.136 ::: 1.37 ::: asymmetric dimethyl arginine ::: NULL ::: NULL ::: NULL ::: NULL ::: n,n-dimethylarginine ::: C0067385 ::: aapp,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00053417.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V0162_25 ::: B6 Medication (row 25), (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: b6 medication  row 25 ,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: pharmaceutical preparations;diagnosis;genetic study ::: C0013227;C0011900;C2827447 ::: phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00059446.v2 ::: phs000128.v3.p3 ::: pht000440.v2 ::: simphen041 ::: chol1 ::: Cranial Hydroencephalic oleo level v1 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v1 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v1 stage;level ::: C0982301;C0457422;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00100051.v1 ::: phs000287.v2.p1 ::: pht001451.v1 ::: BASE2 ::: GLU244 ::: 2 HR GLUCOSE (mg/dl) ::: integer ::: NONE ::: 38 ::: 691 ::: 2 heart rate glucose  magnesium distolingual ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement ::: C0017725;C0202042 ::: bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Clinical Attributes
phv00102833.v1 ::: phs000287.v2.p1 ::: pht001475.v1 ::: YR11 ::: STPMED59 ::: STOP ANY MEDICATION IN PAST MONTH ::: encoded ::: NONE ::: NONE ::: NONE ::: stop any medication in past month ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00122908.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: ACETAMIN ::: Meds: Acetaminophen ::: encoded ::: NONE ::: NONE ::: NONE ::: meds  acetaminophen ::: NULL ::: NULL ::: NULL ::: NULL ::: acetaminophen ::: C0000970 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00106166.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: HFIBF58 ::: HIGH FIBER ::: encoded ::: NONE ::: NONE ::: NONE ::: high fiber ::: NULL ::: NULL ::: NULL ::: NULL ::: dietary fiber;fiber ::: C0012173;C0225326 ::: food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00158213.v1 ::: phs000007.v18.p7 ::: pht002153.v1 ::: ffreq0_22s ::: IODINE ::: FFQ: TAKE IODINE SUPPLEMENT ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  take iodine supplement ::: NULL ::: NULL ::: NULL ::: NULL ::: food;dietary supplements;iodine;iodine, homeopathic preparation ::: C0016452;C0242295;C0021968;C0885449 ::: food;food;elii,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00162631.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: FFD107 ::: DERIVED FIELD:COLA ::: decimal, encoded ::: servings/week ::: 0 ::: 31.5 ::: derived field cola ::: NULL ::: NULL ::: NULL ::: NULL ::: cola flavor;cola ::: C1337205;C1623185 ::: food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00085385.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: prgstn1c ::: PROGESTINS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: progestins ::: NULL ::: NULL ::: NULL ::: NULL ::: progestins ::: C0033306 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00095224.v1 ::: phs000280.v1.p1 ::: pht001348.v1 ::: ARIC_CARE_MSRV3C1 ::: MSCM04B ::: MEDICATION CODE NO. -- REPLACES Q04B ::: string ::: NONE ::: NONE ::: NONE ::: medication code no  replaces q04 b ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00077852.v3 ::: phs000200.v8.p2 ::: pht000992.v3 ::: f145_rel1 ::: EPLDOSE_5 ::: Estrogen pill dose per day ::: encoded value ::: NONE ::: NONE ::: NONE ::: estrogen pill dose per day ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;dose number:number:point in time:^patient:quantitative ::: C0014939;C1114758 ::: horm,phsu,strd;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00012162.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I4890 ::: F35. Did this episode follow increased use of alcohol? IF YES: specify. MOST SEVERE EPISODE. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: f35   did this episode follow increased use of alcohol  if yes  specify  most severe episode   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Drinking History
phv00013622.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I21090 ::: K40b. Have there been times when you did things that other people thought were socially or sexually inappropriate, disorganized or objectionable? For example being too aggressive or doing things that did not make sense? Alcohol. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: k40 b  have there been times when you did things that other people thought were socially or genderually inappropriate, disorganized or objectionable  for example being too aggressive or doing things that did not make sense  alcohol   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: thinking, function;aggressive behavior;alcohols;alcohol measurement ::: C0039869;C0001807;C0001975;C0202304 ::: menp;mobd;orch,phsu;lbpr ::: persons;participant ::: C0027361;C0679646 ::: popg;popg ::: Demographics;Medication Patient;Lab Tests Patient;Mental or Emotional Finding;Drinking History
phv00077525.v3 ::: phs000200.v8.p2 ::: pht000990.v3 ::: f143_rel1 ::: ADDOLIVE_3 ::: Olive oil added after cooking ::: encoded value ::: NONE ::: NONE ::: NONE ::: olive oil added after cooking ::: NULL ::: NULL ::: NULL ::: NULL ::: olive oil;cooking (activity) ::: C0069449;C0335326 ::: lipd,phsu;dora ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Daily or Recreational Activity
phv00062077.v2 ::: phs000128.v3.p3 ::: pht000522.v2 ::: simphen123 ::: chol2 ::: Cranial Hydroencephalic oleo level v2 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v2 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v2 stage;level ::: C0982301;C0457423;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00123789.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: NOAMBAIR ::: Nitric Oxide: Ambient Air ::: decimal ::: NONE ::: 0 ::: 742 ::: nitric oxide  ambient air ::: NULL ::: NULL ::: NULL ::: NULL ::: nitric oxide ::: C0028128 ::: bacs,inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00004095.v1 ::: phs000007.v18.p7 ::: pht000022.v4 ::: ex0_20s ::: FM235 ::: BRAND OF CIGARETTE ::: NONE ::: NONE ::: NONE ::: NONE ::: brand of cigarette ::: NULL ::: NULL ::: NULL ::: NULL ::: 3-bromoacetoxyandrostan-17-one ::: C0645690 ::: phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History
phv00013542.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I12280 ::: K27. Have you ever experienced hearing your thoughts repeated or echoed? Alcohol. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: k27   have you ever experienced hearing your thoughts repeated or echoed  alcohol   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: practice experience;experience;hearing;hearing examination finding;thinking, function;echo protocol;alcohols;alcohol measurement ::: C0237607;C0596545;C0018767;C1455844;C0039869;C0058928;C0001975;C0202304 ::: menp;menp;phsf;fndg;menp;topp;orch,phsu;lbpr ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Mental or Emotional Finding;Drinking History;Therapeutic or Preventive Procedure
phv00033308.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL33A29 ::: Blood glucose profile 8 - mg/dl (quarterly visit 29) ::: int ::: MG/DL ::: NONE ::: NONE ::: blood glucose profile 8 magnesium distolingual  quarterly visit 29 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;profile (lab procedure);plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C1979963;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00029924.v1 ::: phs000086.v2.p1 ::: pht000245.v1 ::: DCCT_f021cmb6 ::: BAG4FII3 ::: Mild hypoglycemia - usual reason: increased exercise level ::: byte ::: NONE ::: NONE ::: NONE ::: mild hypoglycemia usual reason  increased exercise level ::: NULL ::: NULL ::: NULL ::: NULL ::: hypoglycemia;exercise;level;exercise pain management ::: C0020615;C0015259;C2946261;C1522704 ::: dsyn;dora;phsu;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Daily or Recreational Activity
phv00125506.v1 ::: phs000286.v3.p1 ::: pht001936.v1 ::: AFUI16 ::: AFUI2 ::: FINAL STATUS (C,F,R,D,U)          Q2 ::: encoded ::: NONE ::: NONE ::: NONE ::: final status  c,f,r,d,u  q2 ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;r prime ::: C0016327;C2603358 ::: inch,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007304.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT265 ::: CARDIOVASCULAR MEDICATIONS: PERIPHERAL VASODILATORS (HYDRALAZINE, MINOXIDIL, ETC) ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications  peripheral vasodilators  hydralazine, minoxidil, etc ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;peripheral vasodilators;hydralazine;minoxidil ::: C0007220;C0724804;C0020223;C0026196 ::: phsu;phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00099370.v1 ::: phs000287.v2.p1 ::: pht001450.v1 ::: BASE1 ::: MAXINF15 ::: MAXIMAL INFLATION LEVEL ::: integer ::: NONE ::: 120 ::: 260 ::: maximal inflation level ::: NULL ::: NULL ::: NULL ::: NULL ::: total lung capacity;level ::: C0040509;C2946261 ::: fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00142682.v3 ::: phs000209.v10.p2 ::: pht002100.v3 ::: MESA_AncilMesaLungExam1CT ::: DiscordO ::: TWO ORIGINAL RECORDS FOR THIS ID HAVE DIFFERENT VX SIZES OR HAVE DIFFERING NUMBERS OF BREATH ARTIFACTS ::: Numeric ::: NONE ::: NONE ::: NONE ::: two original records for this identification have different vx sizes or have differing numbers of breath artifacts ::: NULL ::: NULL ::: NULL ::: NULL ::: identification (psychology);mammographic difference in size (finding);methylphosphonothioic acid s-(2-(bis(1-methylethyl)amino)ethyl) o-ethyl ester;venous stage vx ::: C0020792;C1268722;C0078433;C0441905 ::: menp;fndg;orch,phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Medical History
phv00056994.v1 ::: phs000007.v18.p7 ::: pht000397.v2 ::: sleep1_2003s ::: THRY2 ::: Thyroid agents ::: NONE ::: NONE ::: NONE ::: NONE ::: thyroid agents ::: NULL ::: NULL ::: NULL ::: NULL ::: thyroid preparation ::: C0279175 ::: horm,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007288.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT249 ::: CALCIUM CHANNEL BLOCKER GROUP ::: NONE ::: NONE ::: NONE ::: NONE ::: calcium channel blocker group ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium channel blockers ::: C0006684 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00150441.v2 ::: phs000209.v10.p2 ::: pht002107.v3 ::: MESA_Exam1DietNutrients ::: sf100n1c ::: NUTRIENTS: SATURATED FATTY ACIDS 10:0 CAPRIC ACID ::: NUMERIC ::: g ::: NONE ::: NONE ::: nutrients  saturated fatty acids 10 0 capric acid ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;decanoic acid ::: C0678695;C0057239 ::: food;lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00119291.v2 ::: phs000285.v2.p2 ::: pht001791.v2 ::: E1F48 ::: E48THERN ::: NUMBER TAKEN (THERAP/THERAGRAN TYPE). Q 4 ::: encoded ::: NONE ::: NONE ::: NONE ::: number taken  therap theragran type   q 4 ::: NULL ::: NULL ::: NULL ::: NULL ::: theragran ::: C0723708 ::: orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00172560.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: Q_OTH_FISH ::: FFQ: Other fish, e.g., cod, haddock, halibut ::: encoded ::: 3 - 5 oz. ::: NONE ::: NONE ::: food frequency questionnaire  other fish, e gram , cod, haddock, halibut ::: NULL ::: NULL ::: NULL ::: NULL ::: food;others;fish (food);haddock - dietary;haddock allergenic extract ::: C0016452;C1955473;C2349190;C1262985;C2740627 ::: food;fndg;food;food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00168306.v1 ::: phs000343.v2.p1 ::: pht002715.v1 ::: alldti ::: DSF1 ::: Prior to your recent stroke, did you ever regularly take multi-vitamins?  (DSF)  Aside from the VISP vitamin, have you regularly taken multi-vitamins during the past year? (FDS) ::: encoded string ::: NONE ::: NONE ::: NONE ::: prior to your recent stroke, did you ever regularly take multi vitamins   dsf  aside from the visp vitamin, have you regularly taken multi vitamins during the past year   fds ::: NULL ::: NULL ::: NULL ::: NULL ::: cerebrovascular accident;vitamins ::: C0038454;C0042890 ::: dsyn;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00004245.v1 ::: phs000007.v18.p7 ::: pht000022.v4 ::: ex0_20s ::: FM204 ::: DAYS PER MONTH TAKING PREMARIN ::: NONE ::: DAYS ::: NONE ::: NONE ::: days per month taking premarin ::: NULL ::: NULL ::: NULL ::: NULL ::: premarin ::: C0699710 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126541.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: ravg_aspt ::: RECALL: aspartame ::: decimal ::: NONE ::: 0 ::: 543.54 ::: recall  aspartame ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;aspartame;recall:-:point in time:^patient:- ::: C0034770;C0003999;C2361119 ::: menp;aapp,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding
phv00018518.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1490 ::: J53e.  Other drugs.  (Participants with European ancestry). DIGS4 ::: NONE ::: Year ::: NONE ::: NONE ::: j53 e  other drugs   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: others;pharmaceutical preparations;diagnosis;genetic study ::: C1955473;C0013227;C0011900;C2827447 ::: fndg;phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00001885.v1 ::: phs000007.v18.p7 ::: pht000014.v3 ::: ex0_12s ::: FE157 ::: INTERIM HISTORY OF ARTHRITIS: PAIN OR STIFFNESS IN HIPS OR THIGHS ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of arthritis  pain or stiffness in hips or thighs ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;arthritis pain (pharmacologic preparation);arthritis pain;stiffness ::: C0262926;C2004062;C0718667;C1999226;C0427008 ::: fndg;fndg;orch,phsu;sosy;sosy ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Clinical Attributes;Medical History
phv00053644.v1 ::: phs000017.v3.p1 ::: pht000368.v1 ::: AA_DiagnosisPage1 ::: V113 ::: Stimulant Abuse/Depend Age last dep. (African American participants). DIGS4. Page 1 ::: NONE ::: Years old ::: NONE ::: NONE ::: stimulant abuse depend age last dep   african american participants   diagnostic interview for genetic studies  page 1 ::: Age;Race ::: age;african american ::: C0001779;C0085756 ::: orga;popg ::: stimulant abuse;1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride;diagnosis;genetic study ::: C1456332;C0057472;C0011900;C2827447 ::: mobd;orch,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Substance Use History;Research Attributes;Medical History
phv00012741.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I10050 ::: J28. Did using (drug) cause you to have any other physical health problems (other than withdrawal)? B STIM. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: j28   did using  drug  cause you to have any other physical health problems  other than withdrawal   b stim   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;pharmacologic substance;physical health problems;withdrawal (dysfunction) ::: C0013227;C1254351;C1446390;C2825032 ::: phsu;phsu;fndg;mobd ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00066806.v2 ::: phs000007.v18.p7 ::: pht000675.v3 ::: avmv1_7s ::: SCORE2 ::: MITRAL VALVE CALCIUM SCORE - FIRST SCAN.  MULTIPLE OBSERVERS MAY HAVE COMPLETED THIS SCORE. ::: NONE ::: AGATSTON ::: NONE ::: NONE ::: mitral valve calcium score first scan  multiple observers may have completed this score ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium;radionuclide imaging;scanning;related to cancer ::: C0006675;C0034606;C0441633;C2826292 ::: bacs,elii,phsu;diap;diap;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure
phv00114475.v2 ::: phs000285.v2.p2 ::: pht001613.v2 ::: B2F09MHM ::: B09HMNUM ::: MEDICATION NUMBER. Q 4.03A ::: integer ::: NONE ::: NONE ::: NONE ::: medication number  q4 03 a ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00004981.v1 ::: phs000007.v18.p7 ::: pht000024.v4 ::: ex0_22s ::: FO128 ::: MEDICATION USE: INSULIN ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use  insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: medication use;insulin;recombinant insulin;pharmaceutical preparations;insulin used ::: C0240320;C0021641;C1533581;C0013227;C0240016 ::: fndg;aapp,horm,phsu;aapp,horm,phsu;phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00056983.v1 ::: phs000007.v18.p7 ::: pht000397.v2 ::: sleep1_2003s ::: PRGSTN2 ::: Progestins ::: NONE ::: NONE ::: NONE ::: NONE ::: progestins ::: NULL ::: NULL ::: NULL ::: NULL ::: progestins ::: C0033306 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00119328.v2 ::: phs000285.v2.p2 ::: pht001791.v2 ::: E1F48 ::: E48ZINCF ::: FREQ (DAY/WEEK/MONTH) TAKEN (ZINC). Q 4 ::: encoded ::: NONE ::: NONE ::: NONE ::: freq  day week month  taken  zinc   q 4 ::: NULL ::: NULL ::: NULL ::: NULL ::: zinc ::: C0043481 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00093899.v1 ::: phs000280.v1.p1 ::: pht001320.v1 ::: ARIC_CARE_ESMCV4C1 ::: ESMC145 ::: COND 20- LEAD 3, EV5 ::: encoded ::: NONE ::: NONE ::: NONE ::: cond 20 lead 3, ev5 ::: NULL ::: NULL ::: NULL ::: NULL ::: hutterite cerebroosteonephrodysplasia syndrome;lead;plumbum metallicum, homeopathic preparation ::: C1856054;C0023175;C1442948 ::: dsyn;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Medical History
phv00000766.v1 ::: phs000007.v18.p7 ::: pht000009.v2 ::: ex0_7s ::: MF314 ::: BLOOD ANALYSIS: TOTAL IODINE, EXAM 5 ::: NONE ::: TENTHS OF A MICROGRAM/100ML ::: NONE ::: NONE ::: blood analysis  total iodine, exam 5 ::: NULL ::: NULL ::: NULL ::: NULL ::: analysis of substances;iodine;iodine, homeopathic preparation;analysis;medical examination ::: C0002778;C0021968;C0885449;C0936012;C0582103 ::: lbpr;elii,phsu;phsu;resa;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Healthcare Activity Finding;Research Attributes
phv00078016.v3 ::: phs000200.v8.p2 ::: pht000993.v3 ::: f146_rel1 ::: EPCH_6 ::: Did you use an estrogen patch? ::: encoded value ::: NONE ::: NONE ::: NONE ::: did you use an estrogen patch ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;plaque (lesion) ::: C0014939;C0332461 ::: horm,phsu,strd;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00001251.v1 ::: phs000007.v18.p7 ::: pht000011.v3 ::: ex0_9s ::: FB74 ::: INTERIM HISTORY OF MEDICINE:  ANTIBACTERIAL ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of medicine  antibacterial ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations ::: C0262926;C2004062;C0013227 ::: fndg;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00073467.v2 ::: phs000180.v2.p2 ::: pht000789.v2 ::: T1DGC_Subject_Phenotypes ::: mody ::: Mature Onset Diabetes of the Young (MODY) status - a monogenic disorder ::: encoded value ::: NONE ::: NONE ::: NONE ::: mature started diabetes of the young  maturity-onset diabetes of youth  status a monogenic disorder ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;diabetes mellitus;diabetes mellitus, non-insulin-dependent;monogen;disease ::: C0011847;C0011849;C0011860;C1435216;C0012634 ::: dsyn;dsyn;dsyn;aapp,phsu;dsyn ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00006929.v1 ::: phs000007.v18.p7 ::: pht000028.v3 ::: ex0_26s ::: FS320 ::: FEMALE HORMONE REPLACEMENT: DOSE/DAY OF PROGESTIN ::: NONE ::: NONE ::: NONE ::: NONE ::: female hormone replacement  dose day of progestin ::: NULL ::: NULL ::: NULL ::: NULL ::: female;hormone replacement therapy;dose number:number:point in time:^patient:quantitative;progestins ::: C0015780;C0282402;C1114758;C0033306 ::: fndg;topp;clna;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00018414.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1386 ::: J39. Opiates.  (Participants with European ancestry). DIGS4 ::: NONE ::: Years old ::: NONE ::: NONE ::: j39   opiates   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: opioid abuse;opiate assay;opiates;diagnosis;genetic study ::: C0029095;C0242401;C0376196;C0011900;C2827447 ::: mobd;lbpr;hops,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00031364.v1 ::: phs000086.v2.p1 ::: pht000263.v1 ::: DCCT_f0217 ::: BADC1A ::: Diabetes control - symptoms of hyperglycemia: during last week - how many nights did patient wake up once to urinate ::: byte ::: NIGHTLY WAKE UPS ::: NONE ::: NONE ::: diabetes control symptoms of hyperglycemia  during last week how many nights did patient wake up once to urinate ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;symptom control (regime/therapy);diabetes mellitus;hyperglycemia;wake ups ::: C0011847;C1274136;C0011849;C0020456;C1170730 ::: dsyn;topp;dsyn;dsyn;orch,phsu ::: patients ::: C0030705 ::: podg ::: Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00049877.v1 ::: phs000086.v2.p1 ::: pht000331.v1 ::: EDIC_f0303 ::: COCYSTRE ::: F. Ophtalmoscopic examination: cystoid changes present - right eye ::: byte ::: NONE ::: NONE ::: NONE ::: f  ophtalmoscopic examination  cystoid changes present right eye ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;physical examination ::: C0016327;C0031809 ::: inch,phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00108248.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: DLTIR06 ::: Immediate-release diltiazem ::: encoded ::: NONE ::: NONE ::: NONE ::: immediate release diltiazem ::: NULL ::: NULL ::: NULL ::: NULL ::: diltiazem ::: C0012373 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00084617.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: mc1v61 ::: MINNESOTA CODE 1 SCORE: V6 LEAD ::: STRING ::: NONE ::: NONE ::: NONE ::: minnesota code 1 score  v6 lead ::: NULL ::: NULL ::: NULL ::: NULL ::: lead;plumbum metallicum, homeopathic preparation ::: C0023175;C1442948 ::: elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00052801.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V1441 ::: J48 Sedatives, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j48  sedatives,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: sedatives;diagnosis;genetic study ::: C0036557;C0011900;C2827447 ::: phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00017420.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V392 ::: E6. Symbyax. Other drugs. (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  symbyax  other drugs   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: symbyax;others;pharmaceutical preparations;diagnosis;genetic study ::: C1330549;C1955473;C0013227;C0011900;C2827447 ::: orch,phsu;fndg;phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00102090.v1 ::: phs000287.v2.p1 ::: pht001474.v1 ::: YR10 ::: TAKMED06 ::: TAKE ANY MEDICATIONS ::: encoded ::: NONE ::: NONE ::: NONE ::: take any medications ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0013227;C0802604;C2598133 ::: phsu;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00019156.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V2128 ::: Q11.  Use of pills, drugs.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: q11   use of pills, drugs   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;diagnosis;genetic study ::: C0013227;C0011900;C2827447 ::: phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00093567.v1 ::: phs000280.v1.p1 ::: pht001318.v1 ::: ARIC_CARE_ESMAV2C1 ::: ESMA113 ::: COND 15- LEAD 3, EV4 ::: encoded ::: NONE ::: NONE ::: NONE ::: cond 15 lead 3, ev4 ::: NULL ::: NULL ::: NULL ::: NULL ::: hutterite cerebroosteonephrodysplasia syndrome;lead;plumbum metallicum, homeopathic preparation ::: C1856054;C0023175;C1442948 ::: dsyn;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Medical History
phv00069148.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: FFD136 ::: DERIVED FIELD: SERVINGS PER WEEK - WHEAT GERM ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  servings per week wheat germ ::: NULL ::: NULL ::: NULL ::: NULL ::: wheatgerm;wheat germ preparation ::: C0452688;C0982459 ::: food;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00086003.v2 ::: phs000209.v10.p2 ::: pht001118.v5 ::: MESA_Exam2Main ::: asa2c ::: ASPIRIN FROM 280804 (ANTI-INFLAM AGENTS) ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: aspirin from 280804   anti inflam agents ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin;anti-anxiety agents ::: C0004057;C0040616 ::: orch,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00079451.v3 ::: phs000200.v8.p2 ::: pht001011.v3 ::: f43_rel1 ::: DESTIME ::: DES Duration (years) ::: decimal ::: years ::: 0.08333 ::: 32 ::: diethylstilbestrol duration  years ::: NULL ::: NULL ::: NULL ::: NULL ::: diethylstilbestrol;duration ::: C0012203;C2926735 ::: horm,orch,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00157050.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: nut_es2mg ::: Derived field: Nutrient value - Vitamin E atoco version from food fortification only synthetic ::: decimal, encoded ::: mg ::: 0 ::: 127.29 ::: derived field  nutrient value vitamin e atoco version from food fortification only synthetic ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;vitamin e;food ::: C0678695;C0042874;C0016452 ::: food;lipd,phsu,vita;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00112949.v2 ::: phs000285.v2.p2 ::: pht001567.v2 ::: A4F06Q18 ::: A06H2O24 ::: AMOUNT OF WATER CONSUMED PER 24 HOURS [OZ]. Q 16 ::: integer ::: NONE ::: 0 ::: 320 ::: amount of water consumed per 24 hours  oz   q 16 ::: NULL ::: NULL ::: NULL ::: NULL ::: water ::: C0043047 ::: inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00053804.v2 ::: phs000001.v3.p1 ::: pht000372.v2 ::: dietary ::: DT_ALC ::: ALCOHOL (G) (ALL PARTICIPANTS) ::: decimal ::: grams ::: NONE ::: NONE ::: alcohol  gram   all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: participant ::: C0679646 ::: popg ::: Medication Patient;Lab Tests Patient;Drinking History
phv00166798.v2 ::: phs000007.v18.p7 ::: pht002566.v2 ::: l_mtbli2_ex05_1_0660s ::: valine ::: Valine ::: decimal, encoded ::: NONE ::: 0.4977 ::: 1.8996 ::: valine ::: NULL ::: NULL ::: NULL ::: NULL ::: valine ::: C0042285 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00015111.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: OTH_ANTIMANIC_AGT_1_SPEC ::: E6. Antimaniac agents Oth Antimanic Agt 1 Spec, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  antimaniac agents oth antimanic agt 1 spec,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: antimanic agents;pharmacologic substance ::: C0242911;C1254351 ::: phsu;phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00159691.v2 ::: phs000179.v2.p2 ::: pht002239.v2 ::: COPDGene_Subject_Phenotypes ::: LtdLvlStop100 ::: Have to stop for breath after 100 yards on level ground ::: encoded value ::: NONE ::: NONE ::: NONE ::: have to stop for breath after 100  yards on level ground ::: NULL ::: NULL ::: NULL ::: NULL ::: level;removal by grinding ::: C2946261;C0185051 ::: phsu;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00095109.v1 ::: phs000280.v1.p1 ::: pht001347.v1 ::: ARIC_CARE_MSRV2C1 ::: MSRB14D ::: TAKE MEDICATION K IN PAST 24 HRS? Q14D ::: encoded ::: NONE ::: NONE ::: NONE ::: take medication k in past 24 hours  q14 d ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00044911.v1 ::: phs000125.v1.p1 ::: pht000320.v1 ::: COGA_SSAGA ::: AL7A_2 ::: While drinking has one or two drinks of alcohol ever caused you to - break out into hives?  -  NOTE: The data values for this variable represent harmonized values; they were derived from information obtained with Sections A and E of the SSAGAI and SSAGAII questionnaires. ::: integer ::: NONE ::: NONE ::: NONE ::: while drinking has one or two drinks of alcohol ever caused you to break out into hives  note  the data values for this variable represent harmonized values  they were derived from information obtained with sections a and e of the ssagai and ssagaii questionnaires ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohol consumption;drinking function;drink (dietary substance);alcohols;alcohol measurement;urticaria;division (surgical procedure) ::: C0001948;C0684271;C0452428;C0001975;C0202304;C0042109;C1293097 ::: inbe;orgf;food;orch,phsu;lbpr;dsyn;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History;Eating or Nutritional Finding;Therapeutic or Preventive Procedure
phv00128516.v1 ::: phs000286.v3.p1 ::: pht001977.v1 ::: TOBA ::: TOBA20 ::: 20: Currently smoke a pipe? ::: encoded ::: NONE ::: NONE ::: NONE ::: 20  currently smoke a pipe ::: NULL ::: NULL ::: NULL ::: NULL ::: smoke;tobacco smoke;piperine extract (standardized) ::: C0037366;C0439994;C1709545 ::: eehu,hops;hops;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History;Substance Use History
phv00126239.v1 ::: phs000286.v3.p1 ::: pht001951.v1 ::: DITA ::: DITA78 ::: PUFA 18:3 (linolenic acid) (g) ::: decimal ::: g ::: 0 ::: 11.4299 ::: polyunsaturated fatty acid 18 3  linolenic acid   gram ::: NULL ::: NULL ::: NULL ::: NULL ::: linolenic acid ::: C0125903 ::: bacs,lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00079522.v3 ::: phs000200.v8.p2 ::: pht001013.v3 ::: f45_rel1 ::: F45POTAS ::: Supplemental Potassium, mg ::: decimal ::: mg ::: 0 ::: 257.143 ::: supplemental potassium, magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: potassium supplement ::: C0304475 ::: inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00027717.v1 ::: phs000086.v2.p1 ::: pht000231.v1 ::: DCCT_ms5exprt ::: PIPE_32 ::: Pipe or cigar smoker: quarterly visit 32 ::: byte ::: NONE ::: NONE ::: NONE ::: pipe or cigar smoker  quarterly visit 32 ::: NULL ::: NULL ::: NULL ::: NULL ::: piperine extract (standardized);cigar smoker;health care visit ::: C1709545;C0337666;C1512346 ::: phsu;inbe;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History
phv00107435.v1 ::: phs000287.v2.p1 ::: pht001491.v1 ::: YR5OLD ::: WARF06 ::: Oral anticoagulants ::: encoded ::: NONE ::: NONE ::: NONE ::: oral anticoagulants ::: NULL ::: NULL ::: NULL ::: NULL ::: anticoagulants, oral ::: C0354604 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00158308.v1 ::: phs000007.v18.p7 ::: pht002153.v1 ::: ffreq0_22s ::: MASH_POT ::: FFQ: POTATOES, BAKED, BOILED, MASHED (1 CUP) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  potatoes, baked, boiled, mashed  1 cup ::: NULL ::: NULL ::: NULL ::: NULL ::: food;potato;solanum tuberosum, potato, homeopathic preparation;furuncle ::: C0016452;C0032846;C0939910;C0242301 ::: food;food;phsu;dsyn ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Eating or Nutritional Finding
phv00155322.v2 ::: phs000200.v8.p2 ::: pht002118.v2 ::: ecg_rel2 ::: QRSA_V2 ::: QRS balance (maximum of R or R') - (maximum of QAMP, SAMP, or S'AMP), lead qrsa_v2 ::: integer ::: NONE ::: -5791 ::: 5093 ::: qrs balance  maximum of r or r    maximum of qamp, samp, or s adenosine monophosphate , lead qrsa_v2 ::: NULL ::: NULL ::: NULL ::: NULL ::: equilibrium;ability to balance;r prime;adenosine monophosphate ::: C0014653;C0560184;C2603358;C0001465 ::: orgf;fndg;clna;bacs,nnon,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure;Medical History
phv00095443.v1 ::: phs000280.v1.p1 ::: pht001351.v1 ::: ARIC_CARE_NUT2V3C1 ::: CAFF ::: Caffeine (mg) ::: decimal ::: NONE ::: 0 ::: 1299.9 ::: caffeine  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: caffeine ::: C0006644 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00113507.v2 ::: phs000285.v2.p2 ::: pht001577.v2 ::: A4F14 ::: A14CMFRT ::: HOW OFTEN PTT WISHES FOR COMFORTING? Q 7 ::: encoded ::: NONE ::: NONE ::: NONE ::: how often ptt wishes for comforting  q 7 ::: NULL ::: NULL ::: NULL ::: NULL ::: activated partial thromboplastin time measurement;comfort brand of hydroxyethyl cellulose ::: C0030605;C1310585 ::: lbpr;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00084618.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: mc4avl1 ::: MINNESOTA CODE 4 SCORE: AVL LEAD ::: STRING ::: NONE ::: NONE ::: NONE ::: minnesota code 4 score  avl lead ::: NULL ::: NULL ::: NULL ::: NULL ::: lead;plumbum metallicum, homeopathic preparation ::: C0023175;C1442948 ::: elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00089117.v1 ::: phs000222.v1.p1 ::: pht001172.v1 ::: Predict_HD_suf ::: suf13b ::: Club drugs/last 6 months ::: encoded value ::: NONE ::: NONE ::: NONE ::: club drugs last 6 months ::: NULL ::: NULL ::: NULL ::: NULL ::: club drugs ::: C1456651 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00123181.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: ACETAMNO ::: 74 On average, how many tablets acetaminophen taken ::: encoded ::: NONE ::: NONE ::: NONE ::: 74 on average, how many tablets acetaminophen taken ::: NULL ::: NULL ::: NULL ::: NULL ::: acetaminophen ::: C0000970 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00010187.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G044 ::: NON-CARDIOVASCULAR MEDICATIONS: ANTI-CHOLESTEROL DRUGS (STATINS - E.G. LOVASTATIN, PRAVASTATIN) ::: NONE ::: NONE ::: NONE ::: NONE ::: non cardiovascular medications  anti cholesterol drugs  statins e gram  lovastatin, pravastatin ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;pharmaceutical preparations;serum total cholesterol measurement;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;hydroxymethylglutaryl-coa reductase inhibitors;lovastatin;pravastatin ::: C0007220;C0013227;C1445957;C0802604;C2598133;C0360714;C0024027;C0085542 ::: phsu;phsu;lbpr;clna;clna;orch,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00078949.v3 ::: phs000200.v8.p2 ::: pht001005.v3 ::: f37_rel1 ::: WRKDIFFP ::: Phys/difficulty perform work ::: encoded value ::: NONE ::: NONE ::: NONE ::: phys difficulty perform work ::: NULL ::: NULL ::: NULL ::: NULL ::: difficulty;perform ::: C1299586;C2947996 ::: fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049472.v1 ::: phs000086.v2.p1 ::: pht000328.v1 ::: EDIC_f0043 ::: ODB5STP ::: B5. Current medication:  if the patient uses no other prescription or non-prescription medication check here and STOP. ::: byte ::: NONE ::: NONE ::: NONE ::: b5  current medication  if the patient uses no other prescription or non prescription medication check here and stop ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;used by;prescription procedure;pharmaceutical preparations ::: C0746467;C1273517;C0033080;C0013227 ::: fndg;fndg;hlca;phsu ::: patients ::: C0030705 ::: podg ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00015058.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: RESTORIL ::: E6. Benzodiazepines Restoril, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  benzodiazepines restoril,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: benzodiazepines;restoril ::: C0005064;C0723045 ::: orch,phsu;orch,phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00169349.v1 ::: phs000179.v2.p2 ::: pht002239.v2 ::: COPDGene_Subject_Phenotypes ::: EmphTreat ::: Emphysema: received medical treatment or used medications/inhaler ::: encoded value ::: NONE ::: NONE ::: NONE ::: emphysema  received medical treatment or used medications inhaler ::: NULL ::: NULL ::: NULL ::: NULL ::: pathological accumulation of air in tissues;pulmonary emphysema;therapeutic procedure;administration procedure;medication use ::: C0013990;C0034067;C0087111;C1533734;C0240320 ::: patf;dsyn;topp;topp;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00072134.v2 ::: phs000007.v18.p7 ::: pht000747.v3 ::: ex1_8s ::: H102 ::: ARE YOU TROUBLED BY SHORTNESS OF BREATH WHEN HURRYING ON LEVEL GROUND OR WALKING UP A SLIGHT HILL? ::: encoded ::: NONE ::: NONE ::: NONE ::: are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill ::: NULL ::: NULL ::: NULL ::: NULL ::: level;walking (activity) ::: C2946261;C0080331 ::: phsu;dora ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Daily or Recreational Activity
phv00161764.v1 ::: phs000007.v18.p7 ::: pht002234.v3 ::: l_mtbli1_ex05_1_0610s ::: tyrosine ::: Tyrosine ::: decimal, encoded ::: NONE ::: 0.6057 ::: 3.2416 ::: tyrosine ::: NULL ::: NULL ::: NULL ::: NULL ::: tyrosine ::: C0041485 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00027648.v1 ::: phs000086.v2.p1 ::: pht000231.v1 ::: DCCT_ms5exprt ::: DRINKS00 ::: Patient reports using alcohol: baseline ::: byte ::: NONE ::: NONE ::: NONE ::: patient reports using alcohol  baseline ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History
phv00168226.v1 ::: phs000343.v2.p1 ::: pht002715.v1 ::: alldti ::: DTI106 ::: How often do you consume Coke, Pepsi, other cola with sugar, or another carbonated beverage with sugar;  1 glass, bottle, can? ::: encoded string ::: NONE ::: NONE ::: NONE ::: how often do you consume coke, pepsi, other cola with sugar, or another carbonated beverage with sugar  1 glass, bottle, can ::: NULL ::: NULL ::: NULL ::: NULL ::: cocaine;cola flavor;cola;sugars;carbonated beverages ::: C0009170;C1337205;C1623185;C0242209;C0007025 ::: hops,orch,phsu;food;phsu;carb,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Eating or Nutritional Finding
phv00100538.v1 ::: phs000287.v2.p1 ::: pht001452.v1 ::: BASEBOTH ::: COX206 ::: Cox-2 inhibitors (NSAID agents); seperat ::: encoded ::: NONE ::: NONE ::: NONE ::: cox 2 inhibitors  nonsteroidal anti-inflammatory drug agents   seperat ::: NULL ::: NULL ::: NULL ::: NULL ::: cyclooxygenase 2 inhibitors;anti-inflammatory agents, non-steroidal;pharmaceutical preparations;pharmacologic substance ::: C1257954;C0003211;C0013227;C1254351 ::: orch,phsu;phsu;phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007352.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT313 ::: NONCARDIOVASCULAR MEDICATIONS: OSTEOPOROSIS MEDICATIONS ::: NONE ::: NONE ::: NONE ::: NONE ::: noncardiovascular medications  osteoporosis medications ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;osteoporosis;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0013227;C0029456;C0802604;C2598133 ::: phsu;dsyn;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00105863.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: F744 ::: FACTOR VII (%) ::: integer ::: NONE ::: 18 ::: 227 ::: factor vii  % ::: NULL ::: NULL ::: NULL ::: NULL ::: blood coagulation factor vii ::: C0015502 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00056974.v1 ::: phs000007.v18.p7 ::: pht000397.v2 ::: sleep1_2003s ::: NSAID2 ::: Non-steroidal anti-inflammatory agents, excluding aspirin ::: NONE ::: NONE ::: NONE ::: NONE ::: non steroidal anti inflammatory agents, excluding aspirin ::: NULL ::: NULL ::: NULL ::: NULL ::: anti-inflammatory agents, non-steroidal;aspirin ::: C0003211;C0004057 ::: phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00099365.v1 ::: phs000287.v2.p1 ::: pht001450.v1 ::: BASE1 ::: SYS0214 ::: ZERO LEVEL ::: integer ::: NONE ::: 2 ::: 34 ::: zero level ::: NULL ::: NULL ::: NULL ::: NULL ::: level ::: C2946261 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00086950.v2 ::: phs000209.v10.p2 ::: pht001120.v7 ::: MESA_Exam4Main ::: ccbir4c ::: IMMEDIATE-RELEASE CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: immediate release calcium channel blockers = nifir or type of medication or verir or type of mediation-dltir  immediate-release diltiazem ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium channel blockers;pharmaceutical preparations;diltiazem ::: C0006684;C0013227;C0012373 ::: phsu;phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00050038.v1 ::: phs000086.v2.p1 ::: pht000333.v1 ::: EDIC_f0423 ::: DBD4A ::: D4a. Treatment of clinical manifestation: given intravenous glucose treatment ::: byte ::: NONE ::: NONE ::: NONE ::: d4 a  treatment of clinical manifestation  given intravenous glucose treatment ::: NULL ::: NULL ::: NULL ::: NULL ::: therapeutic procedure;administration procedure;clinical treatment;parenteral form glucose ::: C0087111;C1533734;C1516635;C0357164 ::: topp;topp;topp;carb,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00030109.v1 ::: phs000086.v2.p1 ::: pht000248.v1 ::: DCCT_ms3exprt ::: RETPAT ::: Level of retinopathy (1 - 4) ::: byte ::: NONE ::: NONE ::: NONE ::: level of retinopathy  1 4 ::: NULL ::: NULL ::: NULL ::: NULL ::: level;retinal diseases;retinopathy adverse event ::: C2946261;C0035309;C1962966 ::: phsu;dsyn;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00004896.v1 ::: phs000007.v18.p7 ::: pht000023.v4 ::: ex0_21s ::: FN438 ::: ECG: R OR S>=20MM IN AV LEAD ::: NONE ::: NONE ::: NONE ::: NONE ::: electrocardiogram  r or s>=20mm in av lead ::: NULL ::: NULL ::: NULL ::: NULL ::: electrocardiogram;r prime;electrocardiography;lead;plumbum metallicum, homeopathic preparation ::: C0013798;C2603358;C1623258;C0023175;C1442948 ::: fndg;clna;diap;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Diagnostic Procedure
phv00020941.v4 ::: phs000007.v18.p7 ::: pht000074.v6 ::: ex3_1s ::: G3A086 ::: IF EVER SMOKED PIPES REGULARLY: WHEN YOU SMOKING A PIPE, DID YOU EVER STOP SMOKING FOR > 6 MONTHS? ::: NONE ::: NONE ::: NONE ::: NONE ::: if ever smoked pipes regularly  when you smoking a pipe, did you ever stop smoking for > 6 months ::: NULL ::: NULL ::: NULL ::: NULL ::: smoking pipe (history);smoking;tobacco smoking behavior;piperine extract (standardized) ::: C0240766;C0037369;C0453996;C1709545 ::: fndg;inbe;inbe;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History
phv00071067.v2 ::: phs000166.v2.p1 ::: pht000702.v2 ::: CARE_CData ::: pred_bursts_event1_month ::: Number of months from Baseline to first prednisone burst.  This is calculated by dividing the number of days between Baseline and the first prednisone burst by 30.25. ::: integer ::: month ::: 0 ::: 35.82 ::: number of months from baseline to first prednisone burst  this is calculated by dividing the number of days between baseline and the first prednisone burst by 30 25 ::: NULL ::: NULL ::: NULL ::: NULL ::: prednisone;calculated (procedure) ::: C0032952;C1443182 ::: horm,phsu,strd;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00046020.v1 ::: phs000017.v3.p1 ::: pht000323.v1 ::: DIGS2and3_Ped_Data ::: smrdcdx1 ::: Source of modified RDC BEFD CODE FOR BEFD1, (Participants with European ancestry). DIGS2 and 3 ::: Num ::: NONE ::: NONE ::: NONE ::: source of modified rdc befd code for befd1,  participants with european ancestry   digs2 and 3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: source;monorden;ring dermoid of cornea ::: C0449416;C0207800;C1867155 ::: fndg;orch,phsu;dsyn ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00087377.v1 ::: phs000209.v10.p2 ::: pht001121.v3 ::: MESA_FamilyExamMain ::: versrfc ::: SLOW-RELEASE VERAPAMIL ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: slow release verapamil ::: NULL ::: NULL ::: NULL ::: NULL ::: patient discharge;verapamil;discharge (release);release (procedure) ::: C0030685;C0042523;C0680255;C1963578 ::: hlca;orch,phsu;hlca;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Therapeutic or Preventive Procedure
phv00156518.v2 ::: phs000200.v8.p2 ::: pht002125.v2 ::: f60_nutr_rel1 ::: F60BIOCHN ::: Dietary Biochanin A (mg) ::: decimal ::: mg ::: 0 ::: 0.31913 ::: dietary biochanin a  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: biochanin a ::: C0053622 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00077725.v3 ::: phs000200.v8.p2 ::: pht000991.v3 ::: f144_rel1 ::: PRGSUP_4 ::: Natural/Progest suppositories ::: encoded value ::: NONE ::: NONE ::: NONE ::: natural progest suppositories ::: NULL ::: NULL ::: NULL ::: NULL ::: progesterone measurement;progest ::: C0373705;C0893455 ::: lbpr;phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00108483.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: INFLAT14 ::: MAXIMUM INFLATION LEVEL ::: integer ::: NONE ::: 30 ::: 260 ::: maximum inflation level ::: NULL ::: NULL ::: NULL ::: NULL ::: total lung capacity;level ::: C0040509;C2946261 ::: fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00155110.v2 ::: phs000200.v8.p2 ::: pht002118.v2 ::: ecg_rel2 ::: BTA_V4 ::: T wave area, lead bta_v4 ::: integer ::: NONE ::: -8972 ::: 10342 ::: t wave area, lead bta_v4 ::: NULL ::: NULL ::: NULL ::: NULL ::: t wave feature;urinary bladder tumor antigen ::: C0429103;C1519830 ::: fndg;aapp,imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure
phv00056788.v1 ::: phs000007.v18.p7 ::: pht000397.v2 ::: sleep1_2003s ::: hi202 ::: Aspirin:  the last two weeks, did you take any aspirin or aspirin-containing medicines such as Bufferin, Anacin, or Ascriptin ::: NONE ::: NONE ::: NONE ::: NONE ::: aspirin  the last two weeks, did you take any aspirin or aspirin containing medicines such as bufferin, anacin, or ascriptin ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin;pharmaceutical preparations;bufferin;anacin;ascriptin ::: C0004057;C0013227;C0719034;C0718504;C0052479 ::: orch,phsu;phsu;orch,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00106165.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: LFIBF58 ::: LOW FIBER ::: encoded ::: NONE ::: NONE ::: NONE ::: low fiber ::: NULL ::: NULL ::: NULL ::: NULL ::: dietary fiber;fiber ::: C0012173;C0225326 ::: food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00096256.v1 ::: phs000280.v1.p1 ::: pht001367.v1 ::: ARIC_CARE_RIPAV3C1 ::: RIPA72 ::: B_3_AE ::: decimal ::: NONE ::: 25 ::: 142.2 ::: b_3 _ae ::: NULL ::: NULL ::: NULL ::: NULL ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid ::: C0378071 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00029072.v1 ::: phs000086.v2.p1 ::: pht000242.v1 ::: DCCT_f003cmb2 ::: OCI2C ::: Standard treatment  - previous day: type of insulin - pork ::: byte ::: INSULIN: PORK ::: NONE ::: NONE ::: standard treatment previous day  type of insulin pork ::: NULL ::: NULL ::: NULL ::: NULL ::: therapeutic procedure;administration procedure;insulin, pork ::: C0087111;C1533734;C0770206 ::: topp;topp;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Daily or Recreational Activity
phv00025787.v1 ::: phs000086.v2.p1 ::: pht000213.v1 ::: DCCT_f0033 ::: OCDM5 ::: Describe insulin regimen (if different from that described in Question 4) ::: byte ::: NONE ::: NONE ::: NONE ::: describe insulin regimen  if different from that described in question 4 ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin;treatment protocols;recombinant insulin ::: C0021641;C0040808;C1533581 ::: aapp,horm,phsu;topp;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00083093.v1 ::: phs000209.v10.p2 ::: pht001111.v3 ::: MESA_AirNRExamMain ::: anar1c1c ::: ANTI-ARRHYTHMICS, CLASS 1C ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: anti arrhythmics, class1 c ::: NULL ::: NULL ::: NULL ::: NULL ::: anti-arrhythmia agents ::: C0003195 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00014809.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: CROHN_S_DISEASE ::: B 3.c.2. Crohn's Disease, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: b 3 c 2  crohn s disease,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: 2,5-dichloro-4-bromophenol;crohn disease ::: C0045550;C0010346 ::: orch,phsu;dsyn ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00169463.v1 ::: phs000200.v8.p2 ::: pht002748.v1 ::: f150_rel2 ::: PPLDUR_X ::: Months used Progesterone pill ::: encoded value ::: NONE ::: NONE ::: NONE ::: months used progesterone pill ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;progesterone ::: C1273517;C0033308 ::: fndg;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00104463.v1 ::: phs000287.v2.p1 ::: pht001488.v1 ::: YR3 ::: LIPID06 ::: Any lipid-lowering medication ::: encoded ::: NONE ::: NONE ::: NONE ::: any lipid lowering medication ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00032642.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL30A00 ::: Post-supper blood glucose mg/dl (quarterly visit 00) ::: int ::: MG/DL ::: NONE ::: NONE ::: post supper blood glucose magnesium distolingual  quarterly visit 00 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00086027.v2 ::: phs000209.v10.p2 ::: pht001118.v5 ::: MESA_Exam2Main ::: apsy2c ::: ANTI-PSYCHOTIC MEDICATIONS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: anti psychotic medications ::: NULL ::: NULL ::: NULL ::: NULL ::: psychotic symptom present;pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0459435;C0013227;C0802604;C2598133 ::: fndg;phsu;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00107426.v1 ::: phs000287.v2.p1 ::: pht001491.v1 ::: YR5OLD ::: TCA06 ::: Tricyclic anti-depressants ::: encoded ::: NONE ::: NONE ::: NONE ::: tricyclic anti depressants ::: NULL ::: NULL ::: NULL ::: NULL ::: tricyclic antidepressive agents ::: C0003290 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00109004.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: EDD06 ::: Erectile dysfunction drugs ::: encoded ::: NONE ::: NONE ::: NONE ::: erectile dysfunction drugs ::: NULL ::: NULL ::: NULL ::: NULL ::: erectile dysfunction;pharmaceutical preparations;erectile dysfunction adverse event ::: C0242350;C0013227;C1961100 ::: dsyn;phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00174119.v1 ::: phs000327.v1.p1 ::: pht003012.v1 ::: ESP_HeartGO_SWISS_Subject_Phenotypes ::: ESP_HTNmeds ::: TAKING HYPERTENSION MEDICATIONS AT TIME OF ASCERTAINMENT ::: STRING ::: NONE ::: NONE ::: NONE ::: taking hypertension medications at time of ascertainment ::: NULL ::: NULL ::: NULL ::: NULL ::: taking medication (activity);hypertensive disease;hypertension adverse event;hypertensive medication ::: C1290952;C0020538;C1963138;C0684167 ::: dora;dsyn;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Daily or Recreational Activity
phv00157741.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: SCORE94 ::: DERIVED FIELD: NUTRIENT VALUE - BETA CAROTENE, 1993 (MCG) ::: NONE ::: mcg ::: NONE ::: NONE ::: derived field  nutrient value beta carotene, 1993   mcg ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;beta carotene ::: C0678695;C0053396 ::: food;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00068709.v2 ::: phs000007.v18.p7 ::: pht000681.v3 ::: ffreq1_6s ::: NUT_VITEIU ::: DERIVED FIELD: NUTRIENT VALUE - VITAMIN E, (RERUN 8/2002) (IU) ::: NONE ::: IU ::: NONE ::: NONE ::: derived field  nutrient value vitamin e,  rerun 8 2002   international unit ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;vitamin e ::: C0678695;C0042874 ::: food;lipd,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00014755.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: MEDICATION_WEEKS___3 ::: B 5. Medication Weeks - 3, (Participants with European ancestry). DIGS3 ::: NONE ::: Weeks ::: NONE ::: NONE ::: b 5  medication weeks 3,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid;pharmaceutical preparations ::: C0378071;C0013227 ::: orch,phsu;phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00169156.v2 ::: phs000424.v2.p1 ::: pht002742.v2 ::: GTEx_Subject_Phenotypes ::: MHHEROIN ::: Heroin Use ::: integer, encoded value ::: NONE ::: NONE ::: NONE ::: heroin use ::: NULL ::: NULL ::: NULL ::: NULL ::: heroin ::: C0011892 ::: hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00005618.v1 ::: phs000007.v18.p7 ::: pht000025.v4 ::: ex0_23s ::: FP099 ::: MEDICATION USE: ANTI-PARKINSON DRUGS (SINEMET, L-DOPA, SYMMETREL, COGENTIN, ETC.) ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use  anti parkinson drugs  sinemet, ldopa, symmetrel, cogentin, etc ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;sinemet;levodopa;symmetrel;cogentin ::: C0013227;C0074559;C0023570;C0026055;C0591275 ::: phsu;orch,phsu;aapp,nsba,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00124002.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: fibrinogenam_orig ::: Fibrinogen am - original value ::: integer ::: NONE ::: -999 ::: 580 ::: fibrinogen am original value ::: NULL ::: NULL ::: NULL ::: NULL ::: fibrinogen ::: C0016006 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00111875.v3 ::: phs000200.v8.p2 ::: pht001517.v3 ::: f60_item_rel1 ::: POULTRY ::: Computed food group: Poultry, med serv/day ::: decimal ::: servings ::: 0 ::: 7.56438 ::: computed food group  poultry, med serv day ::: NULL ::: NULL ::: NULL ::: NULL ::: computed (procedure);food;poultry meat;poultry allergenic extract ::: C1441526;C0016452;C0452888;C2702373 ::: lbpr;food;food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Eating or Nutritional Finding
phv00078794.v3 ::: phs000200.v8.p2 ::: pht001003.v3 ::: f34_rel1 ::: LACTDIET ::: Lactose-free (no milk/dairy foods) diet ::: encoded value ::: NONE ::: NONE ::: NONE ::: lactose free  no milk dairy foods  diet ::: NULL ::: NULL ::: NULL ::: NULL ::: saccharum lactis, homeopathic preparation;milk - dietary;dairy products ::: C1260222;C2825079;C0010947 ::: phsu;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00162465.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: NUT_PCHO ::: Derived field: Nutrient value - Choline from Phosphocholine ::: decimal, encoded ::: mg ::: 1.86 ::: 67.45 ::: derived field  nutrient value choline from phosphocholine ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;choline;phosphorylcholine ::: C0678695;C0008405;C0031716 ::: food;bacs,orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00109716.v1 ::: phs000287.v2.p1 ::: pht001494.v1 ::: YR8 ::: ESTRGN06 ::: Estrogens,  excluding vaginal creams ::: encoded ::: NONE ::: NONE ::: NONE ::: estrogens, excluding vaginal creams ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00012668.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I9320 ::: J22. Did you ever need larger amounts of (drug) to get an effect, or find that you could no longer get high on the amount you used to use? INTERVIEWER: code YES if at least 50% more use. C SED. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: j22   did you ever need larger amounts of  drug  to get an effect, or find that you could no longer get high on the amount you used to use  interviewer  code yes if at least 50% more use  c sed   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;pharmacologic substance;finding;used by ::: C0013227;C1254351;C0243095;C1273517 ::: phsu;phsu;fndg;fndg ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00120725.v2 ::: phs000285.v2.p2 ::: pht001850.v2 ::: F1MOOD ::: FHL12IIT ::: TIME USUALLY WAKE-UP ::: integer ::: NONE ::: 7200 ::: 84600 ::: time usually wake up ::: NULL ::: NULL ::: NULL ::: NULL ::: wake ups ::: C1170730 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00152583.v2 ::: phs000209.v10.p2 ::: pht002109.v2 ::: MESA_MesaFamily_LungCT ::: B_a_int ::: BOTH LUNGS: THE INTERCEPT OF THE LINE AT THE ANKLE ::: Numeric ::: NONE ::: NONE ::: NONE ::: both lungs  the intercept of the line at the ankle ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00149580.v1 ::: phs000209.v10.p2 ::: pht002103.v1 ::: MESA_AncilMesaLungExam4CT ::: RMC_a_int ::: RIGHT LUNG, MIDDLE CORE: THE INTERCEPT OF THE LINE AT THE ANKLE ::: Numeric ::: NONE ::: NONE ::: NONE ::: right lung, middle core  the intercept of the line at the ankle ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126973.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: ravg_vite ::: RECALL: vitamin E (International Units) ::: decimal ::: NONE ::: 1.685 ::: 63.695 ::: recall  vitamin e  international units ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;vitamin e;recall:-:point in time:^patient:- ::: C0034770;C0042874;C2361119 ::: menp;lipd,phsu,vita;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Eating or Nutritional Finding
phv00049548.v1 ::: phs000086.v2.p1 ::: pht000329.v1 ::: EDIC_f0044 ::: ODB5A1 ::: B5a1. Current medication: taking oral contraceptives, years ::: byte ::: Years ::: NONE ::: NONE ::: b5a1   current medication  taking oral contraceptives, years ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;contraceptives, oral;oral contraceptives - consent type ::: C0746467;C0009905;C1548892 ::: fndg;phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00105635.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: DAYFSH06 ::: DAYS TOOK THIS MEDICINE IN LAST TWO WEEK ::: encoded ::: NONE ::: NONE ::: NONE ::: days took this medicine in last two week ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00117464.v2 ::: phs000285.v2.p2 ::: pht001727.v2 ::: D1F9MBCA ::: D09BCTMO ::: DURATION OF BCP USE: CURRENT, MONTHS ::: integer ::: Months ::: 0 ::: 11 ::: duration of birth control pill use  current, months ::: NULL ::: NULL ::: NULL ::: NULL ::: duration;contraceptives, oral;oral contraception ::: C2926735;C0009905;C0029151 ::: phsu;phsu;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00172917.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: nut_prog ::: Derived field: Nutrient value - Progoitrin, Glucosinolate ::: NONE ::: mg ::: 0 ::: 6.49 ::: derived field  nutrient value progoitrin, glucosinolate ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;progoitrin ::: C0678695;C0072094 ::: food;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00110066.v1 ::: phs000287.v2.p1 ::: pht001495.v1 ::: YR9 ::: LIVDIS59 ::: HAVE LIVER DISEASE, CIRRHOSIS, HEPATITIS ::: encoded ::: NONE ::: NONE ::: NONE ::: have liver disease, cirrhosis, hepatitis ::: NULL ::: NULL ::: NULL ::: NULL ::: liver diseases;liver cirrhosis;cirrhosis;hepatitis;hepatitis a;hepatitis a vaccine, inactivated ::: C0023895;C0023890;C1623038;C0019158;C0019159;C0795623 ::: dsyn;dsyn;dsyn;dsyn;dsyn;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00004999.v1 ::: phs000007.v18.p7 ::: pht000024.v4 ::: ex0_22s ::: FO146 ::: MEDICATION USE: ANTICONVULSANTS (DILANTIN, PHENOBARB, TEGRETOL, MYSOLINE, ETC.) ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use  anticonvulsants  dilantin, phenobarb, tegretol, mysoline, etc ::: NULL ::: NULL ::: NULL ::: NULL ::: medication use;anticonvulsants;dilantin;tegretol;mysoline ::: C0240320;C0003286;C0699512;C0700087;C0700016 ::: fndg;phsu;orch,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00125602.v1 ::: phs000286.v3.p1 ::: pht001937.v1 ::: AFUI17 ::: AFUI7F ::: DOCTOR - BLOOD CLOT IN LUNG       Q7F ::: encoded ::: NONE ::: NONE ::: NONE ::: doctor blood clot in lung q7 f ::: NULL ::: NULL ::: NULL ::: NULL ::: thrombus;blood clot;fluorides ::: C0087086;C0302148;C0016327 ::: dsyn;acab;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00106334.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: PPYR58 ::: YEARS TOOK PROGESTIN IN PAST ::: encoded ::: NONE ::: NONE ::: NONE ::: years took progestin in past ::: NULL ::: NULL ::: NULL ::: NULL ::: progestins ::: C0033306 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00087382.v1 ::: phs000209.v10.p2 ::: pht001121.v3 ::: MESA_FamilyExamMain ::: totmedfc ::: TOTAL MEDICATIONS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: total medications ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0013227;C0802604;C2598133 ::: phsu;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00095680.v1 ::: phs000280.v1.p1 ::: pht001355.v1 ::: ARIC_CARE_PFTBV2C1 ::: PFTB45B ::: Hist.of MI Or surg:chst,abd,6 wks  Q45B ::: encoded ::: NONE ::: NONE ::: NONE ::: hist of myocardial infarction or surg chst,abd,6 wks q45 b ::: NULL ::: NULL ::: NULL ::: NULL ::: histamine dihydrochloride;myocardial infarction;myocardial infarction:finding:point in time:^patient:ordinal ::: C0543456;C0027051;C2926063 ::: nsba,orch,phsu;dsyn;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00109746.v1 ::: phs000287.v2.p1 ::: pht001494.v1 ::: YR8 ::: PROB06 ::: Probucol ::: encoded ::: NONE ::: NONE ::: NONE ::: probucol ::: NULL ::: NULL ::: NULL ::: NULL ::: probucol ::: C0033215 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00098340.v1 ::: phs000280.v1.p1 ::: pht001414.v1 ::: ARIC_CARE_VITV3C1 ::: ALCOL ::: Alcohol gm ::: integer ::: gm ::: NONE ::: NONE ::: alcohol gm ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History
phv00093902.v1 ::: phs000280.v1.p1 ::: pht001320.v1 ::: ARIC_CARE_ESMCV4C1 ::: ESMC148 ::: COND 21- LEAD 3, EV1 ::: encoded ::: NONE ::: NONE ::: NONE ::: cond 21 lead 3, ev1 ::: NULL ::: NULL ::: NULL ::: NULL ::: hutterite cerebroosteonephrodysplasia syndrome;lead;plumbum metallicum, homeopathic preparation ::: C1856054;C0023175;C1442948 ::: dsyn;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Medical History
phv00070088.v2 ::: phs000007.v18.p7 ::: pht000680.v3 ::: ffreq1_5s ::: FFD52 ::: DERIVED FIELD: SERVINGS PER WEEK - CABBAGE/COLE SLAW ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  servings per week cabbage cole slaw ::: NULL ::: NULL ::: NULL ::: NULL ::: cabbage - dietary;cabbage preparation ::: C0006619;C1095889 ::: food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00119744.v2 ::: phs000285.v2.p2 ::: pht001809.v2 ::: F1F05 ::: F05CTB3B ::: 4.5ML BLUE TB, CITRATED PLASMA-STORAGE. Q 9 ::: encoded ::: NONE ::: NONE ::: NONE ::: 4 5ml blue tb, citrated plasma storage  q 9 ::: NULL ::: NULL ::: NULL ::: NULL ::: citrate measurement;citrate ::: C0201956;C0376259 ::: lbpr;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00034122.v1 ::: phs000086.v2.p1 ::: pht000282.v1 ::: DCCT_f002cmb4 ::: OBASPIRN ::: Average number of aspirin or other prostaglandin inhibitors - containing tablets per month ::: int ::: ASPIRIN-PROSTAGLANDIN INHIBITORS/MONTH ::: NONE ::: NONE ::: average number of aspirin or other prostaglandin inhibitors containing tablets per month ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin;prostaglandin antagonists ::: C0004057;C0033529 ::: orch,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007731.v3 ::: phs000007.v18.p7 ::: pht000031.v5 ::: ex1_2s ::: B81 ::: MENOPAUSE: EVER TAKEN PREMARIN ::: NONE ::: NONE ::: NONE ::: NONE ::: menopause  ever taken premarin ::: NULL ::: NULL ::: NULL ::: NULL ::: menopause;premarin ::: C0025320;C0699710 ::: phsf;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00050101.v1 ::: phs000086.v2.p1 ::: pht000333.v1 ::: EDIC_f0423 ::: DBJ4A ::: J4a. Potential contributing factors. Sex during 4 hours before hypoglycemic event ::: byte ::: NONE ::: NONE ::: NONE ::: j4 a  potential contributing factors  gender during 4 hours before hypoglycemic event ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: j4;gender:type:point in time:^patient:nominal;hypoglycemic agents ::: C0442779;C0804628;C0020616 ::: fndg;clna;phsu ::: study subject ::: C0681850 ::: grup ::: Demographics;Medication Patient;Substance Use History;Medical History
phv00145062.v1 ::: phs000209.v10.p2 ::: pht002101.v1 ::: MESA_AncilMesaLungExam2CT ::: LLC_a_int ::: LEFT LUNG, LOWER CORE: THE INTERCEPT OF THE LINE AT THE ANKLE ::: Numeric ::: NONE ::: NONE ::: NONE ::: left lung, lower core  the intercept of the line at the ankle ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00161723.v1 ::: phs000385.v1.p1 ::: pht002342.v1 ::: Epigenetic_Colorectal_Cancer_Sample_Attributes ::: Grade/Diff ::: Indicates the level/grade of differentiation ::: encoded values ::: NONE ::: NONE ::: NONE ::: indicates the level grade of differentiation ::: NULL ::: NULL ::: NULL ::: NULL ::: indicated;level;histopathologic grade differentiation ::: C1444656;C2946261;C1511938 ::: fndg;phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00078020.v3 ::: phs000200.v8.p2 ::: pht000993.v3 ::: f146_rel1 ::: ESHT_6 ::: Estrogen shots ::: encoded value ::: NONE ::: NONE ::: NONE ::: estrogen shots ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;childhood immunization ::: C0014939;C1456647 ::: horm,phsu,strd;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00011435.v2 ::: phs000016.v2.p2 ::: pht000052.v2 ::: PACS ::: a7n ::: Rigid and repetitive behaviours - autism spectrum disorders - PACS section 4, now ::: smallint(6) ::: NONE ::: NONE ::: NONE ::: rigid and repetitive behaviours autism spectrum disorders picture archiving and communication system section 4, now ::: NULL ::: NULL ::: NULL ::: NULL ::: muscle rigidity;rigid behavior;behavior;autistic disorder;spectrum-4;disease;division (surgical procedure);behaviors and observations relating to behavior ::: C0026837;C0231517;C0004927;C0004352;C0723421;C0012634;C1293097;C0677505 ::: sosy;inbe;inbe;mobd;orch,phsu;dsyn;topp;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00108755.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: PROGC59 ::: CURRENTLY TAKING PROGESTIN ::: encoded ::: NONE ::: NONE ::: NONE ::: currently taking progestin ::: NULL ::: NULL ::: NULL ::: NULL ::: progestins ::: C0033306 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126526.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: ravg_leuc ::: RECALL: leucine ::: decimal ::: NONE ::: 1.6625 ::: 15.98719 ::: recall  leucine ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;leucine;recall:-:point in time:^patient:- ::: C0034770;C0023401;C2361119 ::: menp;aapp,bacs,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding
phv00120206.v2 ::: phs000285.v2.p2 ::: pht001822.v2 ::: F1F18R ::: F18RG1SH ::: HOME ACT(SHOVEL SNOW) - YR 0, 1 HR/12 MO. Q G1 ::: encoded ::: NONE ::: NONE ::: NONE ::: home act shovel snow  year 0, 1 heart rate 12 mo  q g1 ::: NULL ::: NULL ::: NULL ::: NULL ::: cocaine ::: C0009170 ::: hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Clinical Attributes
phv00017417.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V389 ::: E6. Trileptal. Other drugs. (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  trileptal  other drugs   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: trileptal;others;pharmaceutical preparations;diagnosis;genetic study ::: C0876196;C1955473;C0013227;C0011900;C2827447 ::: orch,phsu;fndg;phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00158423.v1 ::: phs000007.v18.p7 ::: pht002153.v1 ::: ffreq0_22s ::: FFD33 ::: DERIVED FIELD: SERVINGS PER WEEK - CANTALOUPE ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  servings per week cantaloupe ::: NULL ::: NULL ::: NULL ::: NULL ::: cantaloupes;cantaloupe allergenic extract ::: C0949863;C2702356 ::: food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00013682.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I21300 ::: K50. Did you make movements either with your whole body, parts of your body or your face that were unusual or had to be repeated over and over without any ability to control these movements yourself? Alcohol. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: k50   did you make movements either with your whole body, parts of your body or your face that were unusual or had to be repeated over and over without any ability to control these movements yourself  alcohol   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: movement;alcohols;alcohol measurement ::: C0026649;C0001975;C0202304 ::: orgf;orch,phsu;lbpr ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Drinking History
phv00159150.v2 ::: phs000209.v10.p2 ::: pht002195.v2 ::: MESA_Exam1ECGContiWaveform ::: bpaavf1 ::: P Wave Area, Lead AVF (uVmSec) ::: NUMERIC ::: uVmSec ::: NONE ::: NONE ::: p wave area, lead exploring electrode located at the left foot  uvmsec ::: NULL ::: NULL ::: NULL ::: NULL ::: lead;plumbum metallicum, homeopathic preparation ::: C0023175;C1442948 ::: elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Diagnostic Procedure
phv00020993.v4 ::: phs000007.v18.p7 ::: pht000074.v6 ::: ex3_1s ::: G3A138 ::: IF EVER CONSUMED ALCOHOL: HAS THERE EVER BEEN A TIME IN YOUR LIFE WHEN YOU DRANK 5 OR MORE ALCOHOLIC DRINKS OF ANY KIND ALMOST DAILY? ::: NONE ::: NONE ::: NONE ::: NONE ::: if ever consumed alcohol  has there ever been a time in your life when you drank 5 or more alcoholic drinks of any kind almost daily ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement;alcohol consumption;alcoholic intoxication;alcoholic beverage heavy drinker;acute alcoholic intoxication;drink (dietary substance);drinking function;alcoholic beverages ::: C0001975;C0202304;C0001948;C0001969;C0337678;C0394996;C0452428;C0684271;C0001967 ::: orch,phsu;lbpr;inbe;mobd;inbe;mobd;food;orgf;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History;Eating or Nutritional Finding
phv00126671.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: sffq_glyc ::: SFFQ: glycine (gm) ::: decimal ::: gm ::: 0.06759 ::: 17.8047 ::: sffq  glycine  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: glycine ::: C0017890 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00009178.v3 ::: phs000007.v18.p7 ::: pht000034.v5 ::: ex1_5s ::: E225 ::: CALCIUM CHANNEL BLOCKERS ::: NONE ::: NONE ::: NONE ::: NONE ::: calcium channel blockers ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium channel blockers ::: C0006684 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00120351.v2 ::: phs000285.v2.p2 ::: pht001825.v2 ::: F1F48 ::: F48THERN ::: NUMBER TAKEN (THERAP/THERAGRAN TYPE). Q 2 ::: encoded ::: NONE ::: NONE ::: NONE ::: number taken  therap theragran type   q 2 ::: NULL ::: NULL ::: NULL ::: NULL ::: theragran ::: C0723708 ::: orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00011440.v2 ::: phs000016.v2.p2 ::: pht000052.v2 ::: PACS ::: a104 ::: Abnormal forms of language - autism spectrum disorders - PACS section 4, age 4 ::: smallint(6) ::: NONE ::: NONE ::: NONE ::: abnormal forms of language autism spectrum disorders picture archiving and communication system section 4, age 4 ::: Age ::: age ::: C0001779 ::: orga ::: autistic disorder;spectrum-4;disease;division (surgical procedure);language:-:point in time:^patient:- ::: C0004352;C0723421;C0012634;C1293097;C2706915 ::: mobd;orch,phsu;dsyn;topp;clna ::: study subject ::: C0681850 ::: grup ::: Demographics;Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00048670.v1 ::: phs000086.v2.p1 ::: pht000325.v1 ::: EDIC_f0023 ::: OBNPHSUP ::: F3. Diabetes management: units NPH insulin used-supper ::: byte ::: Units ::: NONE ::: NONE ::: f3  diabetes management  units neutral protamine hagedor insulin used supper ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;insulin, neutral;protamines;disease management;diabetes mellitus;used by ::: C0011847;C0063657;C0033603;C0376636;C0011849;C1273517 ::: dsyn;aapp,phsu;aapp,bacs,phsu;hlca;dsyn;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00010176.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G033 ::: CARDIOVASCULAR MEDICATIONS: ANTI-ARRHYTHMICS (QUINIDINE, PROCAINAMIDE, AMIODARONE, SOTALOL DISOPYRAMIDE, ETC.) ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications  anti arrhythmics  quinidine, procainamide, amiodarone, sotalol disopyramide, etc ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;anti-arrhythmia agents;quinidine;procainamide;amiodarone;sotalol;disopyramide ::: C0007220;C0003195;C0034414;C0033216;C0002598;C0037707;C0012702 ::: phsu;phsu;orch,phsu;orch,phsu;orch,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00014797.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: CUSHINGS_D_O ::: B 3.a.4. Cushings D/O, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: b 3 a 4  cushings d o,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid ::: C0378071 ::: orch,phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00024570.v3 ::: phs000007.v18.p7 ::: pht000198.v4 ::: hemostatic1_5s ::: FACTOR7 ::: FACTOR VII (%) ::: NONE ::: NONE ::: NONE ::: NONE ::: factor vii  % ::: NULL ::: NULL ::: NULL ::: NULL ::: blood coagulation factor vii ::: C0015502 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049438.v1 ::: phs000086.v2.p1 ::: pht000327.v1 ::: EDIC_f0042 ::: ODB13 ::: B13. Current medication: specify - use of medication for pain ::: byte ::: NONE ::: NONE ::: NONE ::: b13   current medication  specify use of medication for pain ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;pharmaceutical preparations;pain;pain nos adverse event ::: C0746467;C0013227;C0030193;C1962977 ::: fndg;phsu;sosy;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Clinical Attributes;Medical History
phv00124520.v1 ::: phs000305.v1.p1 ::: pht001918.v1 ::: NSABP_Clinical_Data ::: ParoAfterEntryTime ::: Time to start of paroxetine ::: decimal ::: Months ::: 0.7 ::: 98.6 ::: time to start of paroxetine ::: NULL ::: NULL ::: NULL ::: NULL ::: paroxetine ::: C0070122 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00086931.v2 ::: phs000209.v10.p2 ::: pht001120.v7 ::: MESA_Exam4Main ::: diur4c ::: ANY DIURETIC ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: any diuretic ::: NULL ::: NULL ::: NULL ::: NULL ::: diuretics ::: C0012798 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00104934.v1 ::: phs000287.v2.p1 ::: pht001489.v1 ::: YR4 ::: EYR39 ::: YEAR STOPPED TAKING ESTROGEN ::: integer ::: NONE ::: 40 ::: 92 ::: year stopped taking estrogen ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00011723.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I1310 ::: B5. If yes to B5, specify medication, dosage and duration (Med 4 R's response). (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: b5  if yes to b5, specify medication, dosage and duration  med 4 r s response    participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;duration;disease response;response (communication);r prime ::: C0013227;C2926735;C1704632;C2911692;C2603358 ::: phsu;phsu;fndg;menp;clna ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding
phv00077669.v3 ::: phs000200.v8.p2 ::: pht000990.v3 ::: f143_rel1 ::: PLST2YR_3 ::: Progesterone use last 2 years ::: encoded value ::: NONE ::: NONE ::: NONE ::: progesterone use last 2 years ::: NULL ::: NULL ::: NULL ::: NULL ::: progesterone ::: C0033308 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00012609.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I8770 ::: J9. Did stopping or cutting down ever cause you to feel bad physically? (Co-occurrence of symptoms such as nervousness, insomnia, sweating, nausea, diarrhea). (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: j9  did stopping or cutting down ever cause you to feel bad physically   cooccurrence of symptoms such as nervousness, insomnia, sweating, nausea, diarrhea    participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: stop brand of fluoride;transection (procedure);emotions;symptoms;nervousness;sleeplessness;insomnia adverse event;sweating;nausea;nausea adverse event;diarrhea;diarrhea adverse event ::: C0723457;C0152060;C0013987;C1457887;C0027769;C0917801;C1963237;C0038990;C0027497;C1963179;C0011991;C1963091 ::: inch,phsu;topp;menp;sosy;fndg;sosy;fndg;fndg;sosy;fndg;sosy;fndg ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Self-care Status;Therapeutic or Preventive Procedure;Medical History
phv00017649.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V621 ::: F40f.  Were you sleeping much more than usual? (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: f40 f  were you sleeping much more than usual   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: fluorides;sleep;asleep;diagnosis;genetic study ::: C0016327;C0037313;C0424522;C0011900;C2827447 ::: inch,phsu;orgf;fndg;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes;Daily or Recreational Activity
phv00065683.v1 ::: phs000086.v2.p1 ::: pht000624.v1 ::: EDIC_f0022 ::: OBULTOTH ::: F3. Diabetes management: units Ultralente insulin used - other ::: byte ::: Units ::: NONE ::: NONE ::: f3  diabetes management  units ultralente insulin used other ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;ultralente insulin;disease management;diabetes mellitus;used by ::: C0011847;C0041616;C0376636;C0011849;C1273517 ::: dsyn;aapp,horm,phsu;hlca;dsyn;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00110354.v1 ::: phs000287.v2.p1 ::: pht001495.v1 ::: YR9 ::: ADMMIN12 ::: MINUTE GLUCOSE ADMINISTERED ::: integer ::: NONE ::: 0 ::: 59 ::: minute glucose administered ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement ::: C0017725;C0202042 ::: bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00150462.v2 ::: phs000209.v10.p2 ::: pht002107.v3 ::: MESA_Exam1DietNutrients ::: thrnnn1c ::: NUTRIENTS: THREONINE ::: NUMERIC ::: g ::: NONE ::: NONE ::: nutrients  threonine ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;threonine ::: C0678695;C0040005 ::: food;aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00087368.v1 ::: phs000209.v10.p2 ::: pht001121.v3 ::: MESA_FamilyExamMain ::: sympthfc ::: SYMPATHOMIMETICS, ORAL AND INHALED ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: sympathomimetics, oral and inhaled ::: NULL ::: NULL ::: NULL ::: NULL ::: sympathomimetics;inspiration function ::: C0039052;C0004048 ::: phsu;orgf ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00025827.v1 ::: phs000086.v2.p1 ::: pht000213.v1 ::: DCCT_f0033 ::: OCNA1D ::: Non-adherence to treatment plan: used type of insulin not prescribed ::: byte ::: NONE ::: NONE ::: NONE ::: non adherence to treatment plan  used type of insulin not prescribed ::: NULL ::: NULL ::: NULL ::: NULL ::: non adherence;used by;insulin;recombinant insulin;prescribed ::: C2364041;C1273517;C0021641;C1533581;C0278329 ::: fndg;fndg;aapp,horm,phsu;aapp,horm,phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00087362.v1 ::: phs000209.v10.p2 ::: pht001121.v3 ::: MESA_FamilyExamMain ::: prmrnfc ::: PREMARIN (CONJUGATED ESTROGENS) ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: premarin  conjugated estrogens ::: NULL ::: NULL ::: NULL ::: NULL ::: premarin;estrogens, conjugated (usp) ::: C0699710;C0014938 ::: horm,phsu,strd;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00122931.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: INSULIN ::: Meds: Insulin ::: encoded ::: NONE ::: NONE ::: NONE ::: meds  insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin;recombinant insulin ::: C0021641;C1533581 ::: aapp,horm,phsu;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00055358.v2 ::: phs000007.v18.p7 ::: pht000395.v6 ::: sleep1_1998s ::: LOOP1 ::: Loop diuretics ::: NONE ::: NONE ::: NONE ::: NONE ::: loop diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: loop diuretics ::: C0354100 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00059190.v2 ::: phs000128.v3.p3 ::: pht000432.v2 ::: simphen033 ::: chol1 ::: Cranial Hydroencephalic oleo level v1 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v1 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v1 stage;level ::: C0982301;C0457422;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00162134.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: FED ::: FFQ: IRON SUPPLEMENT DOSE PER DAY ::: encoded ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  iron supplement dose per day ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;iron;dose number:number:point in time:^patient:quantitative;ferrum metallicum, homeopathic preparation;food;iron supplement ::: C0524813;C0302583;C1114758;C1166521;C0016452;C0721124 ::: food;bacs,elii,phsu;clna;phsu;food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00005584.v1 ::: phs000007.v18.p7 ::: pht000025.v4 ::: ex0_23s ::: FP065 ::: MEDICATION USE: RENIN-ANGIOTENSIN BLOCKING DRUGS (CAPTOPRIL, ENALAPRIL, LISINOPRIL) ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use  renin angiotensin blocking drugs  captopril, enalapril, lisinopril ::: NULL ::: NULL ::: NULL ::: NULL ::: medication use;angiotensins;captopril;chymosin;enalapril;lisinopril ::: C0240320;C0003018;C0006938;C0035100;C0014025;C0065374 ::: fndg;aapp,bacs,phsu;aapp,phsu;aapp,enzy,phsu;aapp,phsu;aapp,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00171796.v1 ::: phs000462.v1.p1 ::: pht002844.v1 ::: T2D_GENES_Subject_Phenotypes ::: BPMEDS_3 ::: Hypertension medication? (1=yes; 0=no) at the third study visit ::: encoded value ::: NONE ::: NONE ::: NONE ::: hypertension medication   1=yes  0=no  at the third study visit ::: NULL ::: NULL ::: NULL ::: NULL ::: hypertensive medication;clinical trials;health care visit;study ::: C0684167;C0008976;C1512346;C2603343 ::: phsu;resa;inbe;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Research Attributes
phv00127390.v1 ::: phs000286.v3.p1 ::: pht001954.v1 ::: ECGA ::: ecga271 ::: RPKDAVF - R Peak Duration in lead AVF ::: integer ::: NONE ::: 0 ::: 90 ::: rpkdavf r peak duration in lead exploring electrode located at the left foot ::: NULL ::: NULL ::: NULL ::: NULL ::: duration;r prime;lead;plumbum metallicum, homeopathic preparation ::: C2926735;C2603358;C0023175;C1442948 ::: phsu;clna;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00077854.v3 ::: phs000200.v8.p2 ::: pht000992.v3 ::: f145_rel1 ::: ESHTDUR_5 ::: Months took estrogen shots ::: encoded value ::: NONE ::: NONE ::: NONE ::: months took estrogen shots ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;childhood immunization ::: C0014939;C1456647 ::: horm,phsu,strd;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00014800.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: MIGRAINE ::: B 3.b. Migraine, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: b 3 b  migraine,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid;migraine disorders ::: C0378071;C0149931 ::: orch,phsu;dsyn ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00002739.v1 ::: phs000007.v18.p7 ::: pht000018.v4 ::: ex0_16s ::: FI101 ::: THYROID EXAMINATION: SCAR ::: NONE ::: NONE ::: NONE ::: NONE ::: thyroid examination  scar ::: NULL ::: NULL ::: NULL ::: NULL ::: physical examination;scar tissue;cicatrix;thyroid (usp);thyroid preparation ::: C0031809;C0241158;C2004491;C0040134;C0279175 ::: hlca;fndg;patf;bacs,orch,phsu;horm,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00081803.v1 ::: phs000219.v1.p1 ::: pht001075.v1 ::: d_csa09 ::: ALCAMT ::: Amount of alcohol per day in last 30 days ::: Decimal ::: NONE ::: NONE ::: NONE ::: amount of alcohol per day in last 30 days ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History
phv00018419.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1391 ::: J40. Opiates.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j40   opiates   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: opioid abuse;opiate assay;opiates;diagnosis;genetic study ::: C0029095;C0242401;C0376196;C0011900;C2827447 ::: mobd;lbpr;hops,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00069970.v2 ::: phs000007.v18.p7 ::: pht000680.v3 ::: ffreq1_5s ::: POT_CHIP ::: FFQ: POTATO OR CORN CHIPS (SMALL BAG/1 OZ) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  potato or corn chips  small bag 1 oz ::: NULL ::: NULL ::: NULL ::: NULL ::: food;potato;potato allergenic extract;corn of toe;maize;potato chips;french fries ::: C0016452;C0032846;C2702372;C0010046;C1138842;C0349380;C1510451 ::: food;food;imft,phsu;acab;food;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Eating or Nutritional Finding
phv00090116.v1 ::: phs000209.v10.p2 ::: pht001205.v1 ::: MESA_AncilMesaExam4AbdominalAorticCT ::: agatpm4c ::: MEAN TOTAL AGATSTON CALCIUM SCORE, PHANTOM ADJUSTED ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: mean total agatston calcium score, phantom adjusted ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium ::: C0006675 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00006869.v1 ::: phs000007.v18.p7 ::: pht000028.v3 ::: ex0_26s ::: FS260 ::: CARDIOVASCULAR MEDICATIONS: OTHER ANTI-HYPERTENSIVES ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications  other anti hypertensives ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;others;antihypertensive agents ::: C0007220;C1955473;C0003364 ::: phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00122954.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: OTHREG3 ::: Meds: specify other medication (3) ::: string ::: NONE ::: NONE ::: NONE ::: meds  specify other medication  3 ::: NULL ::: NULL ::: NULL ::: NULL ::: other medications ::: C1115771 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00052753.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V1393 ::: J35 Specify other drug, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j35  specify other drug,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: other drugs;diagnosis;genetic study ::: C2729346;C0011900;C2827447 ::: phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00117681.v2 ::: phs000285.v2.p2 ::: pht001745.v2 ::: D2F06 ::: D06INSDF ::: WATER INSOLUBLE DIETARY FIBER (GM) ::: decimal ::: GM ::: 0.67 ::: 126.85 ::: water insoluble dietary fiber  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: water;dietary fiber ::: C0043047;C0012173 ::: inch,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00015028.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: CELEXA ::: E6. Serotonin specific reuptke inhibitors (SSRIs. Celexa, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: e6  serotonin specific reuptke inhibitors  ssris  celexa,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: serotonin uptake inhibitors;selective serotonin re-uptake inhibitor;celexa ::: C0162758;C0360105;C0719199 ::: phsu;phsu;orch,phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00158255.v1 ::: phs000007.v18.p7 ::: pht002153.v1 ::: ffreq0_22s ::: ST_BEANS ::: FFQ: STRING BEANS (1/2 CUP) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  string beans  1 2 cup ::: NULL ::: NULL ::: NULL ::: NULL ::: food;string bean;string bean allergenic extract ::: C0016452;C0598763;C2702406 ::: food;food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00013578.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I12640 ::: K32. Have you ever experienced any strange smells you couldn't account for or smells that others did not notice? Drugs. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: k32   have you ever experienced any strange smells you couldn t account for or smells that others did not notice  drugs   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: practice experience;experience;smell perception;account number:identifier:point in time:^patient:nominal;others;pharmaceutical preparations ::: C0237607;C0596545;C0037361;C2741673;C1955473;C0013227 ::: menp;menp;orgf;clna;fndg;phsu ::: strangers;participant ::: C2371722;C0679646 ::: popg;popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Medical History
phv00158562.v1 ::: phs000228.v3.p1 ::: pht001187.v3 ::: EMMES_HMP_DCM ::: DCMESTD_C ::: Medication start period is estimated - coded fields ::: String ::: NONE ::: NONE ::: NONE ::: medication start period is estimated coded fields ::: NULL ::: NULL ::: NULL ::: NULL ::: medication commenced ::: C0451613 ::: fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00006466.v1 ::: phs000007.v18.p7 ::: pht000027.v3 ::: ex0_25s ::: FR193 ::: CARDIOVASCULAR MEDICATIONS - BETA BLOCKERS (SPECIFY) ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications beta blockers  specify ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;adrenergic beta-antagonists ::: C0007220;C0001645 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00026199.v1 ::: phs000086.v2.p1 ::: pht000214.v1 ::: DCCT_f0034 ::: OCDM7A1 ::: MDI - prescribed change in insulin regimen because of: symptoms of polyuria, polydipsia ::: byte ::: NONE ::: NONE ::: NONE ::: multiple dose injection prescribed change in insulin regimen because of  symptoms of polyuria, polydipsia ::: NULL ::: NULL ::: NULL ::: NULL ::: injection of therapeutic agent;injection procedure;dose number:number:point in time:^patient:quantitative;prescribed;insulin;treatment protocols;recombinant insulin;symptoms;polyuria;polydipsia ::: C0021485;C1533685;C1114758;C0278329;C0021641;C0040808;C1533581;C1457887;C0032617;C0085602 ::: topp;topp;clna;hlca;aapp,horm,phsu;topp;aapp,horm,phsu;sosy;sosy;sosy ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Therapeutic or Preventive Procedure;Medical History
phv00049871.v1 ::: phs000086.v2.p1 ::: pht000331.v1 ::: EDIC_f0303 ::: COSNVERE ::: F. Ophtalmoscopic examination: are the new vessels greater than or equal to 1/2 DA in size? Right eye ::: byte ::: NONE ::: NONE ::: NONE ::: f  ophtalmoscopic examination  are the new vessels greater than or equal to 1 2 da in size  right eye ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;physical examination;phase i/ii trial ::: C0016327;C0031809;C1519043 ::: inch,phsu;hlca;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Research Attributes
phv00120795.v2 ::: phs000285.v2.p2 ::: pht001854.v2 ::: F2EBCT ::: FR3ARM41 ::: SCAN 1 ARTERY 4 CALCIUM MASS ::: decimal ::: NONE ::: -3857.82 ::: 274.43 ::: scan 1 artery 4 calcium mass ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium;mass of body structure ::: C0006675;C0577559 ::: bacs,elii,phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00033078.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL28A19 ::: Post-lunch blood glucose mg/dl (quarterly visit 19) ::: int ::: MG/DL ::: NONE ::: NONE ::: post lunch blood glucose magnesium distolingual  quarterly visit 19 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00112705.v2 ::: phs000285.v2.p2 ::: pht001564.v2 ::: A4F06BH ::: A06IRON ::: IRON (MG) ::: decimal ::: MG ::: 0 ::: 115.2 ::: iron  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: iron;ferrum metallicum, homeopathic preparation ::: C0302583;C1166521 ::: bacs,elii,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00127944.v1 ::: phs000286.v3.p1 ::: pht001964.v1 ::: MSRA ::: MSRA33 ::: 33: Now taking aspirin? ::: encoded ::: NONE ::: NONE ::: NONE ::: 33  now taking aspirin ::: NULL ::: NULL ::: NULL ::: NULL ::: aspirin ::: C0004057 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00162337.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: NUT_ZN ::: Derived field: Nutrient value - Zinc ::: decimal, encoded ::: mg ::: 2.46 ::: 170.91 ::: derived field  nutrient value zinc ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;zinc ::: C0678695;C0043481 ::: food;bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00145362.v1 ::: phs000209.v10.p2 ::: pht002101.v1 ::: MESA_AncilMesaLungExam2CT ::: LU_a_int ::: LEFT LUNG UPPER: THE INTERCEPT OF THE LINE AT THE ANKLE ::: Numeric ::: NONE ::: NONE ::: NONE ::: left lung upper  the intercept of the line at the ankle ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00069062.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: FFD50 ::: DERIVED FIELD: SERVINGS PER WEEK - STRING BEANS ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  servings per week string beans ::: NULL ::: NULL ::: NULL ::: NULL ::: string bean;string bean allergenic extract ::: C0598763;C2702406 ::: food;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00111747.v3 ::: phs000200.v8.p2 ::: pht001517.v3 ::: f60_item_rel1 ::: CANTALOP ::: Item #4: Cantaloupe, orange melon, etc, med serv/day ::: decimal ::: servings ::: 0 ::: 3 ::: item  number 4  cantaloupe, orange melon, etc, med serv day ::: NULL ::: NULL ::: NULL ::: NULL ::: cantaloupes;cantaloupe allergenic extract;orange (fruit);melons;orange flavor ::: C0949863;C2702356;C0440277;C0440285;C0475654 ::: food;imft,phsu;food;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00122937.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: CELEXA ::: Meds: Celexa ::: encoded ::: NONE ::: NONE ::: NONE ::: meds  celexa ::: NULL ::: NULL ::: NULL ::: NULL ::: celexa ::: C0719199 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00014722.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: SEIZURE ::: B 3.1. Seizure, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: b 3 1  seizure,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid;seizures;seizure adverse event ::: C0378071;C0036572;C1959629 ::: orch,phsu;sosy;fndg ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00079644.v3 ::: phs000200.v8.p2 ::: pht001014.v3 ::: f48_rel1 ::: ESTR_P ::: Estrogen pill past year ::: encoded value ::: NONE ::: NONE ::: NONE ::: estrogen pill past year ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00157381.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: SCORE85 ::: DERIVED FIELD: NUTRIENT VALUE - VITAMIN D WITHOUT VITAMIN PILLS, (IU) ::: NONE ::: IU ::: NONE ::: NONE ::: derived field  nutrient value vitamin d without vitamin pills,  international unit ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;ergocalciferol;vitamin d;vitamins ::: C0678695;C0014695;C0042866;C0042890 ::: food;orch,phsu,vita;phsu,strd,vita;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00009191.v3 ::: phs000007.v18.p7 ::: pht000034.v5 ::: ex1_5s ::: E238 ::: RENIN-ANGIOTENSIN BLOCKING DRUGS ::: NONE ::: NONE ::: NONE ::: NONE ::: renin angiotensin blocking drugs ::: NULL ::: NULL ::: NULL ::: NULL ::: angiotensins;chymosin ::: C0003018;C0035100 ::: aapp,bacs,phsu;aapp,enzy,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00079032.v3 ::: phs000200.v8.p2 ::: pht001005.v3 ::: f37_rel1 ::: MEDSLEEP ::: Take medication for sleep ::: encoded value ::: NONE ::: NONE ::: NONE ::: take medication for sleep ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;sleep ::: C0013227;C0037313 ::: phsu;orgf ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Daily or Recreational Activity
phv00069051.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: FFD39 ::: DERIVED FIELD: SERVINGS PER WEEK - GRAPEFRUIT ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  servings per week grapefruit ::: NULL ::: NULL ::: NULL ::: NULL ::: grapefruit extract;grapefruit (food);grapefruit flavor ::: C0440280;C0995150;C1365950 ::: orch,phsu;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00061085.v2 ::: phs000128.v3.p3 ::: pht000491.v2 ::: simphen092 ::: chol2 ::: Cranial Hydroencephalic oleo level v2 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v2 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v2 stage;level ::: C0982301;C0457423;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00068747.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: NUT_ALCO ::: DERIVED FIELD: NUTRIENT VALUE - ALCOHOL, (GM) ::: NONE ::: gm ::: NONE ::: NONE ::: derived field  nutrient value alcohol,  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;alcohols;alcohol measurement ::: C0678695;C0001975;C0202304 ::: food;orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History;Eating or Nutritional Finding
phv00165203.v1 ::: phs000400.v1.p1 ::: pht002536.v1 ::: HeartGO_CHS_LDL_PhenotypeDataFile ::: ESP_vWF ::: VWF level in % at designated visit (may not be baseline) ::: Numeric ::: % ::: NONE ::: NONE ::: von willebrand factor level in % at designated visit  may not be baseline ::: NULL ::: NULL ::: NULL ::: NULL ::: von willebrand factor;level;health care visit ::: C0042971;C2946261;C1512346 ::: aapp,bacs,phsu;phsu;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00104445.v1 ::: phs000287.v2.p1 ::: pht001488.v1 ::: YR3 ::: PVDL06 ::: Peripheral vasodilators, exclude dipyrid ::: encoded ::: NONE ::: NONE ::: NONE ::: peripheral vasodilators, exclude dipyrid ::: NULL ::: NULL ::: NULL ::: NULL ::: peripheral vasodilators ::: C0724804 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00068262.v2 ::: phs000007.v18.p7 ::: pht000681.v3 ::: ffreq1_6s ::: FEDUR ::: FFQ: IRON SUPPLEMENT YEARS OF DURATION ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  iron supplement years of duration ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;iron;ferrum metallicum, homeopathic preparation;food;iron supplement;duration ::: C0524813;C0302583;C1166521;C0016452;C0721124;C2926735 ::: food;bacs,elii,phsu;phsu;food;phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00016038.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: OPIOIDS_DESPITE_OBJECTION ::: J50. Opioids Despite Objection, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: j50   opioids despite objection,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: opioids ::: C0242402 ::: hops,phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Substance Use History
phv00166859.v2 ::: phs000007.v18.p7 ::: pht002567.v2 ::: l_mtbllipi2_ex05_1_0661s ::: C36_3_PC ::: Phosphatidylcholine (carbon:double bond = 36:3) ::: NONE ::: NONE ::: 0.7456 ::: 1.5705 ::: phosphatidylcholine  carbon double bond = 36 3 ::: NULL ::: NULL ::: NULL ::: NULL ::: lecithin;phosphatidylcholines ::: C0031617;C1959616 ::: bacs,lipd,phsu;bacs,lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00118693.v2 ::: phs000285.v2.p2 ::: pht001771.v2 ::: E1F09MHM ::: E09HMNUM ::: MEDICATION NUMBER: HORMONE MED ::: encoded ::: NONE ::: NONE ::: NONE ::: medication number  hormone med ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00033318.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL27A30 ::: Pre-lunch blood glucose mg/dl (quarterly visit 30) ::: int ::: MG/DL ::: NONE ::: NONE ::: pre lunch blood glucose magnesium distolingual  quarterly visit 30 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00053882.v2 ::: phs000001.v3.p1 ::: pht000373.v2 ::: enrollment_randomization ::: TRIAMTER ::: YEARS TAKING TRIAMTERENE (ALL PARTICIPANTS) ::: enumerated integer ::: NONE ::: NONE ::: NONE ::: years taking triamterene  all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: triamterene ::: C0040869 ::: orch,phsu ::: participant ::: C0679646 ::: popg ::: Medication Patient
phv00123165.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: H2OPILYR ::: 73 Water pills in last yr (L) ::: encoded ::: NONE ::: NONE ::: NONE ::: 73 water pills in last year  l ::: NULL ::: NULL ::: NULL ::: NULL ::: water ::: C0043047 ::: inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00173653.v1 ::: phs000490.v1.p1 ::: pht002965.v1 ::: Atopic_Dermatitis_Phenotype ::: Antineoplastic_Agents ::: Antineoplastic agents that have been prescribed to the patient ::: String ::: NONE ::: NONE ::: NONE ::: antineoplastic agents that have been prescribed to the patient ::: NULL ::: NULL ::: NULL ::: NULL ::: antineoplastic agents;prescribed ::: C0003392;C0278329 ::: orch,phsu;hlca ::: patients ::: C0030705 ::: podg ::: Medication Patient;Healthcare Activity Finding
phv00116712.v2 ::: phs000285.v2.p2 ::: pht001710.v2 ::: D1F06AC ::: D06UNKN ::: USUAL SOURCE OF WATER - UNKNOWN. Q 16 ::: encoded ::: NONE ::: NONE ::: NONE ::: usual source of water unknown  q 16 ::: NULL ::: NULL ::: NULL ::: NULL ::: source;water ::: C0449416;C0043047 ::: fndg;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00014701.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: MOST_RESPONSIBLE_JOB_RESP ::: A 10.a. Most Responsible Job Resp, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: a 10 a  most responsible job resp,  participants with european ancestry   digs3 ::: Employment Status;Ethnicity ::: computer job;ethnic european ::: C2826594;C0239307 ::: mcha;popg ::: antineoplaston a10;responsible to;respiratory rate ::: C0052080;C1273518;C0231832 ::: orch,phsu;fndg;clna ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00004992.v1 ::: phs000007.v18.p7 ::: pht000024.v4 ::: ex0_22s ::: FO139 ::: MEDICATION USE: ANTIULCER (TAGAMET, RANITIDINE, PROBANTHINE, H-ION INHIBITORS) ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use  antiulcer  tagamet, ranitidine, probanthine, hion inhibitors ::: NULL ::: NULL ::: NULL ::: NULL ::: medication use;tagamet;ranitidine;probanthine ::: C0240320;C0592157;C0034665;C0728760 ::: fndg;orch,phsu;orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00013390.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I17654 ::: AA8a. Deterioration from premorbid level of functioning. Subject does not regain his/her premorbid functioning after an acute episode of illness: social functioning. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: aa8 a  deterioration from premorbid level of functioning  subject does not regain his her premorbid functioning after an acute episode of illness  social functioning   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: level;regain;illness (finding) ::: C2946261;C1875723;C0221423 ::: phsu;food;fndg ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Eating or Nutritional Finding
phv00066841.v5 ::: phs000007.v18.p7 ::: pht000676.v6 ::: meds3_1s ::: ther_gp3 ::: Description/Label for therapeutic subgroup - third drug in compound ::: encoded,string ::: NONE ::: NONE ::: NONE ::: description label for therapeutic subgroup third drug in compound ::: NULL ::: NULL ::: NULL ::: NULL ::: the science and art of healing;pharmaceutical preparations;pharmacologic substance ::: C0039796;C0013227;C1254351 ::: topp;phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure
phv00104685.v1 ::: phs000287.v2.p1 ::: pht001489.v1 ::: YR4 ::: INFLAT14 ::: MAXIMUM INFLATION LEVEL ::: integer ::: NONE ::: 110 ::: 270 ::: maximum inflation level ::: NULL ::: NULL ::: NULL ::: NULL ::: total lung capacity;level ::: C0040509;C2946261 ::: fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00079633.v3 ::: phs000200.v8.p2 ::: pht001014.v3 ::: f48_rel1 ::: WHTWINE ::: Glasses white/rose wine drank past 3 m ::: encoded value ::: NONE ::: NONE ::: NONE ::: glasses white rose wine drank past 3 m ::: NULL ::: NULL ::: NULL ::: NULL ::: white wine;alcohol consumption;alcoholic intoxication;alcoholic beverage heavy drinker;acute alcoholic intoxication;drink (dietary substance);drinking function;rose extract ::: C0349372;C0001948;C0001969;C0337678;C0394996;C0452428;C0684271;C0995005 ::: food;inbe;mobd;inbe;mobd;food;orgf;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Drinking History;Eating or Nutritional Finding
phv00010172.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G029 ::: CARDIOVASCULAR MEDICATIONS: RENIN-ANGIOTENSIN BLOCKING DRUGS (ACE) (CAPTOPRIL, ENALAPRIL, LISINOPRIL) ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications  renin angiotensin blocking drugs  angiotensin converting enzyme   captopril, enalapril, lisinopril ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;captopril;chymosin;enalapril;lisinopril ::: C0007220;C0006938;C0035100;C0014025;C0065374 ::: phsu;aapp,phsu;aapp,enzy,phsu;aapp,phsu;aapp,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00172582.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: Q_DIETSODA_NOCAF ::: FFQ: Other low-calorie beverage without caffeine, e.g., Diet 7-Up ::: encoded ::: 1 glass, bottle or can ::: NONE ::: NONE ::: food frequency questionnaire  other low calorie beverage without caffeine, e gram , diet7 up ::: NULL ::: NULL ::: NULL ::: NULL ::: others;beverages;caffeine ::: C1955473;C0005329;C0006644 ::: fndg;food;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00113873.v2 ::: phs000285.v2.p2 ::: pht001591.v2 ::: A5F06A ::: A06COPPR ::: COPPER (MG) ::: decimal ::: MG ::: 0.18 ::: 38.25 ::: copper  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: copper ::: C0009968 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00089190.v1 ::: phs000222.v1.p1 ::: pht001173.v1 ::: Predict_HD_uhdrs ::: uhdrs74 ::: Care level ::: encoded value ::: NONE ::: NONE ::: NONE ::: candidate gene association resource level ::: NULL ::: NULL ::: NULL ::: NULL ::: mental association;level ::: C0004083;C2946261 ::: menp;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding
phv00022262.v3 ::: phs000007.v18.p7 ::: pht000098.v4 ::: act1_5s ::: NWEEK23 ::: EACH OF 46 ACTIVITIES: 23 HARD, HOME: SCRUBBING FLOORS - NUMBER WEEKS PARTICIPATED ACTIVITY IN PAST YEAR (WEEKS) ::: NONE ::: NONE ::: NONE ::: NONE ::: each of 46 activities  23 hard, home  scrubbing floors number weeks participated activity in past year  weeks ::: NULL ::: NULL ::: NULL ::: NULL ::: scrubs;physical activity ::: C2946035;C0026606 ::: phsu;dora ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Daily or Recreational Activity
phv00033170.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL30A23 ::: Post-supper blood glucose mg/dl (quarterly visit 23) ::: int ::: MG/DL ::: NONE ::: NONE ::: post supper blood glucose magnesium distolingual  quarterly visit 23 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00166791.v2 ::: phs000007.v18.p7 ::: pht002566.v2 ::: l_mtbli2_ex05_1_0660s ::: methionine ::: Methionine ::: decimal, encoded ::: NONE ::: 0.561 ::: 2.5113 ::: methionine ::: NULL ::: NULL ::: NULL ::: NULL ::: methionine ::: C0025646 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00162208.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: BEET ::: FFQ: BEETS ::: encoded ::: 1/2 cup ::: NONE ::: NONE ::: food frequency questionnaire  beets ::: NULL ::: NULL ::: NULL ::: NULL ::: food;beets;beets preparation ::: C0016452;C0600054;C1095905 ::: food;food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00163646.v1 ::: phs000387.v1.p1 ::: pht002444.v1 ::: eMERGE_GeM_AAA_Subject_Phenotypes ::: ALCOHOL_USE ::: Use of alcohol by subject. ::: string ::: NONE ::: NONE ::: NONE ::: use of alcohol by subject ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement ::: C0001975;C0202304 ::: orch,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History
phv00172971.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: FFD46 ::: Derived field: Tomato or v8 juice ::: decimal, encoded ::: servings/week ::: 0 ::: 17.5 ::: derived field  tomato or v8 juice ::: NULL ::: NULL ::: NULL ::: NULL ::: tomatoes;tomato preparation;lycopersicum esculentum, tomato;juice ::: C0242772;C0885519;C1145756;C1268568 ::: food;phsu;orch,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00068830.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: FEDUR ::: FFQ: IRON SUPPLEMENT YEARS OF DURATION ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  iron supplement years of duration ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;iron;ferrum metallicum, homeopathic preparation;food;iron supplement;duration ::: C0524813;C0302583;C1166521;C0016452;C0721124;C2926735 ::: food;bacs,elii,phsu;phsu;food;phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00018401.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1373 ::: J37. Cocaine.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j37   cocaine   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: cocaine;cocaine measurement;diagnosis;genetic study ::: C0009170;C0202362;C0011900;C2827447 ::: hops,orch,phsu;lbpr;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes
phv00095446.v1 ::: phs000280.v1.p1 ::: pht001351.v1 ::: ARIC_CARE_NUT2V3C1 ::: SUCR ::: Sucrose (g) ::: decimal ::: NONE ::: 1.44 ::: 277.07 ::: sucrose  gram ::: NULL ::: NULL ::: NULL ::: NULL ::: saccharum officinale, sucrose, cane sugar, homeopathic preparation ::: C1161331 ::: carb,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00058468.v2 ::: phs000128.v3.p3 ::: pht000409.v2 ::: simphen010 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126395.v1 ::: phs000286.v3.p1 ::: pht001952.v1 ::: DPASS_DIET1 ::: lffq_thre ::: LFFQ: threonine (gm) ::: decimal ::: gm ::: 0.622126 ::: 8.696608 ::: lffq  threonine  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: threonine ::: C0040005 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00007287.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT248 ::: CARDIOVASCULAR MEDICATIONS: CALCIUM CHANNEL BLOCKERS ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiovascular medications  calcium channel blockers ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents;calcium channel blockers ::: C0007220;C0006684 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00085335.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: amlod1c ::: AMLODIPINE ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: amlodipine ::: NULL ::: NULL ::: NULL ::: NULL ::: amlodipine ::: C0051696 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00060452.v2 ::: phs000128.v3.p3 ::: pht000471.v2 ::: simphen072 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126182.v1 ::: phs000286.v3.p1 ::: pht001951.v1 ::: DITA ::: DITA21 ::: Glucose (g) ::: decimal ::: g ::: 0 ::: 275.0591 ::: glucose  gram ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement ::: C0017725;C0202042 ::: bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00161128.v1 ::: phs000209.v10.p2 ::: pht002195.v2 ::: MESA_Exam1ECGContiWaveform ::: taravf1 ::: T Wave Area (T + T'), Lead AVF (uVmSec) ::: NUMERIC ::: uVmSec ::: NONE ::: NONE ::: t wave area  t + t  , lead exploring electrode located at the left foot  uvmsec ::: NULL ::: NULL ::: NULL ::: NULL ::: t wave feature;lead;plumbum metallicum, homeopathic preparation ::: C0429103;C0023175;C1442948 ::: fndg;elii,hops;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History;Diagnostic Procedure
phv00026566.v1 ::: phs000086.v2.p1 ::: pht000216.v1 ::: DCCT_f0051 ::: OEC1D ::: Neurological symptom: sensory function of small fibers abnormality ::: NONE ::: NONE ::: NONE ::: NONE ::: neurological symptom  sensory function of small fibers abnormality ::: NULL ::: NULL ::: NULL ::: NULL ::: neurologic symptoms;fiber;abnormality ::: C0235031;C0225326;C1704258 ::: sosy;phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00049317.v1 ::: phs000086.v2.p1 ::: pht000326.v1 ::: EDIC_f0024 ::: OBO2D ::: O2d. Female/ reproductive: was pregnancy test performed ::: byte ::: NONE ::: NONE ::: NONE ::: o2 d  female  reproductive  was pregnancy test performed ::: NULL ::: NULL ::: NULL ::: NULL ::: oxygen;female;reproduction;pregnancy tests;choriogonadotropin beta measurement ::: C0030054;C0015780;C0035150;C0032976;C1880076 ::: elii,phsu;fndg;orgf;diap;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Diagnostic Procedure;Medical History
phv00065404.v3 ::: phs000007.v18.p7 ::: pht000611.v4 ::: wholedxa1_7_0708s ::: wb6_7pelbmc ::: WHOLEBODY PELVIS BMC, EXAM6/7 (GRAMS) ::: NONE ::: grams ::: NONE ::: NONE ::: wholebody pelvis bmc, exam6 7  grams ::: NULL ::: NULL ::: NULL ::: NULL ::: mecarzole ::: C0065839 ::: hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00068722.v2 ::: phs000007.v18.p7 ::: pht000682.v3 ::: ffreq1_7s ::: NUT_CALC ::: DERIVED FIELD: NUTRIENT VALUE - CALCIUM, (MG) ::: NONE ::: mg ::: NONE ::: NONE ::: derived field  nutrient value calcium,  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;calcium ::: C0678695;C0006675 ::: food;bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00103076.v1 ::: phs000287.v2.p1 ::: pht001475.v1 ::: YR11 ::: ANAR1C06 ::: Anti-arrhythmics, class 1C ::: encoded ::: NONE ::: NONE ::: NONE ::: anti arrhythmics, class1 c ::: NULL ::: NULL ::: NULL ::: NULL ::: anti-arrhythmia agents ::: C0003195 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00106435.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: ACE06 ::: ACE Inhibitors without diuretics ::: encoded ::: NONE ::: NONE ::: NONE ::: angiotensin converting enzyme inhibitors without diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: angiotensin-converting enzyme inhibitors;diuretics ::: C0003015;C0012798 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00085076.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: vwf1 ::: PERCENT VON WILLEBRAND FACTOR (vWF) ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: percent von willebrand factor  von willebrand factor ::: NULL ::: NULL ::: NULL ::: NULL ::: von willebrand factor ::: C0042971 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00119722.v2 ::: phs000285.v2.p2 ::: pht001808.v2 ::: F1F02 ::: F02SUMDI ::: 2ND AND 3RD DIAS (R2_RZ2_D + R3_RZ3_D). Q 20 ::: integer ::: NONE ::: 68 ::: 330 ::: 2nd and 3rd dias  r2_rz2_d + r3_rz3 _d   q 20 ::: NULL ::: NULL ::: NULL ::: NULL ::: 4-(4-dihexadecylaminostyryl)n-methylpyridium iodide;desmoplastic infantile astrocytoma ::: C0172658;C0457179 ::: orch,phsu;neop ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00052811.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V1451 ::: J49 Sedatives, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j49  sedatives,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: sedatives;diagnosis;genetic study ::: C0036557;C0011900;C2827447 ::: phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Research Attributes
phv00086053.v2 ::: phs000209.v10.p2 ::: pht001118.v5 ::: MESA_Exam2Main ::: nifir2c ::: IMMEDIATE-RELEASE NIFEDIPINE ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: immediate release nifedipine ::: NULL ::: NULL ::: NULL ::: NULL ::: nifedipine ::: C0028066 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00086924.v2 ::: phs000209.v10.p2 ::: pht001120.v7 ::: MESA_Exam4Main ::: betad4c ::: BETA-BLOCKERS WITH DIURETICS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: beta blockers with diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: adrenergic beta-antagonists;diuretics ::: C0001645;C0012798 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00061309.v2 ::: phs000128.v3.p3 ::: pht000498.v2 ::: simphen099 ::: chol2 ::: Cranial Hydroencephalic oleo level v2 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v2 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v2 stage;level ::: C0982301;C0457423;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00103078.v1 ::: phs000287.v2.p1 ::: pht001475.v1 ::: YR11 ::: ANTPSY06 ::: Anti-psychotic medications ::: encoded ::: NONE ::: NONE ::: NONE ::: anti psychotic medications ::: NULL ::: NULL ::: NULL ::: NULL ::: psychotic symptom present;pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- ::: C0459435;C0013227;C0802604;C2598133 ::: fndg;phsu;clna;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00100211.v1 ::: phs000287.v2.p1 ::: pht001451.v1 ::: BASE2 ::: SUGCER25 ::: SUGAR ADDED TO CEREAL ::: encoded ::: NONE ::: NONE ::: NONE ::: sugar added to cereal ::: NULL ::: NULL ::: NULL ::: NULL ::: sugars;cereals ::: C0242209;C0007757 ::: carb,phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00107434.v1 ::: phs000287.v2.p1 ::: pht001491.v1 ::: YR5OLD ::: VERSR06 ::: Slow-release verapamil ::: encoded ::: NONE ::: NONE ::: NONE ::: slow release verapamil ::: NULL ::: NULL ::: NULL ::: NULL ::: patient discharge;verapamil;discharge (release);release (procedure) ::: C0030685;C0042523;C0680255;C1963578 ::: hlca;orch,phsu;hlca;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Therapeutic or Preventive Procedure
phv00068598.v2 ::: phs000007.v18.p7 ::: pht000681.v3 ::: ffreq1_6s ::: NUT_LUT ::: DERIVED FIELD: NUTRIENT VALUE - LUTEIN AND ZEAXANTHIN 1993 ::: NONE ::: NONE ::: NONE ::: NONE ::: derived field  nutrient value lutein and zeaxanthin 1993 ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;lutein;zeaxanthin ::: C0678695;C0043328;C0078752 ::: food;bacs,orch,phsu;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00157390.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: MULBRND ::: FFQ: MULTIVITAMINS BRAND ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  multivitamins brand ::: NULL ::: NULL ::: NULL ::: NULL ::: food;multivitamin preparation;3-bromoacetoxyandrostan-17-one ::: C0016452;C0301532;C0645690 ::: food;orch,phsu,vita;phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00123956.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: glucose_fast ::: Fasting glucose (mg/dL) ::: integer ::: NONE ::: 38 ::: 300 ::: fasting glucose magnesium d l ::: NULL ::: NULL ::: NULL ::: NULL ::: fasting;glucose;plasma glucose measurement ::: C0015663;C0017725;C0202042 ::: fndg;bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Medical History
phv00034942.v1 ::: phs000021.v3.p2 ::: pht000289.v1 ::: AA_GAIN_phenotype_cases ::: cnf_cs_3 ::: Consensus confidence level assigned to the diagnosis ::: integer ::: NONE ::: NONE ::: NONE ::: consensus confidence level assigned to the diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: self confidence;level;confidence;diagnosis;diagnosis study ::: C0237529;C2946261;C1704726;C0011900;C1704656 ::: menp;phsu;menp;fndg;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Research Attributes
phv00018409.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1381 ::: J38. Opiates.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j38   opiates   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: opioid abuse;opiate assay;opiates;diagnosis;genetic study ::: C0029095;C0242401;C0376196;C0011900;C2827447 ::: mobd;lbpr;hops,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00156811.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: H20MEL ::: FFQ: WATERMELON ::: encoded ::: 1 slice ::: NONE ::: NONE ::: food frequency questionnaire  watermelon ::: NULL ::: NULL ::: NULL ::: NULL ::: food;watermelon preparation;watermelon (dietary);watermelon flavor ::: C0016452;C0874041;C0973455;C1337222 ::: food;orch,phsu;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00011965.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I3280 ::: E4. Have you ever taken medications for your nerves or any emotional or mental problems? MAOI's:  Marplan. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: e4  have you ever taken medications for your nerves or any emotional or mental problems  monoamine oxidase inhibitor s  marplan   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;emotions;emotional;mental problem;monoamine oxidase inhibitors;marplan ::: C0013227;C0802604;C2598133;C0013987;C0849912;C0848067;C0026457;C0591755 ::: phsu;clna;clna;menp;fndg;fndg;phsu;orch,phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Medical History
phv00162204.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: KALE ::: FFQ: KALE, MUSTARD, CHARD GREENS ::: encoded ::: 1/2 cup ::: NONE ::: NONE ::: food frequency questionnaire  kale, mustard, chard greens ::: NULL ::: NULL ::: NULL ::: NULL ::: food;kale - dietary;mustard (food);mustard preparation;chard ::: C0016452;C0330500;C0026872;C1095909;C0678195 ::: food;food;food;phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00049585.v1 ::: phs000086.v2.p1 ::: pht000329.v1 ::: EDIC_f0044 ::: ODB14A5 ::: B14a5. Current medication: Metolazone ::: byte ::: NONE ::: NONE ::: NONE ::: b14a5   current medication  metolazone ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;metolazone ::: C0746467;C0025854 ::: fndg;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00086596.v2 ::: phs000209.v10.p2 ::: pht001119.v5 ::: MESA_Exam3Main ::: pipday3 ::: PIPE:  AVRAGE # SMOKED PER DAY ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: pipe  avrage  number  smoked per day ::: NULL ::: NULL ::: NULL ::: NULL ::: piperine extract (standardized);smoke;smoking;tobacco smoke;tobacco smoking behavior ::: C1709545;C0037366;C0037369;C0439994;C0453996 ::: phsu;eehu,hops;inbe;hops;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History;Substance Use History
phv00065645.v1 ::: phs000086.v2.p1 ::: pht000624.v1 ::: EDIC_f0022 ::: OBHUSEMI ::: F1. Diabetes management: type of insulin - Human Semilente ::: byte ::: NONE ::: NONE ::: NONE ::: f1  diabetes management  type of insulin human semilente ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes type;disease management;insulin, prompt zinc ::: C1320657;C0376636;C0021663 ::: fndg;hlca;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00050102.v1 ::: phs000086.v2.p1 ::: pht000333.v1 ::: EDIC_f0423 ::: DBJ4B ::: J4b. Potential contributing factors. Sex 24 hrs excluding 4 hours before hypoglycemic event ::: byte ::: NONE ::: NONE ::: NONE ::: j4 b  potential contributing factors  gender 24 hours excluding 4 hours before hypoglycemic event ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: j4;gender:type:point in time:^patient:nominal;hypoglycemic agents ::: C0442779;C0804628;C0020616 ::: fndg;clna;phsu ::: study subject ::: C0681850 ::: grup ::: Demographics;Medication Patient;Substance Use History;Medical History
phv00014729.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: HEAD_INJURY ::: B 3.1. Head Injury, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: b 3 1  head injury,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid;craniocerebral trauma ::: C0378071;C0018674 ::: orch,phsu;inpo ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Medical History
phv00169121.v2 ::: phs000424.v2.p1 ::: pht002742.v2 ::: GTEx_Subject_Phenotypes ::: LBPRRVDRL ::: PRR VDRL ::: integer, encoded value ::: NONE ::: NONE ::: NONE ::: rapid plasma reagin venereal disease reaction level ::: NULL ::: NULL ::: NULL ::: NULL ::: rapid plasma reagin measurement;sexually transmitted diseases;level;reaction:finding:point in time:^patient:nominal ::: C0201405;C0036916;C2946261;C1114821 ::: lbpr;dsyn;phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Medical History
phv00058230.v2 ::: phs000128.v3.p3 ::: pht000402.v2 ::: simphen003 ::: chol1 ::: Cranial Hydroencephalic oleo level v1 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v1 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;v1 stage;level ::: C0982301;C0457422;C2946261 ::: lipd,phsu;fndg;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00098385.v1 ::: phs000280.v1.p1 ::: pht001414.v1 ::: ARIC_CARE_VITV3C1 ::: E_WO ::: Vitamin E without vitamin pills mg ::: integer ::: mg ::: NONE ::: NONE ::: vitamin e without vitamin pills magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: vitamin e;vitamins ::: C0042874;C0042890 ::: lipd,phsu,vita;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00106457.v1 ::: phs000287.v2.p1 ::: pht001490.v1 ::: YR5NEW ::: CCBT06 ::: T-type calcium-channel blocker ::: encoded ::: NONE ::: NONE ::: NONE ::: ttype calcium channel blocker ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium channel blockers ::: C0006684 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00020969.v4 ::: phs000007.v18.p7 ::: pht000074.v6 ::: ex3_1s ::: G3A114 ::: IF EVER CONSUMED ALCOHOL: DO YOU DRINK BEER AT LEAST ONCE A MONTH? ::: NONE ::: NONE ::: NONE ::: NONE ::: if ever consumed alcohol  do you drink beer at least once a month ::: NULL ::: NULL ::: NULL ::: NULL ::: alcohols;alcohol measurement;drink (dietary substance);beer ::: C0001975;C0202304;C0452428;C0004922 ::: orch,phsu;lbpr;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Drinking History;Eating or Nutritional Finding
phv00052792.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V1432 ::: J47 Opiates, (African American participants). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: j47  opiates,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: opioid abuse;opiate assay;opiates;diagnosis;genetic study ::: C0029095;C0242401;C0376196;C0011900;C2827447 ::: mobd;lbpr;hops,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00034948.v1 ::: phs000021.v3.p2 ::: pht000289.v1 ::: AA_GAIN_phenotype_cases ::: cnf_cs_5 ::: Consensus confidence level assigned to the diagnosis ::: integer ::: NONE ::: NONE ::: NONE ::: consensus confidence level assigned to the diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: self confidence;level;confidence;diagnosis;diagnosis study ::: C0237529;C2946261;C1704726;C0011900;C1704656 ::: menp;phsu;menp;fndg;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Research Attributes
phv00124292.v1 ::: phs000284.v1.p1 ::: pht001902.v1 ::: CFS_CARe_Subject_Phenotypes ::: HEPDIADAY ::: Days from visit date - Diagnosed Hepatitis ::: integer ::: NONE ::: -21210 ::: -191 ::: days from visit date diagnosed hepatitis ::: NULL ::: NULL ::: NULL ::: NULL ::: diagnosis;hepatitis;hepatitis a;hepatitis a vaccine, inactivated ::: C0011900;C0019158;C0019159;C0795623 ::: fndg;dsyn;dsyn;imft,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00001820.v1 ::: phs000007.v18.p7 ::: pht000014.v3 ::: ex0_12s ::: FE86 ::: INTERIM HISTORY OF MEDICINE USED: NITRITES ::: NONE ::: NONE ::: NONE ::: NONE ::: interim history of medicine used  nitrites ::: NULL ::: NULL ::: NULL ::: NULL ::: medical history;history of previous events;pharmaceutical preparations;used by ::: C0262926;C2004062;C0013227;C1273517 ::: fndg;fndg;phsu;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00126893.v1 ::: phs000286.v3.p1 ::: pht001953.v1 ::: DPASS_DIET1_ES ::: ravg_pant ::: RECALL: pantothenic acid ::: decimal ::: NONE ::: 1.25 ::: 12.2075 ::: recall  pantothenic acid ::: NULL ::: NULL ::: NULL ::: NULL ::: mental recall;recall:-:point in time:^patient:-;pantothenic acid;blood pantothenic acid analysis;vitamin b5 measurement ::: C0034770;C2361119;C0030342;C0696237;C2700255 ::: menp;clna;orch,phsu,vita;lbpr;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Mental or Emotional Finding
phv00157033.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: nut_b2_wo ::: Derived field: Nutrient value - Riboflavin B2 without vitamin pills ::: decimal, encoded ::: mg ::: 0.09 ::: 19.02 ::: derived field  nutrient value riboflavin b2 without vitamin pills ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;riboflavin;vitamins ::: C0678695;C0035527;C0042890 ::: food;orch,phsu,vita;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00065477.v1 ::: phs000126.v1.p1 ::: pht000321.v1 ::: CIDR_PD_Case ::: USED_IN_PRELIM_ANALYSES ::: Clean dataset used to perform pre-computes of association analyses: 0 = Not used; 1 = Used ::: NONE ::: NONE ::: NONE ::: NONE ::: clean dataset used to perform pre computes of association analyses  0 = not used  1 = used ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;perform;computed (procedure);mental association;analysis of substances;analysis ::: C1273517;C2947996;C1441526;C0004083;C0002778;C0936012 ::: fndg;phsu;lbpr;menp;lbpr;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Mental or Emotional Finding;Research Attributes
phv00033342.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL28A31 ::: Post-lunch blood glucose mg/dl (quarterly visit 31) ::: int ::: MG/DL ::: NONE ::: NONE ::: post lunch blood glucose magnesium distolingual  quarterly visit 31 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00006150.v1 ::: phs000007.v18.p7 ::: pht000026.v3 ::: ex0_24s ::: FQ165 ::: MEDICATION USE - THYROID EXTRACT (DESSICATED THYROID) ::: NONE ::: NONE ::: NONE ::: NONE ::: medication use thyroid extract  dessicated thyroid ::: NULL ::: NULL ::: NULL ::: NULL ::: medication use;thyroid preparation ::: C0240320;C0279175 ::: fndg;horm,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00033368.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL30A32 ::: Post-supper blood glucose mg/dl (quarterly visit 32) ::: int ::: MG/DL ::: NONE ::: NONE ::: post supper blood glucose magnesium distolingual  quarterly visit 32 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00066578.v1 ::: phs000092.v1.p1 ::: pht000116.v1 ::: AlcoholDepAdd_Data ::: oth_sx2 ::: Withdrawal from drugs other than marijuana, cocaine or opiates ::: encoded value ::: NONE ::: 1 ::: 9 ::: withdrawal from drugs other than marijuana, cocaine or opiates ::: NULL ::: NULL ::: NULL ::: NULL ::: withdrawal (dysfunction);pharmaceutical preparations;marihuana;cocaine;cocaine measurement;opioid abuse;opiate assay;opiates ::: C2825032;C0013227;C0024808;C0009170;C0202362;C0029095;C0242401;C0376196 ::: mobd;phsu;orch,phsu;hops,orch,phsu;lbpr;mobd;lbpr;hops,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Substance Use History;Medical History
phv00098302.v1 ::: phs000280.v1.p1 ::: pht001413.v1 ::: ARIC_CARE_VITAV3C1 ::: VITA8D ::: ZINC :DOSE PER PILL                 QDE ::: decimal ::: NONE ::: 0 ::: 600 ::: zinc  dose per pill qde ::: NULL ::: NULL ::: NULL ::: NULL ::: zinc;dose number:number:point in time:^patient:quantitative ::: C0043481;C1114758 ::: bacs,elii,phsu;clna ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00108767.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: STPMED59 ::: STOP ANY MEDICATION IN PAST MONTH ::: encoded ::: NONE ::: NONE ::: NONE ::: stop any medication in past month ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00126273.v1 ::: phs000286.v3.p1 ::: pht001951.v1 ::: DITA ::: DITA112 ::: Ash (g) ::: decimal ::: g ::: 0 ::: 138.3491 ::: ash  gram ::: NULL ::: NULL ::: NULL ::: NULL ::: ash preparation ::: C0994955 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00004621.v1 ::: phs000007.v18.p7 ::: pht000023.v4 ::: ex0_21s ::: FN123 ::: ORAL HYPOGLYCEMICS ::: NONE ::: NONE ::: NONE ::: NONE ::: oral hypoglycemics ::: NULL ::: NULL ::: NULL ::: NULL ::: oral hypoglycemic ::: C0359086 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049591.v1 ::: phs000086.v2.p1 ::: pht000329.v1 ::: EDIC_f0044 ::: ODB14G ::: B14g. Current medication: Clonidine ::: byte ::: NONE ::: NONE ::: NONE ::: b14 gram  current medication  clonidine ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;clonidine ::: C0746467;C0009014 ::: fndg;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00066848.v5 ::: phs000007.v18.p7 ::: pht000676.v6 ::: meds3_1s ::: chem_gp4 ::: Description/Label for chemical subgroup - fourth drug in compound ::: encoded,string ::: NONE ::: NONE ::: NONE ::: description label for chemical subgroup fourth drug in compound ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;pharmacologic substance ::: C0013227;C1254351 ::: phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00109022.v1 ::: phs000287.v2.p1 ::: pht001493.v1 ::: YR7 ::: NIFSR06 ::: Slow-release nifedipine ::: encoded ::: NONE ::: NONE ::: NONE ::: slow release nifedipine ::: NULL ::: NULL ::: NULL ::: NULL ::: patient discharge;nifedipine;discharge (release);release (procedure) ::: C0030685;C0028066;C0680255;C1963578 ::: hlca;orch,phsu;hlca;topp ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Therapeutic or Preventive Procedure
phv00070192.v2 ::: phs000007.v18.p7 ::: pht000680.v3 ::: ffreq1_5s ::: NUT_BCARWO ::: DERIVED FIELD: NUTRIENT VALUE - BETA CAROTENE WITHOUT VITAMIN PILLS, (MCG) ::: NONE ::: mcg ::: NONE ::: NONE ::: derived field  nutrient value beta carotene without vitamin pills,  mcg ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;beta carotene;vitamins ::: C0678695;C0053396;C0042890 ::: food;orch,phsu,vita;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00054319.v2 ::: phs000001.v3.p1 ::: pht000381.v2 ::: nsaids ::: ANAPRPIL ::: ANAPROX DS PILLS/DAY (ALL PARTICIPANTS) ::: integer ::: Pills/Day ::: 1 ::: 20 ::: anaprox ds pills day  all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: anaprox ds ::: C0718518 ::: orch,phsu ::: participant ::: C0679646 ::: popg ::: Medication Patient
phv00072359.v2 ::: phs000007.v18.p7 ::: pht000747.v3 ::: ex1_8s ::: H468 ::: ARE YOU ABLE TO DO HEAVY WORK AROUND THE HOUSE, LIKE SHOVELING SNOW OR WASHING WINDOWS, WALLS, OR FLOORS WITHOUT HELP? ::: encoded ::: NONE ::: NONE ::: NONE ::: are you able to do heavy work around the house, like shoveling snow or washing windows, walls, or floors without help ::: NULL ::: NULL ::: NULL ::: NULL ::: able (finding);cocaine ::: C1299581;C0009170 ::: fndg;hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00095055.v1 ::: phs000280.v1.p1 ::: pht001346.v1 ::: ARIC_CARE_MSRV1C1 ::: MSRAHF8 ::: MEDICATION CODE (AHF CODE) - Q11B ::: string ::: NONE ::: NONE ::: NONE ::: medication code  ahf code  q11 b ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations;factor viii ::: C0013227;C0015506 ::: phsu;aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00029812.v1 ::: phs000086.v2.p1 ::: pht000245.v1 ::: DCCT_f021cmb6 ::: BAD44C ::: MDI4  - previous day: units of regular or semi-lente insulin ::: byte ::: I.U. ::: NONE ::: NONE ::: mdi4 previous day  units of regular or semi lente insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin, lente ::: C0021659 ::: aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00105021.v1 ::: phs000287.v2.p1 ::: pht001489.v1 ::: YR4 ::: AMLOD06 ::: Amlodipine ::: encoded ::: NONE ::: NONE ::: NONE ::: amlodipine ::: NULL ::: NULL ::: NULL ::: NULL ::: amlodipine ::: C0051696 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00066731.v4 ::: phs000007.v18.p7 ::: pht000673.v5 ::: pat_2005s ::: C30_60 ::: RATIO BETWEEN MEAN AMPLITUDE OF SEGMENT 30 TO 60 SECONDS POST OCCLUSION TO THE BASELINE AMPLITUDE ON THE CONTROL SIDE ::: NONE ::: NONE ::: NONE ::: NONE ::: ratio between mean amplitude of segment 30 to 60 seconds post occlusion to the baseline amplitude on the control side ::: NULL ::: NULL ::: NULL ::: NULL ::: 60 second;obstruction;cardiovascular occlusion ::: C1702566;C0028778;C1110554 ::: inch,phsu;patf;patf ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00111615.v3 ::: phs000200.v8.p2 ::: pht001515.v3 ::: f150_rel1 ::: PCRMDUR_X ::: Months used Progesterone skin cream ::: encoded value ::: NONE ::: NONE ::: NONE ::: months used progesterone skin cream ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;progesterone ::: C1273517;C0033308 ::: fndg;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00053894.v2 ::: phs000001.v3.p1 ::: pht000373.v2 ::: enrollment_randomization ::: ALLOPURI ::: YEARS TAKING ALLOPURINOL (ALL PARTICIPANTS) ::: enumerated integer ::: NONE ::: NONE ::: NONE ::: years taking allopurinol  all participants ::: NULL ::: NULL ::: NULL ::: NULL ::: allopurinol ::: C0002144 ::: orch,phsu ::: participant ::: C0679646 ::: popg ::: Medication Patient
phv00065927.v1 ::: phs000086.v2.p1 ::: pht000624.v1 ::: EDIC_f0022 ::: OBP12A4R ::: P12a. Medication, grade of right femoral pulse ::: byte ::: NONE ::: NONE ::: NONE ::: p12 a  medication, grade of right femoral pulse ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Clinical Attributes
phv00012775.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I10340 ::: J32a. While using (drug), did you ever have any psychological problems start or get worse, such as feeling depressed, feeling paranoid, trouble thinking clearly, hearing, smelling, or seeing things, or feeling jumpy? IF YES:) Specify which problems, read appropriate sub questions to confirm response and code. Specify. (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: j32 a  while using  drug , did you ever have any psychological problems start or get worse, such as feeling depressed, feeling paranoid, trouble thinking clearly, hearing, smelling, or seeing things, or feeling jumpy  if yes   specify which problems, read appropriate sub questions to confirm response and code  specify   participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations;pharmacologic substance;mental problem;deterioration of status;emotions;feelings;depressed mood;thinking, function;thinking and speaking disturbances;hearing;hearing examination finding;smell perception;hallucinations, visual;jumpy;reading (activity);questioning;disease response;response (communication) ::: C0013227;C1254351;C0848067;C1279889;C0013987;C1527305;C0344315;C0039869;C0233629;C0018767;C1455844;C0037361;C0233763;C0860604;C0034754;C0876928;C1704632;C2911692 ::: phsu;phsu;fndg;fndg;menp;menp;fndg;menp;mobd;phsf;fndg;orgf;sosy;fndg;dora;menp;fndg;menp ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Daily or Recreational Activity
phv00086503.v2 ::: phs000209.v10.p2 ::: pht001119.v5 ::: MESA_Exam3Main ::: alzh3c ::: ACETYLCHOLINE ESTERASE INHIBITORS FOR ALZH'S ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: acetylcholine esterase inhibitors for alzh s ::: NULL ::: NULL ::: NULL ::: NULL ::: acetylcholine;esterase inhibitor;acetylcholine measurement ::: C0001041;C0596537;C0523441 ::: nsba,orch,phsu;phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00034195.v1 ::: phs000086.v2.p1 ::: pht000282.v1 ::: DCCT_f002cmb4 ::: OBHPBEEF ::: Indicate type of insulin used: highly purified beef insulin ::: byte ::: NONE ::: NONE ::: NONE ::: indicate type of insulin used  highly purified beef insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: indicated;insulin;recombinant insulin;used by;insulin, beef ::: C1444656;C0021641;C1533581;C1273517;C0304866 ::: fndg;aapp,horm,phsu;aapp,horm,phsu;fndg;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00115775.v2 ::: phs000285.v2.p2 ::: pht001669.v2 ::: C1F17 ::: C17HE30D ::: TIMES USED HEROIN: PAST 30 DAYS. Q 10 ::: encoded ::: Times ::: NONE ::: NONE ::: times used heroin  past 30 days  q 10 ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;heroin ::: C1273517;C0011892 ::: fndg;hops,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Substance Use History
phv00051759.v1 ::: phs000128.v3.p3 ::: pht000362.v1 ::: cohort ::: blsug4 ::: BLOOD SUGAR mg/dl, EXAM 4 ::: integer ::: mg/dl ::: 43 ::: 137 ::: blood sugar magnesium dl, exam 4 ::: NULL ::: NULL ::: NULL ::: NULL ::: sugars;medical examination ::: C0242209;C0582103 ::: carb,phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding
phv00157410.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: ZNDUR ::: FFQ: ZINC SUPPLEMENT YEARS OF DURATION ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  zinc supplement years of duration ::: NULL ::: NULL ::: NULL ::: NULL ::: food, supplemented;zinc;food;zinc supplement;duration ::: C0524813;C0043481;C0016452;C1268859;C2926735 ::: food;bacs,elii,phsu;food;inch,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00065866.v1 ::: phs000086.v2.p1 ::: pht000624.v1 ::: EDIC_f0022 ::: OBO6A ::: O6a. Female/reproductive: now uses oral contraceptives ::: byte ::: NONE ::: NONE ::: NONE ::: o6 a  female reproductive  now uses oral contraceptives ::: NULL ::: NULL ::: NULL ::: NULL ::: female;reproduction;used by;contraceptives, oral;oral contraceptives - consent type ::: C0015780;C0035150;C1273517;C0009905;C1548892 ::: fndg;orgf;fndg;phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00007363.v1 ::: phs000007.v18.p7 ::: pht000029.v3 ::: ex0_27s ::: FT324 ::: FEMALE HORMONE REPLACEMENT: DOSE/DAY OF PREMARIN CONJUGATED ESTROGENS, OR OTHER ORAL ESTROGEN ::: NONE ::: NONE ::: NONE ::: NONE ::: female hormone replacement  dose day of premarin conjugated estrogens, or other oral estrogen ::: NULL ::: NULL ::: NULL ::: NULL ::: female;hormone replacement therapy;dose number:number:point in time:^patient:quantitative;premarin;estrogens, conjugated (usp);estrogens ::: C0015780;C0282402;C1114758;C0699710;C0014938;C0014939 ::: fndg;topp;clna;horm,phsu,strd;horm,phsu,strd;horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00008782.v3 ::: phs000007.v18.p7 ::: pht000033.v6 ::: ex1_4s ::: D012 ::: LONGER ACTING NITRATES (ISORDIL, CARDILATE, ETC.) ::: NONE ::: NONE ::: NONE ::: NONE ::: longer acting nitrates  isordil, cardilate, etc ::: NULL ::: NULL ::: NULL ::: NULL ::: isordil;cardilate ::: C0590720;C0878296 ::: carb,phsu;carb,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00165310.v2 ::: phs000200.v8.p2 ::: pht002246.v3 ::: WHISP_Subject_Phenotypes ::: esp_fastinsulin_baseline ::: BASELINE INSULIN RIA METHOD ::: DECIMAL ::: ulU/ml ::: NONE ::: NONE ::: baseline insulin radioimmunoassay method ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin;radioimmunoassay;recombinant insulin ::: C0021641;C0034580;C1533581 ::: aapp,horm,phsu;lbpr;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00023237.v3 ::: phs000007.v18.p7 ::: pht000147.v4 ::: ebct1_7s ::: EBCT29 ::: AORTA CALCIUM SCORE - #CALCIFICATIONS:  ARCH ::: NONE ::: NONE ::: NONE ::: NONE ::: aorta calcium score  number calcifications  arch ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium ::: C0006675 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00008779.v3 ::: phs000007.v18.p7 ::: pht000033.v6 ::: ex1_4s ::: D009 ::: ANY CARDIOVASCULAR MEDICATIONS? ::: NONE ::: NONE ::: NONE ::: NONE ::: any cardiovascular medications ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiovascular agents ::: C0007220 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00084537.v2 ::: phs000209.v10.p2 ::: pht001116.v7 ::: MESA_Exam1Main ::: mass21c ::: SCAN 2: CAC ARTERIAL MASS ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: scan 2  coronary artery calcium arterial mass ::: NULL ::: NULL ::: NULL ::: NULL ::: radionuclide imaging;calcium;mass of body structure;scanning;related to cancer ::: C0034606;C0006675;C0577559;C0441633;C2826292 ::: diap;bacs,elii,phsu;fndg;diap;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure;Medical History
phv00154875.v2 ::: phs000335.v2.p2 ::: pht002117.v2 ::: LHS_COPD_Phenotypes ::: A5SLOP2A ::: A5. Methacholine Abs chg in FEV1 vs. cum dose ::: decimal ::: NONE ::: -4.456 ::: 0.105 ::: a5  methacholine abs chg in fev1 vital signs  cum dose ::: NULL ::: NULL ::: NULL ::: NULL ::: methacholine;forced expiratory volume in 1 second finding;taking vital signs;dose number:number:point in time:^patient:quantitative;vital signs;volume^at 1.0 s post forced expiration:volume:point in time:respiratory system:quantitative;pulmonary function test/forced expiratory volume 1 ::: C0600370;C0429706;C0150404;C1114758;C0518766;C0802965;C0849974 ::: irda,orch,phsu;fndg;hlca;clna;fndg;clna;diap ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Clinical Attributes;Medical History
phv00029810.v1 ::: phs000086.v2.p1 ::: pht000245.v1 ::: DCCT_f021cmb6 ::: BAD44A ::: MDI4  - previous day: units of long-acting or ultra-lente insulin ::: byte ::: I.U. ::: NONE ::: NONE ::: mdi4 previous day  units of long acting or ultra lente insulin ::: NULL ::: NULL ::: NULL ::: NULL ::: insulin, lente ::: C0021659 ::: aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00018061.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V1033 ::: G58c.  Alcohol Increase.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: g58 c  alcohol increase   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: alcohols;alcohol measurement;diagnosis;genetic study ::: C0001975;C0202304;C0011900;C2827447 ::: orch,phsu;lbpr;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Drinking History;Research Attributes
phv00121607.v2 ::: phs000285.v2.p2 ::: pht001871.v2 ::: YM106 ::: Y01DTXT ::: TEXT FOR OTHER BASIS FOR DIABETES DIAGNOSIS ::: string ::: NONE ::: NONE ::: NONE ::: text for other basis for diabetes diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: basis;diabetes;diagnosis;diagnosis study;diabetes mellitus ::: C1874451;C0011847;C0011900;C1704656;C0011849 ::: phsu;dsyn;fndg;resa;dsyn ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Research Attributes;Medical History
phv00049742.v1 ::: phs000086.v2.p1 ::: pht000330.v1 ::: EDIC_f0302 ::: COUNHMLE ::: F. Ophthalmoscopic examination:  why do you not plan photocoagulation in the eye(s) with high risk characteristics? Unable to laser left eye due to hemorrhage ::: byte ::: NONE ::: NONE ::: NONE ::: f  ophthalmoscopic examination  why do you not plan photocoagulation in the eye s  with high risk characteristics  unable to laser left eye due to hemorrhage ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;ophthalmoscopy;infantile neuroaxonal dystrophy;light coagulation;unable;hemorrhage ::: C0016327;C0029090;C0270724;C0023694;C1299582;C0019080 ::: inch,phsu;diap;dsyn;topp;fndg;patf ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Therapeutic or Preventive Procedure;Diagnostic Procedure;Medical History
phv00108130.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: EPSX59 ::: TOOK ESTROGEN TO PREVENT OTHER SYMPTOMS ::: encoded ::: NONE ::: NONE ::: NONE ::: took estrogen to prevent other symptoms ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens;prevent (product);symptoms ::: C0014939;C0309872;C1457887 ::: horm,phsu,strd;phsu;sosy ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00163806.v2 ::: phs000159.v4.p2 ::: pht000817.v4 ::: AML_Subject_Phenotypes ::: Neoadjuvant therapy (hydroxyurea) ::: Was the Patient Exposed to Hydroxyurea Prior to Procurement? ::: NONE ::: NONE ::: NONE ::: NONE ::: was the patient exposed to hydroxyurea prior to procurement ::: NULL ::: NULL ::: NULL ::: NULL ::: exposure to;hydroxyurea ::: C0332157;C0020402 ::: clna;orch,phsu ::: patients ::: C0030705 ::: podg ::: Medication Patient
phv00162644.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: FFD120 ::: DERIVED FIELD:CANDY WTHOUT CHOCOLATE ::: decimal, encoded ::: servings/week ::: 0 ::: 42 ::: derived field candy wthout chocolate ::: NULL ::: NULL ::: NULL ::: NULL ::: candy;chocolate;theobroma cacao, cocoa, chocolate;chocolate flavor ::: C0006855;C0008299;C0939909;C1337204 ::: food;food;phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00174003.v1 ::: phs000178.v7.p6 ::: pht003001.v1 ::: TCGA_CRC_Sample_Attributes ::: center_id ::: The identifier for the TCGA GSC or CGCC which performs the molecular analysis of an aliquot of material derived from a patient's tissue ::: integer ::: NONE ::: NONE ::: NONE ::: the identifier for the the cancer genome atlas gsc or cgcc which performs the molecular analysis of an aliquot of material derived from a patient s tissue ::: NULL ::: NULL ::: NULL ::: NULL ::: malignant neoplasms;primary malignant neoplasm;perform ::: C0006826;C1306459;C2947996 ::: neop;neop;phsu ::: patients ::: C0030705 ::: podg ::: Medication Patient;Medical History
phv00108124.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: EPDAY59 ::: DAYS PER MONTH TOOK ESTROGEN ::: integer ::: NONE ::: 1 ::: 31 ::: days per month took estrogen ::: NULL ::: NULL ::: NULL ::: NULL ::: estrogens ::: C0014939 ::: horm,phsu,strd ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00063812.v2 ::: phs000128.v3.p3 ::: pht000576.v2 ::: simphen177 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00150481.v2 ::: phs000209.v10.p2 ::: pht002107.v3 ::: MESA_Exam1DietNutrients ::: caffnn1c ::: NUTRIENTS: CAFFEINE ::: NUMERIC ::: mg ::: NONE ::: NONE ::: nutrients  caffeine ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;caffeine ::: C0678695;C0006644 ::: food;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00001913.v1 ::: phs000007.v18.p7 ::: pht000014.v3 ::: ex0_12s ::: FE197 ::: THYROID EXAMINATION:  SCAR ::: NONE ::: NONE ::: NONE ::: NONE ::: thyroid examination  scar ::: NULL ::: NULL ::: NULL ::: NULL ::: physical examination;scar tissue;cicatrix;thyroid (usp);thyroid preparation ::: C0031809;C0241158;C2004491;C0040134;C0279175 ::: hlca;fndg;patf;bacs,orch,phsu;horm,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00050802.v1 ::: phs000086.v2.p1 ::: pht000340.v1 ::: EDIC_f0704 ::: GOB5G ::: B5g. Does your health insurance provide coverage for: glucose tablets ::: byte ::: NONE ::: NONE ::: NONE ::: b5 gram  does your health insurance provide coverage for  glucose tablets ::: NULL ::: NULL ::: NULL ::: NULL ::: health insurance;provide (product);glucose;plasma glucose measurement ::: C0021682;C0359589;C0017725;C0202042 ::: hlca;food;bacs,carb,phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Eating or Nutritional Finding;Healthcare Activity Finding
phv00146949.v2 ::: phs000209.v10.p2 ::: pht002102.v2 ::: MESA_AncilMesaLungExam3CT ::: LLC_k_int ::: LEFT LUNG, LOWER CORE: THE INTERCEPT OF THE LINE AT THE KNEE ::: Numeric ::: NONE ::: NONE ::: NONE ::: left lung, lower core  the intercept of the line at the knee ::: NULL ::: NULL ::: NULL ::: NULL ::: intercept ::: C0598981 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00015714.v1 ::: phs000017.v3.p1 ::: pht000057.v1 ::: EA_DIGS3_Data ::: ETOH_DRUGS_DANGEROUS_MIX ::: I 30. ETOH+Drugs Dangerous Mix, (Participants with European ancestry). DIGS3 ::: NONE ::: NONE ::: NONE ::: NONE ::: i 30  etoh+drugs dangerous mix,  participants with european ancestry   digs3 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient
phv00050556.v1 ::: phs000086.v2.p1 ::: pht000339.v1 ::: EDIC_f0703 ::: GOB2F ::: B2f. Health care delivery. Podiatrist: ever seen ::: byte ::: NONE ::: NONE ::: NONE ::: b2 f  health candidate gene association resource delivery  podiatrist  ever seen ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;mental association;obstetric delivery;delivery finding ::: C0016327;C0004083;C0011209;C0559563 ::: inch,phsu;menp;topp;fndg ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Therapeutic or Preventive Procedure;Medical History
phv00008780.v3 ::: phs000007.v18.p7 ::: pht000033.v6 ::: ex1_4s ::: D010 ::: CARDIAC GLYCOSIDES ::: NONE ::: NONE ::: NONE ::: NONE ::: cardiac glycosides ::: NULL ::: NULL ::: NULL ::: NULL ::: cardiac glycosides ::: C0007158 ::: carb,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00032902.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL28A11 ::: Post-lunch blood glucose mg/dl (quarterly visit 11) ::: int ::: MG/DL ::: NONE ::: NONE ::: post lunch blood glucose magnesium distolingual  quarterly visit 11 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00060804.v2 ::: phs000128.v3.p3 ::: pht000482.v2 ::: simphen083 ::: chol3 ::: Cranial Hydroencephalic oleo level v3 ::: decimal ::: mg/dl ::: NONE ::: NONE ::: cranial hydroencephalic oleo level v3 ::: NULL ::: NULL ::: NULL ::: NULL ::: oleo;level ::: C0982301;C2946261 ::: lipd,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00162529.v2 ::: phs000007.v18.p7 ::: pht002350.v2 ::: vr_ffreq_ex08_1_0615s ::: NUT_PROTRIM ::: Derived field: Nutrient value - Proanthocyanidin, trimers, USDA, 2007 ::: decimal, encoded ::: NONE ::: 0.32 ::: 82.62 ::: derived field  nutrient value proanthocyanidin, trimers, usda, 2007 ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;proanthocyanidin ::: C0678695;C0072018 ::: food;orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00094219.v1 ::: phs000280.v1.p1 ::: pht001327.v1 ::: ARIC_CARE_HHXCV3C1 ::: HHXC1 ::: REPORT ROSE ANGINA IN AFU?           Q1 ::: encoded ::: NONE ::: NONE ::: NONE ::: report rose angina in annual follow up  q1 ::: NULL ::: NULL ::: NULL ::: NULL ::: angina pectoris;rose extract;reporting;follow-up status;follow-up ::: C0002962;C0995005;C0700287;C0589120;C1522577 ::: sosy;phsu;hlca;fndg;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Healthcare Activity Finding;Medical History
phv00156883.v2 ::: phs000007.v18.p7 ::: pht002150.v2 ::: vr_ffreq_ex01_3_0587s ::: CRAX ::: FFQ: CRACKERS, TRISKETS, WHEAT THINS ::: encoded ::: 1 serving ::: NONE ::: NONE ::: food frequency questionnaire  crackers, triskets, wheat thins ::: NULL ::: NULL ::: NULL ::: NULL ::: food;cracker;wheat (dietary);wheat preparation ::: C0016452;C0452505;C0043137;C1095911 ::: food;food;food;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00097401.v1 ::: phs000280.v1.p1 ::: pht001400.v1 ::: ARIC_CARE_TIAEV4C1 ::: TIAE22F ::: DBL VISION: LIGHTHEADED OR DIZZY  Q22F ::: encoded ::: NONE ::: NONE ::: NONE ::: dbl vision  lightheaded or dizzy q22 f ::: NULL ::: NULL ::: NULL ::: NULL ::: vision;vision:-:point in time:^patient:-;lightheadedness;dizziness;fluorides ::: C0042789;C2707266;C0220870;C0012833;C0016327 ::: orgf;clna;sosy;sosy;inch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00156483.v2 ::: phs000200.v8.p2 ::: pht002125.v2 ::: f60_nutr_rel1 ::: F60TRYPT ::: Dietary Tryptophan (g) ::: decimal ::: g ::: 0 ::: 12.32193 ::: dietary tryptophan  gram ::: NULL ::: NULL ::: NULL ::: NULL ::: diet;tryptophan ::: C0012155;C0041249 ::: food;aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00112952.v2 ::: phs000285.v2.p2 ::: pht001567.v2 ::: A4F06Q18 ::: A06TAP ::: USUAL SOURCE OF WATER:TAP. Q 17 ::: encoded ::: NONE ::: NONE ::: NONE ::: usual source of water tap  q 17 ::: NULL ::: NULL ::: NULL ::: NULL ::: source;water;paracentesis ::: C0449416;C0043047;C0034115 ::: fndg;inch,phsu;hlca ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding;Healthcare Activity Finding
phv00172836.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: nut_betaine ::: Derived field: Nutrient value - Betaine, choline derivative ::: decimal, encoded ::: mg ::: 1.77 ::: 1081.21 ::: derived field  nutrient value betaine, choline derivative ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;betaine;choline ::: C0678695;C0005304;C0008405 ::: food;orch,phsu;bacs,orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00108156.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: ROSEIC ::: INTERMITTENT CLAUDICATION BY ROSE QUESTIONNAIRE ::: encoded ::: NONE ::: NONE ::: NONE ::: intermittent claudication by rose questionnaire ::: NULL ::: NULL ::: NULL ::: NULL ::: intermittent claudication;rose extract ::: C0021775;C0995005 ::: dsyn;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00110634.v1 ::: phs000287.v2.p1 ::: pht001495.v1 ::: YR9 ::: ALZH06 ::: Acetylcholine esterase inhibitors for Al ::: encoded ::: NONE ::: NONE ::: NONE ::: acetylcholine esterase inhibitors for attatchment loss ::: NULL ::: NULL ::: NULL ::: NULL ::: acetylcholine;esterase inhibitor;acetylcholine measurement ::: C0001041;C0596537;C0523441 ::: nsba,orch,phsu;phsu;lbpr ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00083484.v1 ::: phs000209.v10.p2 ::: pht001112.v2 ::: MESA_AirNRSpirometry ::: cpgolda4 ::: COPD - GOLD ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: chronic obstructive pulmonary disease gold ::: NULL ::: NULL ::: NULL ::: NULL ::: chronic obstructive airway disease;gold;pulmonary disease, chronic obstructive, severe early-onset ::: C0024117;C0018026;C1847014 ::: dsyn;elii,phsu;dsyn ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Medical History
phv00173094.v1 ::: phs000007.v18.p7 ::: pht002900.v1 ::: vr_ffreq_ex02_3_0713s ::: FFD145 ::: Derived field: Sugar in beverage/ food ::: NONE ::: servings/week ::: 0 ::: 336 ::: derived field  sugar in beverage  food ::: NULL ::: NULL ::: NULL ::: NULL ::: sugars;beverages;food ::: C0242209;C0005329;C0016452 ::: carb,phsu;food;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00108147.v1 ::: phs000287.v2.p1 ::: pht001492.v1 ::: YR6 ::: DOSNM159 ::: NAME OF FIRST MEDICATION CHANGED ::: string ::: NONE ::: NONE ::: NONE ::: name of first medication changed ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00118761.v2 ::: phs000285.v2.p2 ::: pht001777.v2 ::: E1F09TOB ::: E09SNUFF ::: DO YOU STILL USE SMOKELESS TOB? Q 5.01 ::: encoded ::: NONE ::: NONE ::: NONE ::: do you still use smokeless tob  q 5 01 ::: NULL ::: NULL ::: NULL ::: NULL ::: smokeless ::: C1450035 ::: orch,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Smoking History
phv00181873.v1 ::: phs000462.v1.p1 ::: pht002844.v1 ::: T2D_GENES_Subject_Phenotypes ::: CYSTATIN_C_2 ::: Cystatin C concentration at the second study visit ::: decimal ::: ng/mL ::: 0.7185 ::: 9000 ::: cystatin c concentration at the second study visit ::: NULL ::: NULL ::: NULL ::: NULL ::: cystatin c (substance);mental concentration;clinical trials;health care visit;study ::: C0071744;C0086045;C0008976;C1512346;C2603343 ::: aapp,phsu;menp;resa;inbe;resa ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Mental or Emotional Finding;Research Attributes
phv00052746.v1 ::: phs000017.v3.p1 ::: pht000367.v1 ::: GAIN_AA_DIGS4 ::: V1386 ::: J39 Opiates, (African American participants). DIGS4 ::: NONE ::: Years old ::: NONE ::: NONE ::: j39  opiates,  african american participants   diagnostic interview for genetic studies ::: Race ::: african american ::: C0085756 ::: popg ::: opioid abuse;opiate assay;opiates;diagnosis;genetic study ::: C0029095;C0242401;C0376196;C0011900;C2827447 ::: mobd;lbpr;hops,phsu;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00161755.v1 ::: phs000007.v18.p7 ::: pht002234.v3 ::: l_mtbli1_ex05_1_0610s ::: isoleucine ::: Isoleucine ::: decimal, encoded ::: NONE ::: 0.5716 ::: 2.6314 ::: isoleucine ::: NULL ::: NULL ::: NULL ::: NULL ::: isoleucine ::: C0022192 ::: aapp,bacs,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049726.v1 ::: phs000086.v2.p1 ::: pht000330.v1 ::: EDIC_f0302 ::: COONVELE ::: F. Ophthalmoscopic examination: are there new vessels (NVE) outside 7 standard fields? Left eye ::: byte ::: NONE ::: NONE ::: NONE ::: f  ophthalmoscopic examination  are there new vessels  nve  outside 7 standard fields  left eye ::: NULL ::: NULL ::: NULL ::: NULL ::: fluorides;ophthalmoscopy;no visible estrus ::: C0016327;C0029090;C0232915 ::: inch,phsu;diap;sosy ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Diagnostic Procedure;Medical History
phv00072913.v1 ::: phs000171.v1.p1 ::: pht000760.v1 ::: MS_DATA_LAB ::: TSH_MIU_L ::: Tsh (Thyroid stimulating hormone) - Milli-International-Units (MIU) ::: Decimal ::: MIU/L ::: NONE ::: NONE ::: tsh  thyroid stimulating hormone  milli international units  milli-international unit ::: NULL ::: NULL ::: NULL ::: NULL ::: thyrotropin;blood thyroid stimulating hormone analysis;recombinant thyroid-stimulating hormone ::: C0040160;C0696098;C1535531 ::: aapp,horm,phsu;lbpr;aapp,horm,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00098253.v1 ::: phs000280.v1.p1 ::: pht001413.v1 ::: ARIC_CARE_VITAV3C1 ::: VITA5E ::: VIT E:UNITS                         Q5E ::: encoded ::: NONE ::: NONE ::: NONE ::: vit e units q5 e ::: NULL ::: NULL ::: NULL ::: NULL ::: vitamin e ::: C0042874 ::: lipd,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00158561.v1 ::: phs000228.v3.p1 ::: pht001187.v3 ::: EMMES_HMP_DCM ::: DCMONGO_C ::: Medication ongoing - coded fields ::: String ::: NONE ::: NONE ::: NONE ::: medication ongoing coded fields ::: NULL ::: NULL ::: NULL ::: NULL ::: pharmaceutical preparations ::: C0013227 ::: phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00033350.v1 ::: phs000086.v2.p1 ::: pht000278.v1 ::: DCCT_bgpdat ::: VAL32A31 ::: 3:00 a.m. blood glucose mg/dl (quarterly visit 31) ::: byte ::: MG/DL ::: NONE ::: NONE ::: 3 00 a m  blood glucose magnesium distolingual  quarterly visit 31 ::: NULL ::: NULL ::: NULL ::: NULL ::: glucose;plasma glucose measurement;blood glucose measurement;health care visit ::: C0017725;C0202042;C0392201;C1512346 ::: bacs,carb,phsu;lbpr;lbpr;inbe ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient
phv00157746.v1 ::: phs000007.v18.p7 ::: pht002151.v1 ::: ffreq0_20s ::: SCORE99 ::: DERIVED FIELD: NUTRIENT VALUE - TOTAL OMEGA 3 (F183S+F205+F225+F226), (GM) ::: NONE ::: gm ::: NONE ::: NONE ::: derived field  nutrient value total omega 3  f183s+f205+f225+f226 ,  gm ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;omega-3 fatty acids ::: C0678695;C0015689 ::: food;bacs,lipd,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00012053.v1 ::: phs000017.v3.p1 ::: pht000056.v1 ::: EA_DIGS2_Data ::: I3900 ::: F7a. Did you have trouble sleeping or were you sleeping more than usual? IF YES: were you unable to fall asleep? CURRENT EPISODE (PAST MONTH). (Participants with European ancestry). DIGS2 ::: NONE ::: NONE ::: NONE ::: NONE ::: f7 a  did you have trouble sleeping or were you sleeping more than usual  if yes  were you unable to fall asleep  current episode  past month    participants with european ancestry   digs2 ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: blood coagulation factor vii;sleep;asleep;unable;falls ::: C0015502;C0037313;C0424522;C1299582;C0085639 ::: aapp,bacs,phsu;orgf;fndg;fndg;fndg ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Daily or Recreational Activity
phv00008106.v3 ::: phs000007.v18.p7 ::: pht000031.v5 ::: ex1_2s ::: B759 ::: IRON ::: NONE ::: NONE ::: NONE ::: NONE ::: iron ::: NULL ::: NULL ::: NULL ::: NULL ::: iron;ferrum metallicum, homeopathic preparation ::: C0302583;C1166521 ::: bacs,elii,phsu;phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00049498.v1 ::: phs000086.v2.p1 ::: pht000328.v1 ::: EDIC_f0043 ::: ODB14A ::: B14a. Current medication: has the patient taken diuretics ::: byte ::: NONE ::: NONE ::: NONE ::: b14 a  current medication  has the patient taken diuretics ::: NULL ::: NULL ::: NULL ::: NULL ::: medication.current;diuretics ::: C0746467;C0012798 ::: fndg;phsu ::: patients ::: C0030705 ::: podg ::: Medication Patient
phv00019053.v1 ::: phs000017.v3.p1 ::: pht000058.v1 ::: EA_DIGS4_Data ::: V2025 ::: P30a.  Describe agoraphobic fears.  (Participants with European ancestry). DIGS4 ::: NONE ::: NONE ::: NONE ::: NONE ::: p30 a  describe agoraphobic fears   participants with european ancestry   diagnostic interview for genetic studies ::: Ethnicity ::: ethnic european ::: C0239307 ::: popg ::: ranpirnase;fear (mental process);diagnosis;genetic study ::: C0069919;C0015726;C0011900;C2827447 ::: aapp,enzy,phsu;menp;fndg;resa ::: participant ::: C0679646 ::: popg ::: Demographics;Medication Patient;Mental or Emotional Finding;Research Attributes
phv00157954.v1 ::: phs000007.v18.p7 ::: pht002152.v1 ::: ffreq0_21s ::: KALE ::: FFQ: KALE, MUSTARD, CHARD GREENS (1/2 CUP) ::: NONE ::: NONE ::: NONE ::: NONE ::: food frequency questionnaire  kale, mustard, chard greens  1 2 cup ::: NULL ::: NULL ::: NULL ::: NULL ::: food;kale - dietary;mustard (food);mustard preparation;chard ::: C0016452;C0330500;C0026872;C1095909;C0678195 ::: food;food;food;phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Eating or Nutritional Finding
phv00010252.v3 ::: phs000007.v18.p7 ::: pht000036.v5 ::: ex1_7s ::: G109 ::: WHITE WINE (OR ROSE): ON AVERAGE, LIMIT FOR NUMBER OF DRINKS AT ONE PERIOD OF TIME - GLASS (4 OZ) THERE ARE KNOWN INCONSISTENCIES. (E.G. AVERAGE NUMBER OF DRINKS PER WEEK AND NUMBER OF DAYS DRINK PER WEEK IS NOT ALWAYS CONSISTENT WITH THE AVERAGE LIMIT OF DRINKS AT ONE TIME) ::: NONE ::: DRINKS PER WEEK ::: NONE ::: NONE ::: white wine  or rose   on average, limit for number of drinks at one period of time glass  4 oz  there are known inconsistencies   e gram  average number of drinks per week and number of days drink per week is not always consistent with the average limit of drinks at one time ::: NULL ::: NULL ::: NULL ::: NULL ::: white wine;rose extract;drink (dietary substance) ::: C0349372;C0995005;C0452428 ::: food;phsu;food ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Drinking History;Eating or Nutritional Finding
phv00087544.v1 ::: phs000209.v10.p2 ::: pht001121.v3 ::: MESA_FamilyExamMain ::: agatp1fc ::: SCAN 1: AGATSTON CALCIUM SCORE, PHANTOM-ADJUSTED ::: NUMERIC ::: NONE ::: NONE ::: NONE ::: scan 1  agatston calcium score, phantom adjusted ::: NULL ::: NULL ::: NULL ::: NULL ::: calcium ::: C0006675 ::: bacs,elii,phsu ::: study subject ::: C0681850 ::: grup ::: Medication Patient
phv00068670.v2 ::: phs000007.v18.p7 ::: pht000681.v3 ::: ffreq1_6s ::: NUT_B2WO ::: DERIVED FIELD: NUTRIENT VALUE - VITAMIN B2 (RIBOFLAVIN) WITHOUT VITAMIN PILLS, (MG) ::: NONE ::: mg ::: NONE ::: NONE ::: derived field  nutrient value vitamin b2  riboflavin  without vitamin pills,  magnesium ::: NULL ::: NULL ::: NULL ::: NULL ::: nutrients;riboflavin;riboflavin assay;vitamins ::: C0678695;C0035527;C0373720;C0042890 ::: food;orch,phsu,vita;lbpr;orch,phsu,vita ::: study subject ::: C0681850 ::: grup ::: Medication Patient;Lab Tests Patient;Eating or Nutritional Finding
